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Abbreviation list 
3-PGA 3-phosphoglyceric acid 
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FAS-I Fatty acid synthase I 
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gaMhaGgH Recombinant M. hassiacum glucosylglycerate hydrolase containing 
a N-terminal Gly-Ala dipeptide 
GDP-mannose Guanosine 5′-diphospho-D-mannose 
GG Glucosylglycerate; 2-O-(α-D-glucopyranosyl)-D-glycerate 
GgH Glucosylglycerate hydrolase 
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GGlycolate Glucosylglycolate; 2-O-(α-D-glucopyranosyl)-D-glycolate 
GH Glycoside hydrolase 
Glucose-1P glucose-1-phosphate 
GOL Glycerol (Identifier code) 
GOL_P4K 2:1 of (v/v) glycerol to (w/v) PEG 4,000 solution 
GPG Glucosyl-3-phosphoglycerate 
GpgP Glucosyl-3-phosphoglycerate phosphatase 
GpgS Glucosyl-3-phosphoglycerate synthase  
h Hill slope 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HIV Human immunodeficiency virus 
iPGM 2,3-bisphosphoglycerate independent phosphatase mutase 
IPTG Isopropyl -D-1-thiogalactopyranoside 
KD Dissociation constant 
Khalf Substrate concentration producing a half-maximal enzyme velocity 
Km Michaelis constant 
LAM Lipoarabinomannan 
LB Lysogeny broth  
LM Lipomannan 
LPSN List of Prokaryotic names with Standing in Nomenclature 
mAGP mycolyl-arabinogalactan-peptidoglycan 
Mak Maltokinase 
Maltose-1P Maltose-1-phosphate 
ManT α-(1,4)-mannosyltransferase 
MDR-TB Multidrug-resistant tuberculosis 
MES 2-(N-morpholino) ethanesulfonic acid 
MeT 3-O-methyltransferase 
MG Mannosylglycerate; 2-O-(α-D-mannopyranosyl)-D-glycerate 
MGG mannosylglucosylglycerate 
MgH Mannosylglycerate hydrolase 
MGLP 6-O-methylglucose lipopolysaccharide 
MhaGgH M. hassiacum glucosylglycerate hydrolase 
MhaGgH-His6 Recombinant M. hassiacum glucosylglycerate hydrolase containing 
a C-terminal hexahistidine tag 
MMP 3-O-methylmannose polysaccharide 
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mPGM Monophosphoglycerate mutase 
MST Microscale thermophoresis 
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phosphatase described elsewhere (Zheng, Jiang et al. 2014) 
MtuGpgP Recombinant M. tuberculosis glucosyl-3-phosphoglycerate 
phosphatase described in this thesis 
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NCS Non-crystallographic symmetry 
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NMR Nuclear magnetic resonance 
NTM Nontuberculous mycobacteria 
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PDB Protein data bank 
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SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SeMet-gaMhaGgH Selenomethionine-labelled gaMhaGgH 
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Abstract 
The Mycobacterium genus contains more than 180 species, including the causative 
agents of tuberculosis (Mycobacterium tuberculosis complex), one of the top 10 causes of 
death worldwide. Furthermore, many of the ubiquitous environmental nontuberculous 
mycobacteria are opportunistic pathogens able to cause local to disseminated infections 
in humans, particularly in susceptible individuals. The clinical impact of mycobacterial 
infections relies mostly on their increased resistance to the therapies currently in use, 
which reinforces the need of more active drug development. Mycobacteria produce unique 
intracellular carbohydrates, named polymethylated polysaccharides (PMPSs), which 
comprehend 3-O-methylmannose polysaccharides (MMPs) and 6-O-methylglucose 
lipopolysaccharides (MGLPs). MGLPs seem to be the only PMPSs common to all 
mycobacteria, revealing their importance to mycobacterial survival and the value of their 
biosynthetic pathway as source of new drug targets. Although MGLPs are known for 
about 50 years, their biosynthetic pathway is still not fully understood. Here, two 
mycobacterial enzymes – glucosyl-3-phosphoglycerate phosphatase (GpgP) and 
glucosylglycerate hydrolase (GgH) – proposed to be involved in the MGLPs biosynthetic 
pathway, particularly in glucosylglycerate (GG) metabolism, are structurally characterized.  
GpgP was previously proposed to participate in the second step of MGLPs production by 
dephosphorylating glucosyl-3-phosphoglycerate to GG. The crystallographic structures of 
a recombinant GpgP and of its complex with the phosphate analogue vanadate and the 
reaction product GG enable the identification of the amino acids involved in substrate 
binding and catalysis. Also, the high resolution X-ray diffraction data allowed identifying 
novel trivanadate glycerol ester molecules. GgH is highly conserved among rapid-growing 
mycobacteria and was proposed to be involved in mycobacterial recovery from nitrogen 
starvation by promoting the rapid mobilization of GG accumulated under these conditions. 
In vitro, GgH catalyzes the hydrolysis of GG to glucose and glycerate. Two catalytically 
inactive point mutants were produced and characterized in complex with substrates and 
substrate analogues. The structures of the complexes, as well as the apo-structure of 
GgH, allowed the clarification of the molecular details of substrate specificity, binding and 
hydrolysis. 
The present work contributes for elucidating the structure and reaction mechanism of the 
mycobacterial GpgP and GgH, both involved in the metabolism of GG, one of the earliest 
intermediates of the vital MGLP biosynthetic pathway.  
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Resumo 
O género Mycobacterium contém mais de 180 espécies, incluindo os agentes etiológicos 
da tuberculose (complexo Mycobacterium tuberculosis), a qual se encontra entre as dez 
principais causas de morte a nível mundial. Além disso, muitas das micobactérias 
ambientais não tuberculosas são agentes patogénicos oportunistas capazes de causar 
infeções locais a disseminadas em seres humanos, particularmente em indivíduos 
susceptíveis. O impacto clínico das infeções micobacterianas está principalmente 
relacionado com a crescente resistência das micobactérias às terapias actualmente em 
uso, o que torna urgente o desenvolvimento de fármacos mais eficazes. As micobactérias 
produzem hidratos de carbono intracelulares únicos, designados polissacáridos 
polimetilados (PMPSs), os quais incluem os polissacáridos de 3-O-metilmanose (MMPs) 
e lipopolisacáridos de 6-O-metilglucose (MGLPs). Aparentemente, os MGLPs são os 
únicos PMPSs comuns a todas as micobactérias, o que sugere o seu carácter essencial e 
o valor da sua via biossintética como fonte de novos alvos terapêuticos. Embora os 
MGLPs tenham sido descritos há mais de 50 anos, a via biossintética que leva à sua 
produção ainda não é totalmente conhecida. Aqui são caracterizadas estruturalmente 
duas enzimas micobacterianas, a fosfatase de glucosil-3-fosfoglicerato (GpgP) e a 
hidrolase de glucosilglicerato (GgH), propostas como intervenientes na via de biossíntese 
dos MGLPs, especificamente no metabolismo de glucosilglicerato (GG). 
A GpgP, considerada responsável pelo segundo passo de produção dos MGLPs, catalisa 
in vitro a desfosforilação de glucosil-3-fosfoglicerato a GG. A estrutura cristalográfica de 
uma GpgP recombinante e do seu complexo com o análogo do fosfato, vanadato, e o seu 
produto de reação, GG, permitiu identificar os aminoácidos envolvidos na ligação e na 
catálise do substrato. A elevada resolução dos dados de difracção de raios-X permitiu 
também descrever novos ésteres de trivanadato-glicerol. A GgH, altamente conservada 
entre as micobactérias de crescimento rápido, está implicada na recuperação das 
micobactérias submetidas a privação de azoto através da rápida mobilização do GG 
acumulado nestas condições. In vitro, a GgH é capaz de catalisar a hidrólise de GG a 
glucose e glicerato. Dois mutantes de GgH cataliticamente inactivos foram produzidos e 
caracterizados em complexo com os substratos da GgH e análogos dos mesmos. A 
estrutura dos complexos, assim como a estrutura da apo GgH, permitiu clarificar os 
detalhes moleculares envolvidos na especificidade, ligação e hidrólise dos substratos.  
O presente trabalho contribui para elucidar a estrutura e o mecanismo de reação das 
GpgP e GgH micobacterianas, ambas envolvidas no metabolismo do GG, um dos 
primeiros intermediários na via vital de biossíntese dos MGLPs. 
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1.1. Mycobacteria 
Mycobacteria are acid-fast rod-shaped bacilli, with a high G+C-content genome (65.6%) 
(Cole, Brosch et al. 1998). The genus Mycobacterium contains more than 180 species 
according to the List of prokaryotic names with standing in nomenclature (LPSN, 
www.bacterio.net), and to which the addition of two new species was recently proposed 
(Nouioui, Sangal et al. 2017).  
Traditionally, mycobacteria are divided into slow-growing mycobacteria (SGM), when they 
require at least 7 days to form visible colonies on agar medium, and rapid-growing 
mycobacteria (RGM), when less than 7 days are sufficient (Primm, Lucero et al. 2004). 
Although most mycobacteria are environmental bacteria with saprophytic or symbiotic 
lifestyle, some species are aggressive pathogens such as the well-known Mycobacterium 
tuberculosis and Mycobacterium leprae (Primm, Lucero et al. 2004). Due to their impact in 
human health and for their ability to cause tuberculosis in humans or other mammals, 
mycobacteria are also commonly divided into M. tuberculosis complex (see section 1.1.1) 
and nontuberculous mycobacteria (NTM) (see section 1.1.2), with M. leprae and 
Mycobacterium lepromatosis (Han, Seo et al. 2008, Singh, Benjak et al. 2015), the 
causative agents of leprosy (Smith, Aerts et al. 2017, Steinmann, Reed et al. 2017), 
forming a third distinct group. Although nontuberculous mycobacteria are environmental 
organisms, they may also cause opportunistic infections in humans (Primm, Lucero et al. 
2004). 
Mycobacteria in general display high drug resistance, which makes mycobacterial 
infections a clinical challenge (see section 1.1.3). Despite their differences, mycobacterial 
species share important characteristics. One of the most dominant features of 
mycobacteria is their cell wall, composed of unique carbohydrates and lipids (see section 
1.1.4). Mycobacteria possess the thickest outer membrane known, measuring 9-10 nm 
based on electron microscopy examination (Brennan and Nikaido 1995), that shields the 
cells from the environment, including drugs and the human immune system. Due to its 
contribution for mycobacteria success as pathogens, the pathways involved in the 
mycobacterial cell envelop synthesis are of high interest, especially for the identification of 
targets against which new drugs can be designed. 
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1.1.1. Mycobacterium tuberculosis complex and tuberculosis 
The tubercle bacillus was discovered in 1882 by Robert Koch. Since its discovery, 
tuberculosis (TB) has been associated to several mycobacterial species, including M. 
tuberculosis, M. bovis, M. africanum, M. caprae, M. canettii, M. microti, M. orygis, M. 
pinnipedii, M. suricattae, and M. mungi (Esteban and Muñoz-Egea 2016), altogether 
known as the Mycobacterium tuberculosis complex. 
Although the number of TB deaths fell by 26% in 16 years (from 2000 to 2016), TB 
remains  one of the top 10 causes of death worldwide and the leading cause from a single 
infectious agent (WHO 2017). The World Health Organization (WHO) estimated that in 
2016 there were 10.4 million new TB cases worldwide (1.5% lower than in 2014) and 1.7 
million TB deaths, 0.37 million of which among HIV-infected people (WHO 2017). In 2016, 
TB was also the leading cause of death among HIV-positive people, with 40% deaths due 
to TB (WHO 2017). It is estimated that about one-fourth of the world’s population has 
latent TB infection with approximately 5 to 15% lifetime risk of developing the disease 
(WHO 2017). 
Nowadays, active TB requires a minimum of 6 months of multidrug therapy in two phases: 
the intensive phase, consisting in 2 months of isoniazid (Bernstein, Lott et al. 1952), 
rifampicin (Maggi, Pasqualucci et al. 1966), pyrazinamide (Yeager, Munroe et al. 1952), 
and ethambutol (Thomas, Baughn et al. 1961) administration, followed by the continuation 
stage for 4 months with isoniazid and rifampicin (see Table 1.1 for details) (Zumla, Nahid 
et al. 2013). This treatment was introduced in 1970s and since then no new drugs were 
developed or approved as first-line treatment for TB (Zumla, Nahid et al. 2013). The poor 
adherence to the long-lasting TB treatment is one of the causes contributing for the 
emergence of multidrug-resistant TB (MDR-TB) strains and even extensively drug-
resistant TB (XDR-TB) strains. While MDR-TB strains are resistant to at least isoniazid 
and rifampicin, XDR-TB is defined as MDR-TB plus resistance to at least one 
fluoroquinolone (such as levofloxacin or moxifloxacin) and a second-line injectable agent 
(amikacin, capreomycin or kanamycin), the two most important classes of drugs for MDR-
TB treatment (Zumla, Nahid et al. 2013, WHO 2017). MDR-TB is a public health crisis and 
a health security threat. In 2016, the WHO estimated that there were 490,000 new cases 
of MDR-TB worldwide and an average proportion of MDR-TB cases with XDR-TB of 6.2% 
(WHO 2017). 
In contrast to the standardized first-line anti-TB treatment, MDR-TB requires an 
individualized treatment preferentially planed according to several criteria, including the 
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drug resistance pattern in the local geographic region, drugs previously administered to 
the patient, underlying medical condition of the patient and the drug-associated adverse 
effects (Zumla, Nahid et al. 2013). The treatment of MDR-TB is performed with at least 
four second-line anti-TB drugs, most of them injectable, (see Table 1.1) and requires at 
least a 8 month intense phase and a total therapy duration of at least 20 months. 
The XDR-TB treatment is significantly longer than that of MDR-TB and requires the use of 
third-line anti-TB drugs (see Table 1.1) (Zumla, Nahid et al. 2013). These drugs are 
expensive and often have more side effects than the first- and second-line anti-TB drugs. 
In HIV-infected patients, XDR-TB is associated with highly mortality rates. Worldwide, only 
54% of MDR-TB and 30% of XDR-TB patients are currently successfully treated (WHO 
2017). 
Encouragingly, the development of anti-TB drugs has evolved dramatically over the past 
ten years, and novel drugs are currently in Phase III trials for the treatment of MDR-TB 
(Cole 2016). Among these, a novel member of the diarylquinoline class, named 
bedaquiline (also known as TMC207 and R207910), was the first drug with a new 
mechanism of action to be approved in over 40 years. This drug displays bactericidal 
activity in vitro against M. tuberculosis and other mycobacterial species, by inhibiting the 
c-subunit of ATP-synthase of mycobacteria with high specificity (Andries, Verhasselt et al. 
2005, de Jonge, Koymans et al. 2007, Haagsma, Podasca et al. 2011). Although the 
Phase III trial has not been completed, bedaquiline was approved in 2012 by the United 
States Food and Drug Administration (US-FDA) based on the beneficial effect observed in 
two Phase IIb trials. The accelerated approval of this new drug aims to ensure that some 
eligible patients could benefit from this new drug. However, due to limited experience on 
bedaquiline use, the treatment with this drug should be performed under defined 
conditions and patients should be closely monitored (WHO 2013, WHO 2017). Up to now, 
bedaquiline was only approved for adult patients with pulmonary MDR-TB unresponsive to 
the existing drugs and should be given in combination with the multidrug treatment 
regimen recommended by WHO. 
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Table 1.1 – Main tuberculosis drugs in clinical use and their targets. Adapted from (Zumla, Nahid 
et al. 2013, Wishart, Feunang et al. 2017).  
Drug (year of discovery) Effect Target 
First-line drugs  
Isoniazid (1952) Inhibits mycolic acid biosynthesis Enoyl-[acyl-carrier-protein] reductase 
Rifampicin (1966) Inhibits transcription  -subunit of RNA polymerase 
Pyrazinamide (1952) Inhibits translation and trans-
translation; acidifies cytoplasm 
S1 component of 30S ribosomal 
subunit 
Ethambutol (1961) Inhibits arabinogalactan biosynthesis Arabinosyl transferases 
Second-line drugs  
p-amino salicylic acid 
(1948) 
Inhibits folate biosynthesis  Dihydropteroate synthase 
Streptomycin
a
 (1944) Inhibits protein synthesis  S12 and 16S rRNA components of 
30S ribosomal subunit 
Ethionamide (1961) 
 
Inhibits mycolic acid biosynthesis Enoyl-[acyl-carrier-protein] reductase 
Ofloxacin
 
(1980) 
 
Inhibits DNA supercoiling DNA gyrase and DNA 
topoisomerase 
Capreomycin
a
 (1963) 
 
Inhibits protein synthesis Interbridge B2a between 30S and 
50S ribosomal subunits 
Kanamycin
a
 (1957)  Inhibits protein synthesis 30S ribosomal subunit 
Amikacin
a
 (1972) Inhibits protein synthesis 30S ribosomal subunit 
Cycloserine (1955) Inhibits peptidoglycan synthesis D-alanine racemase and ligase 
Third-line drugs   
Clofazimine (1954) Cell cycle disruption; inhibition of 
potassium transporters function 
DNA; potassium transporters 
Linezolid (1990s) Inhibits protein synthesis S23 rRNA component of 50S 
ribosomal subunit 
Amoxicillin (1985) plus 
clavulanate (1974)
b
 
Inhibition of cell wall synthesis Penicillin-binding protein 
Imipenem (1970s)
a
 
plus cilastatin (1995)
a,c
 
Inhibition of cell wall synthesis 
 
Penicillin-binding protein 
Clarithromycin (1980s) Inhibits protein synthesis S23 rRNA component of 50S 
ribosomal subunit 
a
Belongs to the group of injectable anti-TB drugs. 
b
Clavulanate inhibits a wide variety of β-lactamases commonly found in penicillin-resistant microorganisms, 
improving the action of amoxicillin. 
c
Cilastatin is used to prevent the hydrolysis of imipenem by renal dehydropeptidase-I, through its specific and 
reversible inhibition. 
 
1.1.2. Nontuberculous mycobacteria 
Nontuberculous mycobacteria, also called atypical mycobacteria, Mycobacterium other 
than tuberculosis (MOTT) or environmental mycobacteria (Dawson 2000), include species 
other than the M. tuberculosis complex and M. leprae and accounts for more than 170 
species from the Mycobacterium genus (LPSN, www.bacterio.net). Many of these 
ubiquitous environmental bacteria are opportunistic pathogens, capable of causing 
lymphadenopathy in children, pulmonary, skin and soft tissue infections or even 
disseminated infections, particularly in susceptible individuals (Griffith, Aksamit et al. 
2007, Piersimoni and Scarparo 2008, Henkle and Winthrop 2015). Moreover, the number 
of reported NTM infections seems to be increasing over the last decades likely as a result 
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of improved imaging techniques and new molecular sequencing methods that allow better 
identification of different mycobacterial species (Alcaide, Pena et al. 2017). On the other 
hand, several environmental causes as well as host susceptibility factors may also 
contribute for an increase in NTM infections, including population aging, increased 
incidence of chronic diseases and deficient sanitary control of water-distribution systems 
(Lopez-Varela, Garcia-Basteiro et al. 2015). 
Since NTM are exposed to several environmental challenges, they display high resilience 
against stress conditions including nutrient starvation, desiccation, pH and temperature 
variations, as well as antibiotic and disinfectant action (Falkinham 2010). These 
characteristics allowed them to colonize artificial environments such as domestic and 
hospital water distribution systems, from where they easily access susceptible hosts. 
Moreover, NTM are naturally resistant to common antibiotics and some infections do not 
even respond to aggressive anti-TB treatments (Griffith, Brown-Elliott et al. 2015, 
Shahraki, Heidarieh et al. 2015, Nunes-Costa, Alarico et al. 2016). NTM infections are 
thus becoming a considerable clinical challenge for which therapeutic solutions are 
scarce. No significant treatment advances for NTM infection in general have been recently 
accomplished and the increasing resistance of some mycobacterial species to the 
therapeutics currently in use reinforces the need of more active drug development 
(Nessar, Cambau et al. 2012). 
 
1.1.3. Mycobacterial infections and the need for drug development 
One of the major barriers in mycobacterial infection treatment is the long-duration of the 
therapy that is prone to poor adherence and ultimately promotes drug resistance. Shorter 
periods of treatment have been associated to increased relapse rates, due to the 
presence of a bacterial subpopulation that is able to survive the action of antibiotics 
(Connolly, Edelstein et al. 2007, Dhar and McKinney 2007). The surviving bacteria are 
named persisters (Lewis 2010). One of the features that lead to persistence is the ability 
of some bacteria to slow down or suspend their growth to a viable non-replicating state 
and persist for months or years in a dormant state (Corper and Cohn 1933, Lewis 2007). 
Dormancy can be induced by different stresses, such as hypoxia, nutrient starvation and 
acidification (Lipworth, Hammond et al. 2016). Unfortunately, most of the studies on 
mycobacterial dormancy were so far restricted to M. tuberculosis and M. smegmatis. 
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The antibiotics currently in use mainly counter DNA replication, or RNA, protein or cell wall 
synthesis, indispensable functions for cell growth (Kohanski, Dwyer et al. 2010). Since 
these processes are almost suppressed in dormant cells, they are more likely to survive 
even to long-term therapy. Indeed, dormant cells have been associated to post-treatment 
relapse and development of genetic resistance (Gomez and McKinney 2004, Levin and 
Rozen 2006). Targeting essential molecules for mycobacterial dormancy and resuscitation 
may be a viable path for an effective treatment of mycobacterial infections (Downing, 
Mischenko et al. 2005, Lewis 2007, Kana, Gordhan et al. 2008, Rittershaus, Baek et al. 
2013, Cano-Muniz, Anthony et al. 2018).  
Understanding more in depth the biology of mycobacteria is important to find new, shorter 
and more effective anti-mycobacterial therapies. The cell envelope of mycobacteria is 
highly complex and one of the main reasons for their success as pathogens. One of the 
most characteristic components of the cell wall are the mycolic acids. The biosynthesis of 
mycolic acids precursors seems to be somehow modulated by unique carbohydrates (see 
section 1.2), whose structural uniqueness has been seen as a source of potential 
antigens and targets for new vaccines, diagnostics and drug development. Although they 
were discovered in 1960s, their function and biosynthetic pathway are still not fully 
understood (Mendes, Maranha et al. 2012). The development of new molecular tools 
allowed identifying the genes implicated in their biosynthesis. Since some of these genes 
were shown to be essential for mycobacterial in vitro growth, they represent promising 
drug targets for new anti-mycobacterial drug development (Sassetti, Boyd et al. 2003, 
Griffin, Gawronski et al. 2011, DeJesus, Gerrick et al. 2017). 
 
 
1.1.4. Mycobacterial cell envelope 
The cell envelope of mycobacteria comprises four main layers, named inner membrane, 
periplasm, peptidoglycan-arabinogalactan layer and outer membrane (Figure 1.1) 
(Jankute, Cox et al. 2015). The inner membrane, also termed cytoplasmatic membrane, is 
composed of a phospholipid bilayer similar to that found in other bacteria. The 
cytoplasmatic membrane contains glycolipids, such as diphosphatidylglycerol (DPG) and 
phosphatidylethanolamine (PE), as well as phosphotidyl-myo-inositol (PI), which in 
contrast to the former that are found in all living organisms, is an essential phospholipid of 
eukaryotic cells (Antonsson 1997, Nikawa and Yamashita 1997) rarely found in 
prokaryotes (Kataoka and Nojima 1967, Brennan and Ballou 1968, Yano, Furukawa et al. 
1969, Brennan and Lehane 1971). The glycolipid PI is a precursor of the phosphotidyl-
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myo-inositol mannosides, from which the most abundant are the tri- and tetra-acylated 
phosphatidyl-myo-inositol dimannosides (AcPIM2 and Ac2PIM2, respectively), tri- and 
tetra-acylated phosphatidyl-myo-inositol hexamannosides (AcPIM6 and Ac2PIM6, 
respectively), lipomannan (LM) and lipoarabinomannan (LAM) (Jankute, Cox et al. 2015).  
Outside the cytoplasmatic membrane an electron-transparent periplasmatic space is 
present, displaying a typical bilayer aspect (Zuber, Chami et al. 2008). The periplasm 
contains the lipoglycans LM and LAM attached to the plasma membrane via their 
phosphatidyl-myo-inositol anchor (Chatterjee, Hunter et al. 1992, Khoo, Dell et al. 1995, 
Jankute, Grover et al. 2014). Although not represented in Figure 1.1, LM and LAM are 
also abundant in the outer membrane of mycobacteria and are key immunomodulatory 
molecules (Ortalo-Magné, Lemassu et al. 1996, Pitarque, Larrouy-Maumus et al. 2008). 
The peptidoglycan-arabinogalactan layer is composed of peptidoglycan covalently linked 
to the heteropolysaccharide arabinogalactan. The highly cross-linked network of 
peptidoglycan is one of the main structural elements of the mycobacterial cell wall, 
conferring a structural integrity to the bacterium and withstanding the osmotic pressure 
(Kaur, Guerin et al. 2009).  The peptidoglycan is covalently linked to the complex 
polysaccharide arabinogalactan by a unique α-L-rhamnopyranose–(1→3)-α-D-N-acetyl-α-
D-glucosamine-(1→P) linker unit (McNeil, Daffe et al. 1990). Arabinogalactan is esterified 
at its non-reducing end to long-chains (C70–C90) of mycolic acids (McNeil, Daffe et al. 
1991). The mycobacterial mycolyl-arabinogalactan also contains galactosamine (GalNH2) 
attached to the arabinan chains of the slow-growing mycobacteria (Draper, Khoo et al. 
1997), or succinyl  groups attached to the non-mycolylated arabinogalactans of rapid and 
slow-growing mycobacteria (Bhamidi, Scherman et al. 2008). Altogether, the complex of 
peptidoglycan, arabinogalactan and mycolic acids, known as mycolyl-arabinogalactan-
peptidoglycan (mAGP) complex, is usually referred as the cell wall core of mycobacteria 
(Jackson 2014, Jankute, Cox et al. 2015).  
Mycolic acids are long chain (C60-C90) α-alkyl-β-hydroxy fatty acids and components of the 
electron-dense outer membrane of mycobacteria. These unique fatty acids have three 
distinct subclasses, termed α-, methoxy- and keto- mycolic acids (Watanabe, Aoyagi et al. 
2001, Watanabe, Aoyagi et al. 2002). Although unique, mycolic acids are not exclusive to 
mycobacteria as they were also found in other related genera such as Nocardia, 
Rhodococcus and Corynebacterium (Marrakchi, Laneelle et al. 2014). Beside mycolic 
acids, the outer membrane of mycobacteria also contains extractable lipids, including 
trehalose monomycolates, trehalose dimycolates, phthiocerol dimycocerosate (PDIM), 
sulfoglycolipids (SGL), diacyltrehaloses (DAT), polyacyltrehaloses (PAT), phenolic 
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glycolipids and lipooligosaccharides (Jackson 2014). Some of these lipids are almost 
limited to pathogenic mycobacteria, such as PDIM (Jackson, Stadthagen et al. 2007).  
Also, DAT and PAT seem to be limited to the virulent isolates of M. tuberculosis complex 
and SGL were exclusively found in M. tuberculosis (Jackson, Stadthagen et al. 2007, 
Layre, Paepe et al. 2011, Nobre, Alarico et al. 2014). The components of the 
mycobacterial outer membrane were proposed to be organized in two leaflets (Minnikin 
1982, Rastogi, Hellio et al. 1991, Hoffmann, Leis et al. 2008, Zuber, Chami et al. 2008), 
with the mycolic acids packed in a monolayer and oriented perpendicular to the plasma 
membrane (Nikaido, Kim et al. 1993). While the mycolic acids form the inner leaflet, the 
other lipids form the outer leaflet with their fatty acid chains intercalating into the mycolic 
acid layer (Minnikin 1982, Hoffmann, Leis et al. 2008, Zuber, Chami et al. 2008).  
An additional layer at the outermost compartment of the cell envelope, termed capsule, 
seems to be present in the pathogenic mycobacterial species (Chapman, Hanks et al. 
1959, Daffe and Draper 1998). The components of this capsule-like structure are loosely 
attached and include polysaccharides, proteins and a small fraction of lipids (Seibert 
1949, Lemassu and Daffé 1994, Ortalo-Magne, Dupont et al. 1995, Sani, Houben et al. 
2010). 
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Figure 1.1 – Schematic representation of the mycobacterial cell envelope. The abbreviations are: 
Ac/Ac2PIM2, tri-/tetra-acylated phosphatidyl-myo-inositol-dimannosides; Ac/Ac2PIM6, tri-/tetra-
acylated phosphatidyl-myo-inositol-hexamannosides; AG, arabinogalactan; DAT, diacyltrehalose; 
DPG, diphosphatidylglycerol; GalNH2, galactosamine; k, keto; LAM, lipoarabinomannan; LM, 
lipomannan; m, methoxyl; PDIM, phthiocerol dimycocerosate; PE, phosphatidylethanolamine; PG, 
peptidoglycan; PI, phosphatidyl-myo-inositol; PAT, polyacyltrehalose; SGL, sulfoglycolipid. The α-L-
rhamnopyranose–(1→3)-α-D-N-acetyl-α-D-glucosamine-(1→P) linker unit is indicated. Adapted 
from (Jankute, Cox et al. 2015). 
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1.2. Polymethylated polysaccharides 
Polymethylated polysaccharides (PMPSs) are a family of unusual carbohydrates unique to 
the order Actinomycetales (Jackson and Brennan 2009). These cytoplasmatic 
(lipo)polysaccharides are composed of 10 to 20 sugar units, many of which partially O-
methylated, which contributes to their hydrophobicity. In mycobacteria two classes of 
PMPSs were found, named 3-O-methylmannose polysaccharides (MMPs) (Gray and 
Ballou 1971, Maitra and Ballou 1977) and 6-O-methylglucose lipopolysaccharides 
(MGLPs) (Lee and Ballou 1964, Lee 1966) (Figure 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 – Structures of mycobacterial PMPSs. A – MGLP from M. bovis BCG. B – MMP from M. 
smegmatis. R1, R2 and R3 represent octanoate, succinate and acetate groups, respectively (blue). 
Methyl groups are coloured green. Adapted from (Mendes, Maranha et al. 2012, Maranha, 
Moynihan et al. 2015).  
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MMPs are linear chains of 10 to 13 α-(1→4)-linked 3-O-methyl-D-mannoses, containing a 
single α-(1→4)-linked unmethylated D-mannose at the non-reducing end and an α-methyl 
aglycon at the reducing end (Figure 1.2B) (Maitra and Ballou 1977).  Structurally, MGLPs 
display higher complexity compared to MMPs. MGLPs are composed of α-(1→4)-linked 
glucose and 6-O-methylglucose units, terminated at the non-reducing end by a 3-O-
methylglucose unit and at the reducing end by an α-(1→6)-linked α-D-glucopyranosyl-(1, 
2)-D-glycerate  (Figure 1.2A) (Tuffal, Albigot et al. 1998). Also, two β-(1→3)-linked 
branching glucoses are present at the first and third glucoses of the MGLPs main chain 
(Tuffal, Albigot et al. 1998). MGLPs are composed of 15 to 20 sugar units that may 
possess variable chemical modifications with acyl groups, including acetate, propionate 
and isobutyrate, at the glucose units close to the non-reducing end, and succinate, 
esterified to the branching glucose units (Keller and Ballou 1968, Smith and Ballou 1973). 
An octanoate modification is also present close to the reducing end of MGLPs, likely at 
the atom O6 of the second glucose unit (Smith and Ballou 1973, Maranha, Moynihan et al. 
2015). An unusual monosaccharide, named 2-N-acetyl-2,6-dideoxy-β-glucopyranose, was 
so far identified only in the MGLP of M. bovis BCG (Tuffal, Albigot et al. 1998). 
While MMPs have been isolated from multiple non-pathogenic RGM species, such as M. 
smegmatis and M. phlei, MGLPs have been found in both RGM and SGM species (Table 
1.2). Interestingly, MMPs were never detected in SGM, raising the hypothesis that this 
group of organisms might be unable to produce mannosylated PMPSs. Moreover, the 
ability of both RGM and SGM, as well as of other members of the Actinobacteria phylum, 
to produce MGLPs, indicates that their biosynthesis must be fundamental for 
mycobacterial survival. Although PMPSs were first isolated in 1960s (Lee and Ballou 
1964, Lee 1966, Keller and Ballou 1968), the knowledge about PMPS function (see 
section 1.2.1) and biogenesis (see sections 1.2.2 and 1.2.3) is still limited.  
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Table 1.2 – Distribution of PMPSs among mycobacteria and other related genera. 
Species MGLPs MMPs Growth type References 
Mycobacterium     
M. smegmatis   Rapid-growing (Keller and Ballou 1968, 
Bergeron, Machida et al. 
1975, Weisman and Ballou 
1984, Kamisango, Dell et al. 
1987) 
M. phlei   Rapid-growing (Lee 1966, Saier and Ballou 
1968, Gray and Ballou 
1971, Weisman and Ballou 
1984) 
M. parafortuitum   Rapid-growing (Weisman and Ballou 1984) 
M. aurum (M. 
cuneactum, M. 
petrophilum) 
  Rapid-growing (Weisman and Ballou 1984) 
M. chitae   Rapid-growing (Weisman and Ballou 1984) 
M. vaccae   Rapid-growing (Tian, Li et al. 2000) 
M. tuberculosis   Slow-growing (Lee 1966) 
M. bovis   Slow-growing (Tuffal, Albigot et al. 1998) 
M. leprae   Slow-growing (Hunter, Gaylord et al. 1986) 
M. xenopi   Slow-growing (Tuffal, Ponthus et al. 1995) 
Nocardia     
N. otitidis-caviarum    (Pommier and Michel 1986) 
N. brasiliense    (Pommier and Michel 1986) 
N. farcinica    (Pommier and Michel 1986) 
N. kirovani    (Pommier and Michel 1986) 
N. corallina n.d.   (Saier and Ballou 1968) 
Streptomyces     
S. griseus    (Candy and Baddiley 1966, 
Harris and Gray 1977) 
Corynebacterium     
“C. adiphtheriae” n.d.   (Pommier and Michel 1986) 
C. pseudodiphtheriticum n.d.   (Pommier and Michel 1986) 
C. xerosis n.d.   (Saier and Ballou 1968) 
Propionibacterium     
P. shermanii n.d.   (Saier and Ballou 1968) 
n.d. not demonstrated. 
 
 
1.2.1. Physiological role 
The PMPSs were proposed to play a role in fatty acid biosynthesis, with MMPs and 
MGLPs sharing similar properties. In vitro, PMPSs are able to form stable 1:1 ratio 
complexes with fatty acyl-coenzyme A (acyl-CoA) derivatives, preferentially with chain 
length ranging from C16 to C22 (Machida and Bloch 1973). Also, PMPSs seem to increase 
the overall rate of fatty acid synthesis by fatty acid synthase I (FAS-I) and shift the length 
of synthesized chains from long (C20-24) to short (C14-18) (Ilton, Jevans et al. 1971, Flick 
and Bloch 1974, Wood, Peterson et al. 1977). In agreement, PMPSs markedly lower the 
Km of FAS-I for acyl-CoA substrates, which enable fatty acids biosynthesis to proceed at 
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low substrate concentrations, as well as may shift product distribution in favour of more 
rapidly diffusing short-chain fatty acid products (Ilton, Jevans et al. 1971, Vance, 
Mitsuhashi et al. 1973, Banis, Peterson et al. 1977). On the other hand, PMPSs seem to 
facilitate the release of de novo synthetized fatty acid chains by sequestering them from 
FAS-I, contributing for enzyme turnover and earlier termination of fatty acid chain 
elongation (Banis, Peterson et al. 1977). 
PMPSs were also proposed to act as fatty acyl carriers, regulating their processing for the 
synthesis of longer, and more complex and insoluble fatty acids, including mycolic acids, 
by increasing the mycobacteria tolerance to high cytoplasmatic concentrations of these 
compounds (Kawaguchi and Bloch 1976, Yabusaki and Ballou 1979, Mita and Yasumasu 
1981), as well as protecting them from enzymatic degradation (Yabusaki and Ballou 
1979). These findings are also in agreement with the proposed PMPS structure (Figure 
1.3). Both MMPs and MGLPs were proposed to adopt a coiled conformation in solution, 
with a hydrophobic interior determined by the inward projection of the methyl groups, in 
which PMPSs can accommodate their hydrophobic ligands. (Bergeron, Machida et al. 
1975, Yabusaki and Ballou 1978, Yabusaki, Cohen et al. 1979, Maggio 1980, Tuffal, 
Ponthus et al. 1995). Thus, PMPS may physically avoid the access of enzymes to the 
fatty acids, while coating fatty acids with a hydrophilic surface that increases their 
solubility. More recently, molecular dynamic simulations revealed that the MMP helix with 
a hydrophobic channel lined by methyl groups immediately unfolds into disordered 
conformations and results in unrealistic carbohydrate ring conformations (Liu, Siuda et al. 
2016). A lower energy conformation was found for helical MMP with 3-O-methyl groups 
along the outside of the helical axis. When bound to fatty acid chain, hydrophilic hydroxyl 
and 3-O-methyl groups of MMP are solvent exposed and shield the fatty acid chain from 
water molecules (Figure 1.3A). Molecular dynamic simulations also pointed for the lower 
energy required for MMP-fatty acid complex when the carboxyl group of the fatty acid is 
oriented towards the reducing end of MMP (Liu, Siuda et al. 2016). 
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Figure 1.3 – Three-dimensional representation of PMPSs. A – Structural model of a lauric acid 
molecule (spheres) bound to a MMP chain (sticks), whose methyl groups are indicated by black 
arrows. Adapted from (Liu, Siuda et al. 2016). B – Structural model of the stearic acid (green 
spheres) bound to a 6-O-methylglucose polysaccharide chain containing 20 glucose units, of which 
12 are O-methylated (sticks). Adapted from (Jackson and Brennan 2009). 
 
However, physiological evidence for the role of PMPSs in lipid metabolism regulation is 
still limited. A M. smegmatis spontaneous mutant with half of the wild-type production of 
MGLPs and only residual production of MMPs displayed no significant change in fatty 
acids synthesis, and surprisingly showed higher accumulation of short-chain fatty acids 
instead of the expected long-chain fatty acids (Maloney and Ballou 1980). Since the 
production of fatty acids still occurred in near absence of MMPs, MGLPs are likely to 
display a more important role in fatty acids metabolism than MMPs. 
PMPSs may also play a role in mycobacterial thermal adaptation. Indeed, it was observed 
that mutants with limited production of MGLPs were more sensitive to high temperatures, 
displaying a lower growth rate or inability to grow at temperatures usually well tolerated by 
the wild-type strain (Stadthagen, Sambou et al. 2007). The growth temperature seems 
also to influence the production of mycolic acids. During growth at high temperatures, 
increased synthesis of long-chain mycolic acids and a decrease in unsaturated fatty acids 
were observed for M. phlei (Toriyama, Yano et al. 1980). In agreement, an increase in 
short-chain mycolic acids synthesis, with a concomitant decrease in long-chain mycolic 
acids production, were observed for M. smegmatis growing at low temperatures (Baba, 
Kaneda et al. 1989). Since PMPS-deficient strains are more sensitive to temperature and 
the proportion of short to long fatty acid chains is temperature-dependent, PMPSs are 
likely involved in thermal adaptation by modulating fatty acid chain length. 
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Therefore, the physiological role of these unique PMPSs in fatty acids metabolism still 
needs to be clarified. Also, the existence of two types of PMPSs apparently with 
redundant functions in some mycobacteria is puzzling. For a better understanding of 
PMPSs physiological role it is necessary to identify the genes involved in PMPSs 
biosynthesis, to evaluate their relevance in bacterial survival and virulence, and to 
characterize functional and structurally their coding proteins.    
 
1.2.2. MMP biosynthesis 
The currently knowledge on the biosynthesis of MMPs is limited to the work performed by 
Ballou’s research group from 1970s to 1980s and more recently by the Lowary laboratory 
(Xia, Zheng et al. 2012, Xia 2013). A model for MMP biosynthesis was proposed after the 
isolation of MMP precursors (Maitra and Ballou 1977, Yamada, Cohen et al. 1979) and 
the characterization of an α-(1,4)-mannosyltransferase (ManT) (Weisman and Ballou 
1984) and a 3-O-methyltransferase (MeT) (Weisman and Ballou 1984) from M. smegmatis 
cell-free extracts. According to the proposed model, MMPs are likely to be elongated by a 
linear alternating process of mannosylation and O-methylation, using GDP-mannose as 
sugar donor and S-adenosylmethionine (SAM) as source of methyl groups (Figure 1.4) 
(Weisman and Ballou 1984). 
When the MMP chain reaches 10 to 13 units of 3-O-methylmannose the elongation 
process ends (Maitra and Ballou 1977). At this length, the polysaccharide displays good 
fatty acid-binding properties and the MMP-fatty acid complex is no longer available as 
substrate for MeT, resulting in the termination of the elongation reaction (Weisman and 
Ballou 1984). Also, since the Km of MeT for the polysaccharide-fatty acid complex is 
significantly higher than that of ManT, the MMP chain ends with an unmethylated 
mannose (Weisman and Ballou 1984).  
The MMP biosynthetic gene cluster of M. smegmatis mc2155 was recently proposed (Xia 
2013). This cluster includes three genes predicted to encode for an α-(1,4)-
mannosyltransferase (MSMEG_6484), a 3-O-methyltransferase (MSMEG_6483) and 
another methyltransferase (MSMEG_6482). The function of a recombinant MSMEG_6484 
encoding protein was evaluated in vitro and confirmed to display α-(1,4)-
mannosyltransferase activity (Xia 2013). 
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Figure 1.4 – Proposed MMP biosynthetic pathway. The proposed pathway for MMP biosynthesis 
involves the sequential mannosylation and methylation reactions performed by a α-(1,4)-
mannosyltransferase (ManT) and a 3-O-methyltransferase (MeT), respectively. The ManT uses 
GDP-mannose as mannose donor, whereas MeT uses S-adenosylmethionine (SAM) as source of 
methyl groups, releasing S-adenosyl-homocysteine (SAH). The elongation ends when the MMP is 
long enough (10 to13 mannose units) to bind fatty acids and is no longer available as substrate for 
MeT. Adapted from (Stadthagen, Sambou et al. 2007). 
 
1.2.3. MGLP biosynthesis 
The steps that led to MGLP formation started to be defined after the partial purification 
and characterization of a methyltransferase able to transfer methyl groups from SAM to 
glucose units of the polysaccharide (Ferguson and Ballou 1970, Grellert and Ballou 1972), 
and of an acyltransferase that catalysed the acylation of MLGP with acetyl, propionyl, 
isobutyl, succinyl and octanoyl groups from acyl-CoA derivatives (Tung and Ballou 1973). 
The acylation and methylation steps were proposed to occur together during the synthesis 
of MGLPs, with one process affecting the extent and direction of the other (Grellert and 
Ballou 1972). Approximately 14 years later, free 2-O-(α-D-glucopyranosyl)-D-glycerate 
(glucosylglycerate, GG) and α-D-glucopyranosyl-(1→6)-α-D-glucopyranosyl-(1→2)-D-
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glycerate [α-(1→6)-diglucosylglycerate, α-(1→6)-DGG] were detected in cell extracts of M. 
smegmatis and were considered the precursors of MGLPs (Kamisango, Dell et al. 1987). 
A new biosynthetic mechanism was proposed, in which MGLP elongation would occur 
stepwise through sequential glucosylation and methylation reactions from the reducing 
end to the non-reducing end (Kamisango, Dell et al. 1987). 
Although the pathway leading to the production of MGLPs is still not fully understood, the 
availability of the whole-genome sequence of M. tuberculosis and of closely related 
microorganisms, as well as the development of tools for genetic manipulation of 
mycobacteria, have significantly contributed to the identification and functional 
characterization of the genes potentially involved in MGLP biosynthesis. 
 
1.2.3.1. Initiation of the pathway 
It is currently accepted that the MGLP pathway is initiated by the production of glucosyl-3-
phosphoglycerate (GPG) by the glucosyl-3-phosphoglycerate synthase (GpgS), using 
UDP-glucose as donor substrate and 3-phosphoglyceric acid (3-PGA) as acceptor 
substrate (Figure 1.5). This GpgS activity was initially identified in methanogenic archaea 
and in hyperthermophilic bacteria (Costa, Empadinhas et al. 2006, Costa, Empadinhas et 
al. 2007). The non-homologous mycobacterial GpgS was identified 1 year later: 
recombinant enzymes from M. smegmatis and M. bovis BCG were biochemically 
characterized (Empadinhas, Albuquerque et al. 2008), and the crystallographic structure 
of a recombinant M. tuberculosis GpgS was determined (Figure 1.6A) (Pereira, 
Empadinhas et al. 2008), being the first enzyme of the MGLP pathway to have its three-
dimensional structure unveiled. In M. tuberculosis H37Rv, this enzyme is encoded by the 
Rv1208 gene that was considered essential for mycobacterial in vitro growth (Sassetti, 
Boyd et al. 2003, Griffin, Gawronski et al. 2011, DeJesus, Gerrick et al. 2017). Also, the 
inactivation of the Rv1208 ortholog in M. smegmatis dramatically decreased the MGLP 
levels, suggesting the involvement of this gene in MGLP biosynthesis (Kaur, Pham et al. 
2009). Other studies followed to better characterize this enzyme, including site-directed 
mutagenesis (Kumar, Guan et al. 2014) and co-crystallization with substrates (Albesa-
Jove, Mendoza et al. 2015, Albesa-Jove, Romero-Garcia et al. 2017), which allowed a 
more clear understanding of the molecular details of the reaction. 
The reaction product of GpgS is subsequently dephosphorylated by the glucosyl-3-
phosphoglycerate phosphatase (GpgP), producing GG. In M. tuberculosis, the GpgP 
  Chapter 1 
42 
 
activity was associated to the Rv2419c gene (Mendes, Maranha et al. 2011), which was 
considered non-essential for mycobacterial growth since mycobacteria lacking this gene 
were still able to grow in vitro (Sassetti, Boyd et al. 2003, Griffin, Gawronski et al. 2011, 
DeJesus, Gerrick et al. 2017). Nevertheless, no studies were performed to evaluate the 
impact of Rv2419c-disrupted gene in bacterial virulence and survival in the host, as well 
as in MGLP production. Although Rv2419c was first annotated as coding for a putative 
phosphoglycerate mutase, GpgP was proved recently to display only residual mutase 
activity (Mendes, Maranha et al. 2011). The recombinant GpgP from M. tuberculosis 
displays dephosphorylating activity against mannosyl-3-phosphoglycerate, 
mannosylglucosyl-3-phosphoglycerate and, with much higher specificity, against GPG 
(Mendes, Maranha et al. 2011). Highlighting its function, it was reclassified as glucosyl-3-
phosphoglycerate phosphatase (EC 3.1.3.85). In this thesis, the structure of GpgP is 
elucidated, as well as the molecular details of substrate binding and catalysis (Chapter 2). 
For this reason, the histidine phosphatase superfamily to which GpgP belongs is 
described in more detail in section 1.3. 
 
1.2.3.2. MGLP Elongation 
As initially proposed, GG is considered the precursor of α-(1→6)-DGG that in turn is the 
starting moiety for the α-(1→4)-glycosidic elongation of MGLP (Kamisango, Dell et al. 
1987). The gene Rv3032, coding for a α-(1→4)-glycosyltransferase, was proposed to be 
involved in MGLP elongation (Stadthagen, Sambou et al. 2007). This gene displays a 
limited distribution within prokaryotes, with orthologs only among mycobacteria species. 
Moreover, the disruption of gene Rv3032 led to impairment of mycobacterial in vitro 
growth (Sassetti, Boyd et al. 2003, Griffin, Gawronski et al. 2011, DeJesus, Gerrick et al. 
2017). The mutation of this gene in M. smegmatis conduced to a significant reduction of 
MGLP production, concomitant with a reduction of MGLP chain length (Stadthagen, 
Sambou et al. 2007). In agreement, the introduction of an exogenous gene to the Rv3032-
deficient strain restored the production of MGLP and shifted the MGLP length towards the 
mature forms (Stadthagen, Sambou et al. 2007). Although Rv3032 seems to be clearly 
involved in MGLP biosynthesis, the low levels of MGLP that were found in the RV3032-
deficient strain suggest that a compensatory mechanism may exist, and that another gene 
may partially replace Rv3032 function. Indeed, a second gene (Rv1212c) encoding an α-
(14)-glycosyltransferase (GlgA) and known to be involved in glycogen and capsular 
glucan synthesis was shown to compensate the absence of gene Rv3032 (Sambou, 
Dinadayala et al. 2008). However, unlike the Rv3032 mutant, the Rv1212c-disrupted 
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strain was still able to produce wild-type amounts of MGLP. Curiously, overexpression of 
gene Rv3032 fully restored the production of glucan synthesis in the Rv1212c mutant 
(Sambou, Dinadayala et al. 2008). Also, the Rv3032 mutant revealed an important 
decrease in glycogen content compared to the wild-type strain (Stadthagen, Sambou et al. 
2007). Therefore, these two genes seem to have partially redundant functions, although 
Rv1212c seems to be preferentially used for glucan synthesis, whereas Rv3032 is 
preferred to synthetize glycogen and MGLP. A double knockout mutant for genes 
Rv1212c and Rv3032 was never recovered, suggesting that at least one of these genes is 
strictly essential for mycobacterial survival (Sambou, Dinadayala et al. 2008). 
Rv3032 is separated by only 32 bp from gene Rv3031, suggesting that they might be 
expressed together. Gene Rv3031 was reported as essential for mycobacterial in vitro 
growth (Sassetti, Boyd et al. 2003, Griffin, Gawronski et al. 2011, DeJesus, Gerrick et al. 
2017). Up to date, only a single study highlighted the contribution of Rv3031 for MGLP 
biosynthesis. Disruption of the M. smegmatis MSMEG_2349 gene induced a significant 
reduction in MGLP cell content and shifted the chain type production from mature to short 
polysaccharide chains (Stadthagen, Sambou et al. 2007). MSMEG_2349 is an ortholog of 
Rv3031, with MSMEG_2349 and Rv3031 encoding proteins sharing 80% sequence 
identity for 99% sequence coverage (Kapopoulou, Lew et al. 2011). This suggested that 
Rv3031 might be implicated in MGLP production, however unequivocal functional 
evidence is still needed. The Rv3031 gene displays sequence similarity with enzymes 
from the glycoside hydrolase family 57 (GH57) (CAZy database, 
http://www.cazy.org/Glycoside-Hydrolases.html). Within GH57 there are two structurally 
characterized enzymes that catalyse α-(1→6)-branching points in polysaccharides (EC 
2.4.1.18). These proteins are produced by Thermococcus kodakaraensis (Murakami, 
Kanai et al. 2006, Santos, Tonoli et al. 2011) and Thermus thermophilus (Palomo, Pijning 
et al. 2011) and with which Rv3031-encoding protein displays 30 and 34% sequence 
identity, respectively. Although the sequence identity is relatively low, the overall structure 
and function are usually better preserved. Therefore, Rv3031 is a potential candidate for 
α-(1→6)-DGG synthesis. The proposed mechanism for the T. thermophilus branching 
enzyme suggests that this enzyme acts on α-(1→4)-linked polysaccharide, hydrolysing 
the α-(1→4)-linkage and promoting a new α-(1→6)-linkage between the same sugar units 
(Palomo, Pijning et al. 2011). If the Rv3031-encoding enzyme catalyses the α-(1→6)-
DGG formation through an identical mechanism, it is likely that a α-D-glucopyranosyl-
(1,4)-α-D-glucopyranosyl-(1,2)-D-glycerate (α-(1→4)-DGG) molecule precedes the 
reported α-(1→6)-DGG. 
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In close vicinity to Rv3031 and Rv3032, there are three additional genes coding for two 
putative S-adenosylmethionine-dependent methyltransferases (Rv3030 and Rv3037c) 
and one putative acyltransferase (Rv3034c), which are also likely to play a role in MGLP 
biosynthesis (Stadthagen, Sambou et al. 2007). Analysis of gene essentiality by Himar1-
based transposon mutagenesis indicated that Rv3030 (Sassetti, Boyd et al. 2003, Griffin, 
Gawronski et al. 2011, DeJesus, Gerrick et al. 2017) and Rv3034c (Griffin, Gawronski et 
al. 2011, DeJesus, Gerrick et al. 2017) are essential for mycobacterial in vitro growth. 
Although Rv3037c was considered non-essential for mycobacterial in vitro growth 
(Sassetti, Boyd et al. 2003, DeJesus, Gerrick et al. 2017), this gene was predicted to be 
required for mycobacterial survival in macrophages (Rengarajan, Bloom et al. 2005). 
Recently, the function of gene Rv2418c (adjacent to the GpgP-encoding gene) was 
elucidated by in vitro analysis of the activity of recombinant protein orthologs from M. 
smegmatis and M. hassiacum (Maranha, Moynihan et al. 2015). This gene encodes an 
acyltransferase, named octanoyltransferase (OctT), that transfers in vitro the ester groups 
from octanoyl- and hexanoyl-CoA preferentially to the α-(1→6)-DGG (Maranha, Moynihan 
et al. 2015). Since methylation of MGLP was only observed for partially acylated gluco-
oligosaccharides (Grellert and Ballou 1972), OctT may be responsible for the initial 
acylation of the polysaccharide required for 6-O-methylation to occur. Although gene 
Rv2418c was considered essential for mycobacterial in vitro growth (Sassetti, Boyd et al. 
2003, Griffin, Gawronski et al. 2011), a more recent study reported only an in vitro growth 
defect for a Rv2418c-disrupted strain (DeJesus, Gerrick et al. 2017).  
An octanoyl group was previously suggested to be present at the glycerate moiety of 
MGLP (Smith and Ballou 1973), however the analysis of the reaction product obtained in 
vitro by OctT showed that octanoate was added to the O6 atom of the second glucose unit 
of α-(1→6)-DGG (Maranha, Moynihan et al. 2015). The presence of octanoate at atom O6 
may impair the addition of a new α-(1→6)-linked glucose, directing to α-(1→4)-glucan 
elongation. Distinct acyl groups were initially proposed to be added to MGLP by a single 
enzyme, however the same report showed that octanoyl-CoA is a poor substrate for the 
acetyltransferase enzyme preparation analysed (Tung and Ballou 1973). In contrast, OctT 
displays in vitro significantly lower efficiency for shorter chain fatty acids (Maranha, 
Moynihan et al. 2015). Altogether, these studies suggest that more than one 
acyltransferase may be required for MGLP maturation. As previously mentioned, the 
Rv3034c gene is likely to encode an acyltransferase, and due to its localization in the 
mycobacterial genome its transcription may occur simultaneously to other MGLP 
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biosynthetic enzymes. Therefore, Rv3034c is a promising candidate for catalysing an 
acylation reaction other than octanylation using MGLP as acceptor substrate. 
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Figure 1.5 – Proposed pathways for MGLP biosynthesis. The GpgS-GpgP and TreS-Mak-GlgE 
pathways are highlighted in blue and wheat, respectively. The enzymes catalysing the indicated 
reactions and their encoding genes are in bold and italic, respectively. The genes with question 
marks were proposed to be involved in the corresponding reaction. Essential genes are coloured 
red. Enzymes marked with an asterisk were characterized structurally. The glycosylation, 
methylation and most of the acylation reactions occur at unknown stages of MGLP biosynthesis. 
Methyl and acyl groups [octanoate (R1), succinate (R2), and acetate, propionate and isobutyrate 
(R3)] are coloured in green and blue, respectively. A GgH, apparently restricted to rapid-growing 
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mycobacteria, may be responsible for GG recycling (dashed line). The enzymes structurally 
characterized in this thesis are in dotted squares. The abbreviations are: 3-PGA, 3-
phosphoglyceric acid; α-(1→4)-GT, α-(1→4)-glucosyltransferase; α-(1→6)-DGG, α-(1→6)-
diglucosylglycerate; β-(1→3)-GT, β-(1→3)-glucosyltransferase; AcT, acetyltransferase; GG, 
glucosylglycerate; GgH, glucosylglycerate hydrolase; glucose-1P, glucose-1-phosphate; GPG, 
glucosyl-3-phosphoglycerate; GpgP, glucosyl-3-phosphoglycerate phosphatase; GpgS, glucosyl-3-
phosphoglycerate synthase; maltose-1P, maltose-1-phosphate; Mak, maltokinase; MeT, 
methyltransferase; OctT, octanoyltransferase; TreS, trehalose synthase; SAM, S-
adenosylmethionine; SAH, S-adenosyl-homocysteine. Adapted from (Mendes, Maranha et al. 
2012, Alarico, Costa et al. 2014, Maranha, Moynihan et al. 2015). 
 
1.2.3.3. Alternative pathway  
An alternative pathway for MGLP biosynthesis has also been hypothesized, starting with 
the disaccharide trehalose (Figure 1.5) (Kalscheuer, Syson et al. 2010). This pathway 
seems to be controlled by three genes: Rv0126, Rv0127, and Rv1327c, coding for a 
trehalose synthase (TreS), a maltokinase (Mak), and a maltosyltransferase (GlgE), 
respectively. Three studies have evaluated the essentiality of these genes by Himar1-
based transposon mutagenesis (Sassetti, Boyd et al. 2003, Griffin, Gawronski et al. 2011, 
DeJesus, Gerrick et al. 2017). While Rv1327c was considered an essential gene for 
mycobacterial in vitro growth in all these studies, the essentiality of Rv0126 and Rv0127 
was only reported by two (Sassetti, Boyd et al. 2003, Griffin, Gawronski et al. 2011) and 
one (Griffin, Gawronski et al. 2011) of them, respectively. An in vivo study linked the 
Rv1327c essentiality to the accumulation of toxic levels of maltose-1-phosphate (maltose-
1P) in a Rv1327c-deleted mutant (Kalscheuer, Syson et al. 2010). 
This alternative pathway involves three enzymatic steps, including the conversion of 
trehalose into maltose by TreS (Figure 1.6B) (Caner, Nguyen et al. 2013, Miah, Koliwer-
Brandl et al. 2013), followed by maltose phosphorylation by Mak (Figure 1.6C) (Mendes, 
Maranha et al. 2010, Roy, Usha et al. 2013, Li, Guan et al. 2014, Fraga, Maranha et al. 
2015) and finally the transference of the maltose moiety from maltose-1P to the non-
reducing end of α-1,4-glucans by GlgE (Figure 1.6D) through an α-retaining catalytic 
mechanism (Kalscheuer, Syson et al. 2010, Syson, Stevenson et al. 2011, Lindenberger, 
Veleti et al. 2015). This alternative pathway is dispensable for viability and virulence as 
long as the GpgS-GpgP pathway is functioning. Indeed, the simultaneous inhibition of 
both pathways proved to be lethal for M. tuberculosis H37Rv (Kalscheuer, Syson et al. 
2010). GlgA, one of the candidates for MGLP elongation (section 1.2.3.2), was recently 
  Chapter 1 
48 
 
demonstrated to catalyse the formation of maltose-1P using ADP-glucose and glucose-1-
phosphate (glucose-1P) as donor and acceptor substrates, respectively (Koliwer-Brandl, 
Syson et al. 2016). Furthermore, GlgA was clearly more efficient in catalysing the 
formation of the maltose-1P than in elongating the non-reducing ends of glycogen using 
ADP-glucose as a donor substrate, suggesting that mycobacterial GlgA may play only a 
minor direct role in α-glucan elongation (Koliwer-Brandl, Syson et al. 2016).  
The gene coding for GlgE is adjacent to a gene encoding an α-1,6-branching enzyme 
(Rv1327c) that is also suspected to be implicated in MGLP pathway. This glycogen 
branching enzyme, named GlgB (EC 2.4.1.18), catalyses the introduction of α-(1→6)-
linked branches into linear α-1,4-glucans. Its coding gene was found essential for 
mycobacterial survival (Sambou, Dinadayala et al. 2008) and later on, its essentiality was 
linked to the intracellular accumulation of maltose-1P (Kalscheuer, Syson et al. 2010, 
Miah, Bibb et al. 2016). It was hypothesized that in the absence of GlgB, the activity of 
GlgE is limited by the availability of acceptor substrate, leading to toxic build-up of 
maltose-1P (Kalscheuer, Syson et al. 2010).  
The assembly mechanism of α-glucans by GlgE and GlgB was proposed recently 
(Rashid, Batey et al. 2016). According to this mechanism, the polysaccharide synthesis is 
initiated by GlgE and its donor substrate maltose-1P. GlgE yields a linear polysaccharide 
sufficiently long (16 sugar units) for GlgB to introduce a branch. The branching by M. 
tuberculosis GlgB seems to be strictly intrachain. After branching, GlgE preferentially 
extends the new chain until it is long enough to undergo a new GlgB branching. These 
simultaneous events generate the arboreal structure of the α-glucans. The length of α-
glucans is likely controlled by the ability of GlgE to catalyse a disproportionation reaction 
through maltosyl transference between malto-oligosaccharides. The M. tuberculosis GlgB 
transfers maltosyl units from a donor to an acceptor polysaccharide, both at least four 
sugar units long (Kalscheuer, Syson et al. 2010). During MGLP biosynthesis, the activity 
of GlgB may be limited by the methyl and acyl groups introduced at atom O6 of the 
glucose units. 
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Figure 1.6 – Three-dimensional structure of mycobacterial GpgS, TreS, Mak and GlgE. The α-
helices and β-strands of M. tuberculosis GpgS (A, PDB accession code 3E26), M. smegmatis TreS 
(B, PDB accession code 3ZO9), M. tuberculosis Mak (C, PDB accession code 4O7O) and M. 
tuberculosis GlgE (D, PDB accession code 4U33) are represented by cylinders and flat arrows, 
respectively. Oligomerization is highlighted in different colour shades. 
 
1.2.3.4. GG bioversatility and potential roles 
Glucosylglycerate, one of the earlier intermediates in MGLP biosynthesis, is widespread 
among microorganisms. At least four distinct GG-containing molecules are known, 
including MGLPs, α-(1→6)-DGG, mannosylglucosylglycerate (MGG) and GG-containing 
glycolipids (Nunes-Costa, Maranha et al. 2017). The first GG-containing molecules to be 
described were the MGLPs (Lee 1966), which have been isolated from several species of 
Mycobacterium, Nocardia and Streptomyces genera (Table 1.2). α-(1→6)-DGG, also a 
precursor of the mycobacterial MGLPs, was found in the hyperthermophilic bacterium 
Persephonella marina, which seems to accumulate α-(1→6)-DGG as a response to salt 
stress (Lamosa, Rodrigues et al. 2013). Up to now, GG-containing glycolipids were only 
isolated from Nocardia caviae (Pommier and Michel 1981). The most recently discovered 
GG-containing molecule, MGG, was detected for the first time in thermophilic anaerobic 
bacterium Petrotoga miotherma (Jorge, Lamosa et al. 2007) and later in Petrotoga mobilis 
and mesophilic Rhodopirellula baltica (Fernandes, Mendes et al. 2010, d'Avo, Cunha et 
al. 2013). Two pathways for MGG production in P. mobilis was proposed and one of which 
uses GG as a precursor molecule (Fernandes, Mendes et al. 2010). 
GG is also considered a compatible solute that can be accumulated intracellularly even at 
very high levels without affecting the cell functions (Empadinhas and da Costa 2011). 
Free GG was found in diverse organisms and its accumulation proposed as a strategy to 
cope with salt stress and nitrogen starvation. In the cyanobacterium Synechococcus 
PCC7002 (formaly known as Agmenellum quadruplicatum), the intracellular GG levels 
were shown to increase during growth in nitrogen poor medium, pointing for the novel role 
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of GG during nitrogen starvation (Kollman, Hanners et al. 1979). Later, the accumulation 
of GG in this species was also associated with salt stress and shown to be considerable 
stimulated by salt stress and nitrogen starvation combined (Engelbrecht, Marin et al. 
1999, Klahn, Steglich et al. 2010). Similarly, in the marine cyanobacterium 
Prochlorococcus marinus the accumulation of GG during growth in high salinity medium 
was exacerbated by low nitrogen availability (Klahn, Steglich et al. 2010). Interestingly, 
both Synechococcus spp. and P. marinus accumulate glutamate when nitrogen is 
available, however when nitrogen is limited the intracellular glutamate is reduced and 
replaced by the negatively charged GG (Klahn, Steglich et al. 2010). The planctomycete 
Gimesia maris also replaces the glutamate with GG as main anionic solute when growing 
under high salt and low nitrogen conditions (Ferreira, Soares et al. 2016). The 
accumulation of GG instead of glutamate in hypertonic and nitrogen-deficient medium was 
also observed for the marine α-proteobacterium Dinoroseobacter shibae (Kleist, Ulbrich et 
al. 2017).   
Although in the previous examples both nitrogen scarcity and osmotic pressure were 
necessary to induce significant GG accumulation, in Hydrogenothermus marinus and 
Mycobacterium spp. that was not observed. In H. marinus the salt stress was shown to be 
sufficient to trigger the accumulation of GG (Beblo-Vranesevic, Galinski et al. 2017). On 
the other hand, in M. smegmatis and M. hassiacum the accumulation of GG occurred 
under nitrogen starvation and was shown to be independent on osmotic pressure 
(Behrends, Williams et al. 2012, Alarico, Costa et al. 2014). In M. smegmatis, the 
accumulation of GG was linked to the up-regulation of GpgS encoding gene 
(MSMEG_5084) that catalyzes the first step of GG synthesis (Behrends, Williams et al. 
2012). In agreement, a gpgS deleted mutant, unable to produce detectable amounts of 
GG, showed a slight reduction in growth rate under nitrogen-limiting conditions compared 
to wild-type (Behrends, Williams et al. 2012). Although GG seems not essential for 
mycobacterial survival under low nitrogen, the phenotypic effect observed suggest that it 
may contribute for bacterial fitness in diverse environmental situations. 
In vitro, GG was shown to increase the thermostability of proteins and prevent the loss of 
activity for a number of enzymes (Faria, Mingote et al. 2008, Sawangwan, Goedl et al. 
2010, Sato, Kitamoto et al. 2014). Additionally, GG also displays a protective effect 
against DNA scission (Sato, Kitamoto et al. 2014). Thus, the accumulation of intracellular 
GG may increase the stability of macromolecules, such as nucleic acids and proteins, 
fundamental for keeping cell viability until improvement of the environmental conditions. 
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1.2.3.5. GG recycling 
The GG stored during mycobacterial growth under nitrogen limited conditions was shown 
to decrease when the nitrogen availability was restored (Alarico, Costa et al. 2014). The 
reduction of intracellular GG in M. hassiacum was linked to the up-regulation of a gene 
encoding for a glucosylglycerate hydrolyse (GgH, EC 3.2.1.-) that catalyses in vitro the 
hydrolysis of GG to glucose and glycerate (Alarico, Costa et al. 2014). Therefore, GgH 
seems to contribute for recycling the accumulated GG, allowing the assimilation of the 
metabolite when nitrogen availability is restored, and the rapid energy mobilisation 
required for cell growth and division.  
Although no information is available regarding the importance of GgH for bacterial survival 
and pathogenicity, this enzyme is highly conserved among rapid-growing mycobacteria 
and members of related genera, reflecting its evolutive importance. On the basis of its 
amino acid sequence, GgH is grouped into the glycoside hydrolase family 63 (GH63). In 
Chapter 3, the three-dimensional structure of recombinant M. hassiacum GgH (MhaGgH) 
is presented, highlighting its molecular determinants of substrate specificity. An overview 
of glycoside hydrolases classification, structural features and mechanism of reaction is 
given in section 1.4. 
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1.3. Histidine phosphatases 
The histidine phosphatases are found in both prokaryotic and eukaryotic organisms, 
forming a group with an impressive range of activities, including regulatory and signalling 
functions (Rigden 2008). These proteins share a small RHG motif at the beginning of their 
amino-acid sequence, whose histidine is transiently phosphorylated during the catalytic 
reaction (see section 1.3.1) (Rigden 2008).  
The histidine phosphatase superfamily (clan ID CL0071) of the Pfam database (Finn, 
Coggill et al. 2016) hosts all histidine phosphatases. However, due to their sequence 
divergence, histidine phosphatases are subdivided into two branches, named branch 1 
(Pfam family ID PF00300) and branch 2 (Pfam family ID PF00328). In the present version 
of the Pfam database (Pfam 31.0, March 2017, http://pfam.xfam.org/), branch 1 is 
composed mainly of prokaryotic proteins (17027 prokaryotic sequences against 9272 
eukaryotic sequences), whereas branch 2 contains a higher number of eukaryotic 
members (5975 eukaryotic sequences against 305 prokaryotic sequences).  
The development of bioinformatics tools allowed the fast annotation of the genomic data 
produced over the years. However, automated genome annotation tools are also prone to 
mis- and over-annotation (Friedberg 2006). The sequence and functional diversity of the 
histidine phosphatase superfamily represent a particular challenge. Also, since the 
histidine phosphatase superfamily has a mutase-dominated history, many members found 
in the genomes have been annotated as mutases (see section 3.3), when phosphatase 
activity is much more likely (Rigden 2008). Thus, the functional and structural 
characterization of these enzymes is essential to validate the annotated function and 
optimize future annotations by increasing knowledge regarding structure-function 
relationships. 
 
1.3.1. Mechanism of reaction 
The catalytic activity of histidine phosphatases is centred in the phosphorylation and 
dephosphorylation of a highly conserved histidine (Figure 1.7) usually localized closer to 
the N-terminus, immediately after the first β-sheet.  
The transference of the phosphoryl group from the substrate to the enzyme is aided by 
several surrounding residues, which are responsible for holding the phosphoryl group 
during the course of reaction (Wang, Liu et al. 2006). These residues include a pair of 
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arginines and an additional histidine that are highly conserved among the members of the 
histidine phosphatase superfamily (Rigden 2008). Additionally, a highly conserved glycine, 
occasionally replaced by an alanine, is part of the well-known and characteristic RHG 
motif. This residue forms a hydrogen bond via its carbonyl group with the catalytic 
histidine side chain, important for keeping it in an appropriate position for catalysis. The 
phosphate pocket also contains other less conserved residues (represented as PP in 
Figure 1.7) involved in additional phosphoryl group interactions, including an asparagine 
(Hamada, Kato et al. 2005) and a glutamine (Rigden, Littlejohn et al. 2003). 
Other important component of the catalytic machinery is the proton donor, required to 
donate a proton to the leaving group of the substrate upon the transference of the 
phosphoryl group to the catalytic histidine. Most of the branch 1 members have a 
glutamate as proton donor (Lin, Li et al. 1992), however is was predicted that in other 
members an aspartate is likely to perform this function (Hamada, Kato et al. 2005). 
Although for the branch 2 members it is consensus that the proton donor is an aspartate 
(Ostanin and Van Etten 1993), an histidine residue was proposed to act as secondary 
proton donor (Lee, Cottrill et al. 2003). The proton donor is usually localized shortly after 
strands β1 or β3 in branch 1, or β4 in branch 2 members. 
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Figure 1.7 – Schematic representation of the catalytic mechanism of histidine phosphate superfamily members. The catalytic histidine residue becomes 
phosphorylated during the course of the reaction, while the surrounding residues interact electrostatically with the phosphoryl group. Neutral or positively 
charged residues (PP) may also contribute for phosphoryl group stabilization by hydrogen bonding. The proton donor (PD), an aspartate or glutamate, is 
indicated. Adapted from (Rigden 2008). 
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1.3.2. Vanadate as transition-state mimic 
The identification of the residues involved in substrate binding and catalysis is usually 
performed by engineered site-specific amino acid substitutions and/or by structure 
determination in complex with substrates, substrate analogues or inhibitors. 
In general, phosphatases are inhibited by oxometalate anions such as arsenate, 
molybdate, tungstate and vanadate, which are often described as phosphate analogues 
(Dennis Chasteen 1983, Zhang, Zhou et al. 1997, Foster, Young et al. 1998, Reiter, White 
et al. 2002, Hamada, Kato et al. 2005, Peck, Sunden et al. 2016). Among these 
compounds, vanadate is the most commonly used due to its structural and chemical 
similarities to phosphate and to its high binding affinity (Crans, Smee et al. 2004). 
Vanadate and phosphate are structural analogues of similar size, displaying 
circumscribing spheres of 125 and 105 Å3, respectively (Rehder 2013). The most 
significant difference between vanadate and phosphate is the ability of vanadate to easily 
reach a stable penta-coordination, commonly in a trigonal bi-pyramidal geometry, while 
this type of coordination is just a transition state in the case of phosphate (Crans, Tarlton 
et al. 2014, Rehder 2015). Thus, vanadate can mimic the transition-state of the 
phosphoryl group transfer, by forming a stable complex with the catalytic residue (Figure 
1.8). Moreover, the formation of this complex leads to enzyme inhibition since the active 
site is no longer accessible to the substrate.  
Vanadate is thus a powerful tool for the structural study of phosphatases in general 
(Davies and Hol 2004). In one hand, vanadate is able to form a highly stable complex with 
the enzyme and mimic the transition-state of phosphoryl group transfer, allowing the 
identification of the residues involved in substrate binding and providing information about 
the enzyme mechanism. On the other hand, its high affinity of binding is important to 
promote the fast formation of stable complexes, increasing the molecular homogeneity 
necessary to produce high quality and easily interpretable structural data.  
 
 
 
 
 
 
 
 
  Chapter 1 
56 
 
 
 
 
 
 
 
 
 
Figure 1.8 – Analogy between phosphate and vanadate. Penta-coordinated species produced by 
the interaction of phosphate (A) and vanadate (B) with a histidine residue. Phosphate forms a labile 
transition state, symbolized by a dashed bond between phosphorus and nitrogen atoms, whereas 
vanadate forms a stable complex. Adapted from (Rehder 2015).  
 
1.3.3. Histidine phosphate mutases 
Although most histidine phosphatases are responsible for the simple removal of a 
phosphoryl group from the substrate (EC 3.1.3.-), other members can act as mutases (EC 
5.4.2.-) (Rigden 2008). The phosphatase mutases (PGMs) are divided in two groups, 
named monophosphoglycerate mutases (mPGMs) and bisphosphoglycerate mutases 
(bPGMs), based on the number of phosphoryl groups in the reaction product glycerate. 
Since mPGMs may or not require 2,3-bisphosphoglycerate as initiator of the reaction, they 
are also subdivided into 2,3-bisphosphoglycerate dependent (dPGM) and 2,3-
bisphosphoglycerate independent PGMs (iPGMs), respectively. 
While mPGMs catalyse the interconversion between 2-phosphoglycerate and 3-
phosphoglycerate (EC 5.4.2.11, dPGMs; EC 5.4.2.12, iPGMs), bPGMs are involved in the 
production of 2,3-bisphosphoglycerate from 1,3-bisphosphoglycerate (EC 5.4.2.4). The 
activity of dPGMs and bPGMs is interconvertible, although at a much lower reaction rate 
(Fothergill-Gilmore and Watson 1989).  
The difference between mutases and phosphatases is the ability of the former to keep the 
intermediates in the active site, allowing their reorientation and protecting the 
phosphorylated enzyme from hydrolysis (Rigden 2008). This protection is likely promoted 
by the C-terminal tail. Indeed, its removal was associated to a reduction of the mutase 
activity (Walter, Nairn et al. 1999). Moreover, the structure of the C-terminal tail was only 
  Chapter 1 
57 
 
determined for the phosphorylated form of dPGMs and found to interact with the residues 
implicated in substrate binding (Bond, White et al. 2001, Rigden, Littlejohn et al. 2003). 
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1.4. Glycoside hydrolases 
Glycoside hydrolases (GHs), also known as glycosidases or glycosyl hydrolases (EC 
3.2.1.-), are enzymes that catalyse the hydrolysis of the glycosidic linkage of glycosides 
(Figure 1.9), producing a hemiacetal or hemiketal sugar and the corresponding free 
aglycon (Withers and Williams 2017).  
 
 
 
 
 
 
Figure 1.9 – General reaction catalysed by a glycoside hydrolase. Adapted from (Withers and 
Williams 2017). 
 
These enzymes act on a variety of carbohydrates, and due to their ubiquity in nature, GHs 
are of high interest in human health and disease, as well as in biotechnology industries. 
GHs form a diverse group of enzymes that are classified based on their amino acid 
sequence and according to the Carbohydrate-Active Enzymes (CAZy) database system 
(http://www.cazy.org/Glycoside-Hydrolases.html) (Lombard, Golaconda Ramulu et al. 
2014). Up to date, GHs are divided into 149 families (numbered from 1 to 149), and 
approximately one-third of the total number of families are grouped into 17 clans (named 
from GH-A to GH-Q), highlighting their folding similarities.  
 
1.4.1. Mechanisms of reaction 
The gross mechanisms of GHs were first proposed more than 60 years ago (Koshland 
1953), remaining largely true today. The hydrolysis of the glycosidic bond occurs via a 
general acid catalysis, involving two critical residues, an acid and a nucleophile/base 
(Koshland 1953). The reaction consists in the nucleophilic substitution at the anomeric 
carbon by two possible mechanisms, named retaining and inverting mechanism according 
to the stereochemical outcomes for the hydrolysis of the glycosidic bond (Koshland 1953). 
While the retaining mechanism leads to the overall conservation of the anomeric 
configuration, the inversion mechanism induces its inversion (see sections 1.4.1.1. and 
  Chapter 1 
59 
 
1.4.1.2. for details). Therefore, GHs are also classified into retaining and inverting GHs 
according to the type of hydrolysis mechanism used. 
The increasing knowledge on GHs reaction mechanism has been promoted by the 
structural analysis of GHs and of their complexes with ligands. In addition to the vast 
number of GHs that operate by the classical Koshland retaining and inverting 
mechanisms, a growing number of enzymes acting on glycosides by slightly different to 
new mechanisms are coming to light (see section 1.4.1.3. for more details). 
 
1.4.1.1. Classical inverting mechanism 
The inverting mechanism, thus named due to the inversion of the anomeric configuration 
of the glycosyl group, comprises a single step reaction involving the formation of an 
oxocarbenium ion-like transition state (Figure 1.10A) (Koshland 1953). The reaction 
occurs via the nucleophilic attack by a water molecule, previously activated by a 
negatively charged base, and concomitantly to proton transfer from an acidic residue. This 
reaction involves typically glutamates or aspartates, which are usually separated by 9.0 
and 9.5 Å in α-glycosidases and β-glycosidases, respectively (McCarter and Withers 
1994).  
 
1.4.1.2. Classical retaining mechanism 
The glycoside hydrolysis via a retaining mechanism occurs by a two-step reaction marked 
by the formation of two transition states and the preservation of the anomeric 
stereochemistry (Figure 1.10B) (Koshland 1953). During the first step, the nucleophilic 
attack is performed directly by an amino acid residue (nucleophile) to the anomeric 
carbon, concomitantly to proton transfer from the acidic residue to the glycosidic oxygen. 
The first oxocarbenium ion-like transition state is formed. As soon as the glycosidic 
oxygen is protonated, the aglycon is displaced whereas the glycosyl group remains 
covalently bound to the nucleophile. Due to the formation of this glycosyl-enzyme 
intermediate, this step is often referred as glycosylation step.  
In a second reaction step, the residue previously acting as acid, is now negatively charged 
and acts as a base, activating a water molecule. The activated water performs a 
nucleophilic attack against the anomeric carbon of the glycosyl group and the second 
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oxocarbenium ion-like transition state forms. Once the glycosydic oxygen becomes 
protonated, the glycosyl group is released. At the end of the reaction, the charge of the 
nucleophile and the protonation state of the acid are re-established. The retaining 
mechanism usually involves glutamates and aspartates as catalytic residue, which are 
closer (~4.8 and 5.3 Å for α-glycosidases and β-glycosidases, respectively) than those of 
inverting GHs (McCarter and Withers 1994). 
 
1.4.1.3. Variations of the classical retaining mechanism 
A variation of the classical retaining mechanism was found among myrosinases, S-
glycosidases responsible for hydrolysing the plant anionic 1-thio-β-D-glucosides 
(glucosinolates) and whose products of reaction were linked to plant defence (Bones and 
Rossiter 1996, Cottaz, Henrissat et al. 1996). Although belonging to the GH family 1 
(GH1), myrosinases are unusual members in this family in that they lack the classical 
acid/base residue (glutamate) at their active site. The catalytic glutamate residue of the 
classical β-glucosidases is replaced by a glutamine in myrosinases that contributes for the 
correct positioning of the nucleophilic water (Burmeister, Cottaz et al. 1997). The 
nucleophilic water seems to be activated by the co-factor ascorbic acid, used by 
myrosinases as an alternative base (Burmeister, Cottaz et al. 2000). 
Another variation was observed on sialidases and trans-sialidases. Sialidases, also known 
as neuraminidases, and trans-sialidases hydrolyse or transfer sialic acids with retention of 
the anomeric configuration (Chong, Pegg et al. 1992, Kao, Lerner et al. 1997, Todeschini, 
Mendonca-Previato et al. 2000). While sialidases are separated into three distinct families 
based on their amino acid sequence similarities (GH33, GH34 and GH83), trans-
sialidases are found in a single GH family (GH33). Despite their amino acid sequence 
differences, they seem to share a common active-site machinery. These enzymes use a 
tyrosine as catalytic nucleophile, instead of the usual acidic residue. Since tyrosine is a 
neutral amino acid, an adjacent base residue (glutamate) is required to enhance its 
nucleophilicity (Watson, Dookhun et al. 2003, Watts, Damager et al. 2003, Amaya, Watts 
et al. 2004). 
Some enzymes, belonging to GH families 18, 20, 25, 56, 84 and 85, hydrolyse substrates 
containing an N-acetyl group at the 2-position. These enzymes lack the catalytic 
nucleophile and use the 2-acetyl group as intramolecular nucleophile, leading to the 
formation of an oxazolinium ion intermediate (Terwisscha van Scheltinga, Armand et al. 
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1995, Drouillard, Armand et al. 1997, Mark, Vocadlo et al. 2001, Vocadlo and Withers 
2005). 
Finally, the two GH families that stand out mechanistically are GH4 and GH109. The 
enzymes from these families are unique among GHs because they require NAD+ for 
catalysis. The mechanism involves elimination and redox reactions, leading to the 
formation of anionic intermediates rather than the oxocarbenium ion-like transition states 
of the classical Koshland mechanisms. In GH4, NAD+ effects a transient oxidation of the 
substrate, whereas a divalent cation, usually Mn2+, stabilizes the negative charges that 
develop during the reaction (Rajan, Yang et al. 2004, Yip, Varrot et al. 2004). Although 
GH109 seems to follow a mechanism very similar to that of the GH4 family, GH109 does 
not require a metal cofactor for its activity (Liu, Sulzenbacher et al. 2007). 
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Figure 1.10 – General glycosidase mechanism for inverting α-glycosidase (A) and retaining α-
glycosidase (B). Adapted from (Withers and Williams 2017). 
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2.1. Introduction 
 
The genus Mycobacterium contains more than 180 species including those belonging to 
the Mycobacterium tuberculosis complex, the causative agents of tuberculosis. Although 
the number of TB deaths has fallen by 26% from 2000 to 2016, TB remains one of the 
top 10 causes of death worldwide (WHO 2017). It is estimated that about one-fourth of the 
world’s population has latent TB infection with 5 to 15% lifetime risk of developing the 
disease (WHO 2017). The increasing number of multidrug resistant and even extensively 
drug-resistant TB strains urges for the identification of novel targets against which efficient 
drugs can be designed. 
Mycobacteria have one of the thickest biological membranes known, rich in complex 
carbohydrates and unique lipids, namely mycolic acids, to which mycobacteria owe much 
of their pathogenicity (Jackson 2014, Jankute, Cox et al. 2015). It has been proposed that 
the biosynthesis of fatty acids, such as mycolic acids, is regulated by intracellular 
polymethylated polysaccharides (Ilton, Jevans et al. 1971, Machida and Bloch 1973, Flick 
and Bloch 1975, Banis, Peterson et al. 1977). Two types of PMPSs are known: the 
methylmannose polysaccharides and the methylglucose lipopolysaccharides (Lee 1966, 
Gray and Ballou 1971). Interestingly, while the two types of PMPSs were found in the 
environmental mycobacteria, MGLPs were the only ones found in slow-growing 
pathogenic mycobacteria, such as M. tuberculosis (Mendes, Maranha et al. 2012).  
The biosynthesis of MGLPs is a complex process that involves different classes of 
enzymes (Mendes, Maranha et al. 2012). The first intervenient enzyme in the MGLP 
biosynthetic pathway is a glucosyl-3-phosphoglycerate synthase (GpgS), and it was also 
the first enzyme to be biochemical and structurally characterized (Empadinhas, 
Albuquerque et al. 2008, Pereira, Empadinhas et al. 2008). GpgS synthesizes in vitro 
glucosyl-3-phosphoglycerate from UDP-glucose and 3-phosphoglyceric acid 
(Empadinhas, Albuquerque et al. 2008). The reaction product of GpgS is the substrate of 
the second intervenient enzyme, glucosyl-3-phosphoglycerate phosphatase. In vitro, this 
enzyme dephosphorylates GPG producing glucosylglycerate (Mendes, Maranha et al. 
2011). 
The gene coding for GpgP is highly conserved among mycobacteria and related genera. 
Although it was reported as non-essential for mycobacterial in vitro growth (Sassetti, Boyd 
et al. 2003), the high conservation of this gene suggests that it may confer an evolutive 
advantage. Indeed, its reaction product, GG, is a compatible solute involved in 
osmoadaptation and a precursor of other molecules such as glycolipids and 
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polysaccharides (Pommier and Michel 1981, Kamisango, Dell et al. 1987, Jorge, Lamosa 
et al. 2007, Empadinhas and da Costa 2011, Behrends, Williams et al. 2012, Alarico, 
Costa et al. 2014, Nunes-Costa, Maranha et al. 2017). The impairment of GG production 
by targeting GpgP activity may reduce the ability of mycobacteria to adapt to a fluctuating 
environment, which is highly important during infection. Therefore, GpgP appears as 
potential target for drug development against mycobacteria infections, including TB. 
Here, the crystallographic structure of a recombinant M. tuberculosis GpgP (MtuGpgP) is 
presented. Moreover, the substrate binding mode of MtuGpgP is also proposed based on 
the structure of its complex with the phosphate mimic vanadate and the product of 
reaction GG. The high resolution of the data allowed the identification of the amino-acid 
residues involved in substrate binding, orientation and catalysis. 
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2.2. Materials and methods 
2.2.1. Expression and purification of recombinant MtuGpgP 
Escherichia coli BL21 (DE3) cells transformed with a pET30a-derived plasmid harbouring 
the optimized Rv2419c gene sequence (Mendes, Maranha et al. 2011) were grown in LB 
medium supplemented with 50 μg mL–1 kanamycin at 37°C to an OD600 of 0.6-0.8. At this 
point, the temperature was decreased to 20°C and expression induced with 1 mM IPTG. 
After 4 h growth, cells were harvested, resuspended in 20 mM sodium phosphate 7.5, 500 
mM NaCl, 20 mM imidazole, 5 mM β-ME (buffer A) and stored at -20°C. Thawed cells 
were stirred gently on ice for 1 h after adding 5 μg mL–1 lysozyme, 5 μg mL–1 DNAse I, 5 
mM MgCl2, 1 mM PMSF and one tablet of cOmplete
TM EDTA-free protease inhibitor 
cocktail (Roche). The protein extract was clarified by centrifugation and loaded onto an 
immobilized metal affinity column (GE Healthcare) loaded with nickel and pre-equilibrated 
with buffer A. Bound MtuGpgP was eluted with 175 mM imidazole in buffer A. Fractions 
containing MtuGpgP protein were pooled and loaded onto a HiPrep 26/60 Sephacryl 200 
(GE Healthcare) size exclusion column using 20 mM Tris-HCl pH 7.5, 200 mM NaCl, 10 
mM DTT as mobile phase. The purest MtuGpgP-containing fractions were dialyzed 
against 50 mM BTP pH 7.0, 50 mM NaCl, 10 mM DTT and concentrated on a 3 kDa cutoff 
ultrafiltration device (Millipore). The concentration of the purified MtuGpgP was estimated 
by measuring the absorbance at 280 nm on a NanoDrop ND-1000 Spectrophotometer 
(NanoDrop Technologies). The protein was flash-frozen in liquid nitrogen and kept at -
80°C until needed. 
 
 
2.2.2. Analytical size-exclusion chromatography 
MtuGpgP was analysed by size exclusion chromatography on a Superdex 200 increase 
5/150 GL column (GE Healthcare) pre-equilibrated with 50 mM BTP pH 7.0, 50 mM NaCl, 
10 mM DTT. The column was calibrated using ferritin (400 kDa), aldolase (158 kDa), 
ovalbumin (43 kDa) and ribonuclease A (13.7 kDa) as standards. The Kav vs log MW was 
calculated based on the equation 𝐾𝑎𝑣 =
𝑉𝑒− 𝑉0
𝑉𝑡−𝑉0
, where Ve is the elution volume of the 
protein, V0 is the void volume of the column and Vt is the column bed volume. 
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2.2.3. Differential scanning fluorimetry 
The melting temperature of MtuGpgP was determined by a thermal shift (Thermofluor) 
assay. After centrifugation at 13,000xg and 4°C for 15 min, MtuGpgP (0.2 mg mL–1) was 
mixed with 5x SYPRO Orange (Life Technologies) in 50 mM BTP pH 7.0, 50 mM NaCl, 10 
mM DTT, and loaded in white 96-well PCR plates (Bio-Rad) sealed with Optical-Quality 
Sealing Tape (Bio-Rad). The plate was heated from 25 to 95°C in 0.5°C steps with 30 s 
hold time per step on an iCycler iQ5 Multicolor Real-Time PCR Detection System (Bio-
Rad) and the fluorescence was followed over time using a Cy3 dye filter (545 nm 
excitation, 585 nm emission). The experiment was performed in triplicate. The melting 
curves were analysed using the CFX Manager software (Bio-Rad), and the melting 
temperature determined as the inflexion point of the melting curve.  
 
2.2.4. Chemical synthesis of glucosylglycerate 
The chemical synthesis of glucosylglycerate [GG, 2-O-(α-D-glucopyranosyl)-D-glycerate)], 
was performed by Eva Lourenço and Rita Ventura (Bioorganic Chemistry Group, ITQB – 
Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Portugal) as 
previously described (Lourenco, Maycock et al. 2009, Lourenco and Ventura 2011). 
 
2.2.5. Crystallization of MtuGpgP 
Initial crystallization conditions were screened at 293 K using the sitting-drop vapour-
diffusion method with commercial sparse-matrix crystallization screens (Hampton 
Research). The drops consisted of equal volumes (1 μL) of protein (at 13 mg mL–1 in 50 
mM BTP pH 7.0, 50 mM NaCl, 10 mM DTT) and precipitant solution and were equilibrated 
against 300 μL of precipitant. Crystals were obtained after 6 days using solution number 7 
[0.2 M calcium chloride dihydrate, 20% (w/v) PEG 3,350] of PEG/Ion Crystallization 
Screen (Hampton Research) as precipitant. The condition was refined and improved 
crystals were obtained from 15 to 30% (w/v) PEG 3,350 both in presence and absence of 
0.1 M MES pH 6.5 or 6.7. The MtuGpgP-vanadate and MtuGpgP-vanadate-GG 
complexes were obtained by co-crystallization of MtuGpgP with approximately 50-fold 
molar excess of activated sodium orthovanadate (Sigma) and from drops composed of 1 
μL each of protein and precipitant solutions and 2 μL of 10 mM sodium orthovanadate. 
For the MtuGpgP-vanadate-GG complex, protein was previously incubated with a 10-fold 
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molar excess of GG for 1h on ice. Crystals appeared after approximately 15 days, were 
cryo-protected in mother liquor solution supplemented with 15% (v/v) glycerol and were 
flash-cooled in liquid nitrogen. Iodide-containing crystals were obtained from a second 
crystallization condition consisting of 0.2 M sodium iodide, 0.12 M MES pH 6.0, 20% (w/v) 
PEG 6,000. Crystals were cryo-protected in mother liquor solution containing 10% (v/v) 
glycerol and were flash-cooled in liquid nitrogen. The initial MtuGpgP crystallization 
conditions were determined by Fernando Vilela and Sara Fernandes (IBMC, Porto, 
Portugal). 
 
2.2.6. Data collection and processing 
High-resolution data sets were collected from cryo-cooled (100 K) single crystals on a 
PILATUS 6M detector (Dectris) at beamlines ID29 (de Sanctis, Beteva et al. 2012) and 
ID23-1 (Nurizzo, Mairs et al. 2006) of the European Synchrotron Radiation Facility (ESRF, 
Grenoble, France) and PROXIMA-1 of the French National Synchrotron Source (SOLEIL, 
Gif-sur-Yvette, France). All data sets were processed with XDS (Kabsch 2010) and 
reduced with utilities from the CCP4 software suite (Winn, Ballard et al. 2011), except for 
MtuGpgP-vanadate-GG complex data, which were processed using the Grenoble 
Automatic Data ProcEssing pipeline (Monaco, Gordon et al. 2013). X-ray diffraction data 
collection and processing statistics are summarized in Table 2.1. 
 
2.2.7. Structure determination, model building and refinement 
The structure of MtuGpgP was solved by SAD using the anomalous signal from an iodide-
derivative crystal with the SAS protocol of Auto-Rickshaw pipeline (Panjikar, 
Parthasarathy et al. 2005, Panjikar, Parthasarathy et al. 2009). The refined coordinates 
were used as search model to solve the structure of all other MtuGpgP complexes by 
molecular replacement with PHASER (McCoy, Grosse-Kunstleve et al. 2007). Alternating 
cycles of model building with Coot (Emsley, Lohkamp et al. 2010) and refinement with 
PHENIX (Adams, Afonine et al. 2010) were performed until model completion. Refinement 
statistics are summarized in Table 2.2. 
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2.2.8. Analysis of crystallographic structures  
The crystallographic models were superposed with Coot (Emsley, Lohkamp et al. 2010) 
and the secondary structure elements were identified with DSSP (Kabsch and Sander 
1983, Touw, Baakman et al. 2015). The interface area between the monomers was 
determined using PISA (Krissinel and Henrick 2007). The electrostatic potential surface 
was calculated with APBS (Baker, Sept et al. 2001) using the AMBER force field (Cornell, 
Cieplak et al. 1995). Figures depicting molecular models were created using PyMOL 
(Schrödinger). 
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2.3. Results and discussion 
2.3.1. Biophysical analysis and crystallization of MtuGpgP 
Recombinant Mycobacterium tuberculosis GpgP (MtuGpgP) containing a C-terminal 
hexahistidine tag was produced in E. coli and purified to homogeneity by a combination of 
immobilized metal-affinity and size-exclusion chromatography. The purity of MtuGpgP was 
assessed by analytical size-exclusion chromatography and SDS-PAGE (Figure 2.1A and 
B). In SDS-PAGE MtuGpgP migrated with an apparent MW of 25 kDa, which is consistent 
with the theoretical MW of 25.7 kDa. In the analytic size-exclusion chromatography, 
MtuGpgP eluted with an apparent MW of 53.2 kDa, almost twice the theoretical MW of 
monomeric MtuGpgP, suggesting that a dimer may form in solution. 
The thermostability of MtuGpgP was evaluated by differential scanning fluorimetry (Figure 
2.1C). MtuGpgP displays a typical denaturation curve with a clear and sharp temperature 
transition, allowing the straightforward estimation of a melting temperature (Tm) of 44ºC in 
50 mM BTP pH 7.0, 50 mM NaCl, 10 mM DTT. As previously proposed, the Tm of a 
molecule can be used to estimate its crystallization propensity (Dupeux, Rower et al. 
2011). In agreement, the Tm of MtuGpgP suggests that it is likely to crystallize at 293K. 
Thus, initial crystallization experiments were performed at this temperature and high 
quality crystals were obtained from two different crystallization conditions. The first 
crystallization condition yielding crystals used PEG 3,350 as precipitant (Figure 2.1D). The 
second crystallization condition contained sodium iodide and used PEG 6,000 as 
precipitant.  
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Figure 2.1 – Biophysical characterization and crystallization of recombinant MtuGpgP. A – 
Analytical size-exclusion chromatogram. The standards (1, Ferritin; 2, Aldolase; 3, Ovalbumin; 4, 
Ribonuclease A) used for column calibration are indicated by downward black triangles. B – SDS-
PAGE analysis of purified MtuGpgP. The MW of the standards (lane 1) is indicated in kDa to the 
left of the gel. MtuGpgP (lane 2) displays an apparent MW of 25 kDa. C – Melting curve of 
MtuGpgP (solid line) obtained by differential scanning fluorimetry and its first derivative curve 
(dashed line). MtuGpgP displays a melting temperature of 44C in the assay conditions. D – 
Monoclinic crystals of recombinant MtuGpgP belonging to space group C2. 
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2.3.2. Overall structure of MtuGpgP 
Diffraction data were collected from recombinant MtuGpgP crystals at synchrotron 
radiation sources (Supplemental figure S2.1). Crystals obtained from the iodide-containing 
condition and belonging to the monoclinic space group P21 (Supplemental figure S2.2A) 
were measured with 1.5498 Å radiation to maximize the anomalous signal of iodide 
(Supplemental figure S2.3). Two data sets were collected to increase the completeness 
and multiplicity of the data. At this wavelength, the crystals diffracted X-rays to beyond 2.5 
Å resolution (Table 2.1). The phase problem was subsequently solved by single-
wavelength anomalous diffraction (SAD), using the anomalous signal of iodide with the 
SAS protocol of the Auto-Rickshaw pipeline (http://www.embl-hamburg.de/Auto-
Rickshaw/) (Panjikar, Parthasarathy et al. 2005, Panjikar, Parthasarathy et al. 2009). The 
input diffraction data was first prepared and converted for use in the Auto-Rickshaw 
pipeline using programs of the CCP4 software suite (Winn, Ballard et al. 2011). Fifty six 
heavy atom sites were identified using SHELXD (Sheldrick 2010) with CCall and CCweak of 
40.5 and 19.9%, respectively. The correct hand for the substructure was determined using 
ABS (Hao 2004) and SHELXE (Sheldrick 2010), followed by refinement of the 
substructure atom occupancy using BP3 (Winn, Ballard et al. 2011). The twofold NCS 
operator was found using RESOLVE (Terwilliger 2000). Density modification, phase 
extension and NCS-averaging were performed with DM (Cowtan 1994), resulting in a 
FOM of 0.713 and real-space-free-residual of 0.131. A partial α-helical model containing 
49 α-carbons was produced using HELICAP, an ARP/wARP module for tracing helices 
and strands (Langer, Cohen et al. 2008). A partial model, containing 279 out of the total 
944 residues in the asymmetric unit, was finally obtained with BUCCANEER (Cowtan 
2006).  
The partial model was subsequently improved with the MRSAD protocol, which combines 
molecular replacement and SAD phasing. This was performed with PHASER (McCoy, 
Grosse-Kunstleve et al. 2007), which analysed the heavy atom sites based on the starting 
model. Heavy atom occupancy was refined with MLPHARE (Otwinowski 1991) and 
density modification was performed with PIRATE (Cowtan 2000) followed by NCS 
detection and density modification with RESOLVE (Terwilliger 2000). A step of model 
building with SHELXE (Sheldrick 2010) was followed by amino acid sequence docking in 
the SHELXE model using RESOLVE (Terwilliger 2003). The resulting model was refined 
with REFMAC5 (Murshudov, Vagin et al. 1997) and PHENIX (Adams, Afonine et al. 
2010). A final step of model building was performed with BUCCANEER (Cowtan 2006) 
and the model obtained was refined in two steps with REFMAC5 (Murshudov, Vagin et al. 
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1997) and PHENIX (Adams, Afonine et al. 2010). These steps of phasing, model building 
and refinement were performed twice. The resulting model, containing 872 out of the 944 
total amino acid residues, displayed a Rwork of 25.2% and Rfree of 31.6%, with 86.5% of the 
residues in most favoured regions and only 0.4% in disallowed regions. 
The automatically generated model was subsequently improved with alternating cycles of 
manual building with Coot (Emsley, Lohkamp et al. 2010) and refinement with PHENIX 
(Adams, Afonine et al. 2010). The asymmetric unit contained four MtuGpgP monomers 
(named A, B, C and D), corresponding to a Mathews coefficient of 2.18 Å3Da-1 and a 
solvent content of 43.6% (Table 2.1). These four molecules were modelled from Ala3 to 
Ser219 (molecule A) or Ala 216 (molecule D), and from Arg2 to Ala 216 (molecule B) or 
Val218 (molecule C). The polypeptide segment from residues 196 to 202 was not entirely 
modelled for any of the molecules due to the absence of interpretable electron density 
(see Table 2.2 for details). 
Higher resolution data (1.45 Å) were collected from a single cryo-protected crystal, 
belonging to space group C2 (Supplemental figure S2.2B). The phase problem was 
solved by molecular replacement with PHENIX using the coordinates of the lower-
resolution structure as search model. Two molecules were located in the asymmetric unit, 
corresponding to a Matthews coefficient of 2.13 Å3Da-1 and a solvent content of 42.4% 
(Table 2.1). The high-resolution structure was improved with alternating cycles of manual 
building with Coot (Emsley, Lohkamp et al. 2010) and refinement with PHENIX (Adams, 
Afonine et al. 2010). The molecules present in the asymmetric unit, named molecule A 
and molecule B, were modelled from Met1 to His234, and from Met1 to His233, 
respectively (see Table 2.2 for details).  
The MtbGpgP monomer displays an elongated shape and is composed of 6 β-strands (β1 
to β6) arranged into a single twisted β-sheet flanked by 11 α-helices (α1 to α11) (Figure 
2.2). The recombinant MtuGpgP contains an extra helix (α12) induced by the engineered 
C-terminal KLAAALEHHHHHH sequence, which includes a hexahistidine tag preceded by 
a linker to the native MtuGpgP sequence. The strands β1, β2, β3, β4 and β6 run parallel, 
whereas β5 runs antiparallel. An uncommon ψ-loop from amino acid residue 158 to 
residue 189, involving strands β1, β4 and β5, is also present. 
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Table 2.1. Data collection and processing statistics
a
. 
Crystal 
MtuGpgP 
iodide 
MtuGpgP 
MtuGpgP 
vanadate 
MtuGpgP 
vanadate-GG 
Synchrotron Radiation 
Facility 
ESRF ESRF SOLEIL ESRF 
Beamline ID29 ID29 PROXIMA 1 ID23-1 
Wavelength (Å) 1.54980 0.97718 0.97934 0.97934 
Frames 3,600 + 3,600 2,400 1,200 2,600 
Rotation (°) 0.1 0.1 0.2 0.1 
Space Group P21 C2 C2 C2 
Unit Cell Dimensions 
a=97.0 Å; b=46.1 
Å; c=103.2 Å; 
=104.3° 
a=99.0 Å; b=48.8 
Å; c=93.48 Å; 
=104.3° 
a=98.7 Å; b=49.0 
Å; c=93.6 Å; 
=104.0° 
a=98.8 Å, b=48.9 
Å; c= 93.4 Å; 
=103.8° 
Resolution range (Å) 
50.0 – 2.50 
(2.60 – 2.50) 
47.5 – 1.45 
(1.47 – 1.45) 
47.9 – 1.49 
(1.58 – 1.49) 
47.3 – 1.54 
(1.59 – 1.54) 
Reflections 
(measured/unique) 
336,664/27,533 332,291/75,999 300,810/69,647 306,935/63,815 
Completeness (%) 88.7 (49.8) 99.0 (98.9) 98.8 (94.1) 99.3 (98.0) 
Multiplicity 12.2 (7.8) 4.4 (4.4) 4.3 (4.2) 4.8 (4.8) 
Anomalous completeness 87.7 (46.3) - - - 
Anomalous multiplicity 6.3 (4.1) - - - 
Rmerge
b 
0.085 (0.433) 0.082 (1.427) 0.068 (0.900) 0.084 (0.847) 
Rmeas
c 
0.089 (0.464) 0.093 (1.614) 0.077 (1.026) 0.094 (0.947) 
Rp.i.m.
d
 0.025 (0.162) 0.043 (0.739) 0.036 (0.484) 0.041 (0.414) 
Half-set correlation CC1/2 0.999 (0.911) 0.998 (0.506) 0.998 (0.543) 0.998 (0.624) 
Half-set anomalous 
correlation CCAnom 
0.605 (-0.007)    
Mean (I)/ (I) 26.1 (4.3) 8.4 (1.1) 10.2 (1.3) 11.9 (1.8) 
Protomers per asymmetric 
unit 
4 2 2 2 
Matthews coefficient (Å
3
Da
-
1
) 
2.18 2.13 2.14 2.13 
Solvent content (%) 43.6 42.4 42.6 42.4 
Average mosaicity (º) 0.10 0.13 0.11 0.15 
a 
Values in parenthesis correspond to the outermost resolution shell. 
b 𝑅𝑚𝑒𝑟𝑔𝑒 =  ∑  ∑  |𝐼𝑖(ℎ𝑘𝑙) − 〈𝐼ℎ𝑘𝑙〉|𝑖 ℎ𝑘𝑙   ∑ ∑ 𝐼𝑖(ℎ𝑘𝑙)𝑖 ℎ𝑘𝑙 ⁄ , where 𝐼𝑖(ℎ𝑘𝑙) is the observed intensity and 〈𝐼ℎ𝑘𝑙〉 is the average intensity of 
multiple observations of symmetry-related reflections. 
c 𝑅𝑚𝑒𝑎𝑠 = ∑ √
𝑛
𝑛−1ℎ𝑘𝑙
∑ |𝐼𝑖(ℎ𝑘𝑙) − 〈𝐼ℎ𝑘𝑙〉|
𝑛
𝑖=1 ∑ ∑ 𝐼𝑖(ℎ𝑘𝑙)𝑖ℎ𝑘𝑙⁄ , where 𝐼𝑖(ℎ𝑘𝑙)  is the observed intensity and 〈𝐼ℎ𝑘𝑙〉 is the average intensity 
of multiple observations of symmetry-related reflections. 
d 𝑅𝑝.𝑖.𝑚. = ∑ √
1
𝑛−1
 ∑  |𝐼𝑖(ℎ𝑘𝑙) − 〈𝐼ℎ𝑘𝑙〉| 
𝑛
𝑖=1ℎ𝑘𝑙  ∑  ∑ 𝐼𝑖(ℎ𝑘𝑙)𝑖 ℎ𝑘𝑙⁄ , where 𝐼𝑖(ℎ𝑘𝑙)  is the observed intensity and 〈𝐼ℎ𝑘𝑙〉   is the average 
intensity of multiple observations of symmetry-related reflections. 
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Table 2.2. Refinement statistics and structure solution. 
Crystal 
MtuGpgP 
iodide 
MtuGpgP 
MtuGpgP 
vanadate 
MtuGpgP 
vanadate-GG 
Resolution range (Å) 50.0 – 2.50 47.5 – 1.45 47.9 – 1.50 47.3 – 1.54 
Rfactor/Free Rfactor (%) 19.0/23.2 17.5/20.0 16.8/20.0 16.7/19.9 
Unique reflections 
(working/test set) 
52,752/2,532 75,971/3,676 69,633/3,430 63,810/3,223 
Completeness 
(working/test) (%) 
88.0/4.8 98.9/4.8 98.8/4.9 99.3/5.1 
Wilson B-factor (Å
2
) 38.2 19.6 20.9 16.8 
Total number of atoms 6,761 4,179 4,212 4,338 
B-factor (Å
2
)     
Overall 48.2 32.6 33.0 26.6 
Protein 48.3 31.4 32.2 25.0 
Ligand 75.8 52.3 22.3 28.2 
Water 42.3 41.4 41.7 36.6 
RMSD     
Bond lengths (Å) 0.009 0.009 0.007 0.009 
Bonds angles () 1.244 1.029 0.845 0.876 
DPI 0.312 0.068 0.074 0.080 
Ramachandran     
Favoured (%) 94.9 97.0 97.6 97.4 
Outliers (%) 1.57 0.86 0.65 0.43 
Polypeptide length  
A: 234 (Ala3 – Ser219) 
B: 232 (Arg2 – Ala216) 
C: 231 (Arg2 – Val218)  
D: 229 (Ala3 – Ala216) 
A: 234 (Met1 – 
His234) 
B: 233 (Met1 – 
His233) 
A: 231 (Met1 – 
His231) 
B: 235 (Met1 – 
His235) 
A: 231 (Met1 – 
His231) 
B: 236 (Met1 – 
His236) 
Polypeptide gaps 
4 (A, B: Trp196 – Ala198; 
C: Ala197 – Phe202; D: 
Trp196 – Ser200) 
0 0 0 
Water molecules 175 472 438 586 
Ligands
a
 Iodide ion 
 
VO4, TVG1, TVG2 
VO4, TVG1, TVG2, 
9WN 
a 
VO4, 9WN, TVG1 and TVG2 correspond to orthovanadate, GG, and trivanadate glycerol 1 and 2, respectively. 
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Figure 2.2 – Structural arrangement of MtuGpgP. A – Topology diagram of recombinant MtuGpgP. 
Secondary structural elements are coloured salmon (α-helices, from α1 to α12) and blue (β-
strands, from β1 to β6) and their boundaries are indicated. C and N-termini are highlighted in 
yellow. The dashed box indicates the secondary structure induced by the engineered C-terminal 
linker and hexahistidine tag. B – Tertiary structure of MtuGpgP coloured as in A. 
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2.3.3. Quaternary structure of MtuGpgP 
 
The quaternary structure of MtuGpgP was initially evaluated by analytical size-exclusion 
chromatography. Since MtuGpgP eluted with an apparent MW twice the theoretical value, 
a dimer was expected to form in solution (see section 2.3.1).  
In agreement, the crystallographic structure of MtuGpgP was analysed with PISA 
(Krissinel and Henrick 2007), which allows the evaluation of the molecular interfaces 
occurring in the asymmetric unit and between the symmetry-related molecules in the 
crystal. The largest molecular interface area was found for the two molecules present in 
the asymmetric unit. Molecules A and B share a total interface area of 904 Å2, which 
corresponds to ~8% of the total surface area of each monomer (Table 2.3). This interface 
contains mainly β6-β6 and β6-α10 interactions (Figure 2.3), predominantly of hydrophobic 
character (Table 2.3). This dimer composed of molecules A and B is probably that formed 
in solution (Figure 2.3).   
 
 
Table 2.3 – Analysis of the quaternary structure of MtuGpgP using PISA (Krissinel and Henrick 
2007). 
  
Total surface area 
(Å
2
) 
Total interface area 
(Å
2
) 
Interaction (No.) 
Hydrogen 
bonds 
Salt bridges 
Non-bonded 
contacts 
Monomer 
A 10,996.2     
B 10,974.9     
Interface A:B  904.0 13 1 103 
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Figure 2.3 – Three-dimensional structure of recombinant MtuGpgP. Homodimeric MtuGpgP is 
shown in two different orientations. Monomers are coloured wheat and blue. The α-helices and β-
sheets are labelled. The engineered C-terminal peptide linker and partially modelled tag are 
represented as sticks. Strand β6 and helix α10 are localized at the interface between the 
monomers. 
 
Homodimeric MtuGpgP displays twofold symmetry with the active sites localized at 
opposite positively charged clefts (Figure 2.4). Each cleft is shaped by both monomers 
and lined by the side chain of arginine and histidine amino acid residues, resulting in an 
overall basic character. The complementary contribution of the monomers for the active 
site clefts suggests that the dimer might be the minimal functional unit of MtuGpgP. 
Indeed, the inability of the individual monomers to perform the dephosphorylation of the 
synthetic substrate p-nitrophenyl phosphate (PNPP) was reported previously (Zheng, 
Jiang et al. 2014).  
The active site cleft of molecule B is larger than that of molecule A, which probably results 
from crystal packing constrains. Indeed, the segment Trp196-Ile205 (Figure 2.4B) of 
molecule A is stabilised by a symmetry-related molecule, forcing a superopen state of the 
active site cleft of molecule B, whereas in molecule B this segment displays higher 
mobility (Supplemental figure S2.4). The superopen state of the active site cleft of 
molecule B is also accompanied by the loss of an hydrogen bond between the carbonyl 
group of Leu181 and the side chain of Arg123, the position of which may be important for 
substrate binding (see section 2.3.4). 
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Figure 2.4 – Electrostatic potential of MtuGpgP surface. A – Solid surface representation of 
dimeric MtuGpgP coloured according to the electrostatic surface potential [contoured from -8kT/e 
(red) to 8kT/e (blue)], highlighting the positively charged active sites (dashed ellipses) and the 
position of the engineered C-terminus. B – Cross section of the MtuGpgP homodimer oriented as 
in A. The catalytic His11 (yellow sticks) is localized at the bottom of the active site cleft (marked 
with an asterisk) flanked by Arg10 and Arg60 (yellow sticks). The entrance to the active sites is 
indicated by the arrows. The molecular surface was coloured by electrostatic potential as in A. 
 
2.3.4. MtuGpgP in complex with vanadate 
In order to understand the molecular details of substrate binding, recombinant MtuGpgP 
was crystallized in the presence of sodium orthovanadate. Vanadate is a phosphate 
analogue that mimics the transition-state of the phosphoryl group transfer, by forming a 
stable complex with the catalytic residue. Here, sodium orthovanadate was used to induce 
the formation of a stable transition-state that could allow the identification of the residues 
involved in phosphoryl group stabilisation and transfer. 
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Several crystals grown in the presence of sodium orthovanadate were measured and 
analysed. The active site of MtuGpgP crystallized with orthovanadate is occupied by a 
large residual electron density, over 6 Å long. The anomalous difference electron density 
map, calculated from data collected at 0.98 Å, reveals three positive difference peaks 
compatible with vanadium atoms (Figure 2.5A). Two peaks are localized close to the side 
chains of His11 and Glu84, suggesting the presence of covalent bonds to these residues 
(see distances in Figure 2.6D). The third peak is equally distant from the other two (3Å), 
suggesting the existence of bonds between them. The superposition of the anomalous 
difference map with the 2Fo-Fc electron density map shows that the vanadium atoms are 
flanked by other atoms, which are likely the oxygens of orthovanadate (Figure 2.5A).  
The anomalous difference peaks assigned to vanadium atoms display distinct heights: the 
histidine-bound vanadium corresponds to the highest peak, with the other two having 
identically lower heights (Figure 2.5A). This may arise from different occupancies of the 
vanadium atoms, suggesting that different species of vanadate may simultaneously exist 
in the active site of different subpopulations of molecules. 
One of the chemical species compatible with the electron density map is a penta-
coordinated vanadate (VO4) bound to His11 Nɛ2 (Figure 2.5B). The interatomic distances 
within VO4 suggest that a double bond may exist between V and O1 or O2 (Figure 2.6A 
and D). When bound to histidine, this oxometalate displays trigonal bipyramidal geometry 
and is a well-known mimic of the much less stable phophohistidine intermediate (Davies, 
Staker et al. 2011, Crans, Tarlton et al. 2014). The VO4-histidine complex is stabilised by 
a complex network of hydrogen bonds with the side chains of Arg10, Asn17, Gln23, 
Arg60, Glu84 and His159, and backbone nitrogen of Gly160 (Figure 2.5B). These 
hydrogen bonds are likely involved in orientation and stabilisation of the substrate 
phosphoryl group during the phosphorylation and dephosphorylation of the catalytic 
histidine. 
The remaining electron density at the active site of MtuGpgP can be explained by the 
presence of a trivanadate glycerol ester. Vanadate may occur as a polymeric structure 
and its cleavage into monomeric species is usually referred as activation (Gordon 1991) 
since it increases vanadate ability to inhibit phosphatases. However, vanadate activation 
is not an irreversible reaction and vanadate can shift back to oligomeric forms, a process 
especially favoured at neutral to acidic pH (Davies and Hol 2004). The presence of a 
trimeric form of vanadate at the active site reveals its tendency to oligomerize in the 
slightly acidic crystallization condition. Also, trivanadate displays higher occupancy 
compared to VO4 (70%), which suggests a relatively higher ability to outcompete for the 
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active site compared to all the other vanadate species that may be present in the solution, 
including the monomeric species VO4. 
Moreover, vanadate esters can form readily in aqueous solution (Crans, Smee et al. 
2004). The trivanadate glycerol ester species proposed to be occupying the active site 
resulted from the reaction between vanadate and glycerol from the crystal cryo-protectant. 
Indeed, the derivatization of vanadate by glycerol is not without precedent and similar 
reactions were observed previously (Rath, Rajak et al. 1998, Davies, Interthal et al. 2002, 
Davies, Staker et al. 2011, Moise, Gallup et al. 2015). In the trivanadate glycerol ester 
(TVG1) molecule, the O1 and O3 atoms of glycerol (GOL) are bound to the V3 and V2 
atoms of trivanadate, respectively (Figure 2.6B). The interatomic distances suggest that 
double bonding is likely to occur between V1 and O1 or O2, V2 and O6, and V3 and O7 
(Figure 2.6B and D). In the active site, TVG1 V1 and V3 are covalently bound to His11 
Nɛ2 and Glu84 Oɛ, respectively (Figure 2.5C). All vanadium atoms are penta-coordinated 
in a trigonal bipyramidal geometry. The interactions with other active site residues are 
comparable to those observed for VO4, except for new water-mediated contacts with the 
side chain of Asn17 and the carbonyl group of Arg21. 
Finally, there is an electron density feature in the vicinity of the TVG1 that suggests the 
presence of a third molecular species at the active site (Figure 2.5C). This third species is 
identical to the previously described trivanadate glycerol ester (TVG1), except for that 
GOL O3 is not bound to V2, being replaced by an additional oxygen atom (Figure 2.5D 
and Figure 2.6C). This third species is here referred as TVG2. 
The glycerol moiety of TVG1 and TVG2 establishes additionally hydrophobic contacts with 
Leu87, Met22, and Trp109. During substrate dephosphorylation, these residues are likely 
to be involved in substrate orientation by creating a hydrophobic surface where the 
glucose ring may lay and be further stabilised by polar contacts with Arg123, His95 and 
Arg110 (Figure 2.5D). 
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Figure 2.5 – Active site content of MtuGpgP crystallized in the presence of sodium orthovanadate. 
A – The 2Fo-Fc electron density map (blue) contoured at 1σ and the anomalous difference map 
(pink) contoured at 5 σ highlight the three anomalous difference peaks assigned to vanadium 
atoms. Catalytic residues are labelled in red. B – Penta-coordinated orthovanadate (VO4) 
covalently bound to His11 and stabilised by a complex network of hydrogen bonds (dashed lines).  
C – Trivanadate glycerol (TVG1) covalently bound to His11 and Glu84 (labelled in red). Vanadium, 
oxygen and carbon atoms of TVG1 are in purple, red and yellow, respectively. Hydrogen bonds are 
represented by dashed lines. The 2Fo-Fc electron density map is contoured as in A. The dotted 
ellipse highlights the electron density feature that suggests the presence of the species in D.  D – 
Trivanadate glycerol (TVG2) covalently bound to His11 and Glu84 (labelled in red). The glycerol 
moiety is oriented by hydrophobic contacts with Met22, Leu87 and Trp109, and stabilised by a 
polar contact with His95. The atoms of TVG2 are coloured as in C. Catalytic residues are labelled 
as in A. The 2Fo-Fc electron density map is contoured as in A. 
Chapter 2 
84 
 
 
Figure 2.6 – Vanadate species present in the active site of MtuGpgP. A – Orthovanadate (VO4) 
covalently bound to His11 and displaying a trigonal bipyramidal geometry. B and C – Trivanadate 
glycerol ester species (B – TVG1; C – TVG2), obtained from the reaction between vanadate 
(wheat) and glycerol (brown), and covalently bound to His11 and Glu84. All vanadium atoms are 
penta-coordinated with trigonal bipyramidal geometry. D – Interatomic distances in VO4 and TVG 
molecules. The bond type was assigned based on interatomic distances (
a
). The vanadium-oxygen 
double bond in histidine-bonded vanadate can occur with atom O1 or O2 (
b
). 
 
In a previous work, the crystallographic structure of Bacillus stearothermophilus 
phosphatase (PhoE) in complex with trivanadate was reported (Rigden, Littlejohn et al. 
2003). This phosphatase displays 34% amino acid sequence identity with GpgP from M. 
tuberculosis and they share a conserved active site. As for MtuGpgP, the trivanadate 
present in the active site of PhoE is covalently bound to the catalytic residues His10 and 
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Glu83 (PhoE sequence numbering). However, trivanadate was modelled as V3O8 (ligand 
ID VN3), instead of V3O9
2-, with tetra-coordinated vanadium atoms. 
More recently, the structure of a recombinant MtbGpgP in complex with vanadate was 
reported (Zheng, Jiang et al. 2014). Bound vanadate was modelled as metavanadate 
(VO3
2-, ligand ID VO3) covalently bound to the catalytic histidine, and displaying a 
pyramidal geometry. There is also a coordinating water molecule opposed to the histidine, 
suggesting penta-coordination of the vanadium. Moreover, the V-O interatomic distances 
are significantly shorter (1.60 Å) than the distances to His Nɛ2 (2.00 Å) or the water 
molecule (2.25 Å). Given the covalent link to histidine, smaller differences in the 
interatomic distances would be expected.  
The structures of PhoE and MtbGpgP were determined at 2.0 and 2.3 Å resolution, 
respectively (Rigden, Littlejohn et al. 2003, Zheng, Jiang et al. 2014). The electron density 
maps (2Fo-Fc and Fo-Fc) of PhoE generated automatically in Coot (Emsley, Lohkamp et 
al. 2010) from PDB entry 1H2F and those of the MtbGpgP in complex with vanadate (PDB 
entry 4QIH) calculated with PHENIX (Adams, Afonine et al. 2010) after conversion of the 
structure factor file format from the PDB database (Berman, Westbrook et al. 2000) with 
the online SF-tool (http://sf-tool.wwpdb.org/), revealed difficult to interpret residual electron 
density, which may have impaired the correct identification of the ligands. The 
considerably higher resolution (1.49Å) of MtuGpgP-vanadate complex presented here 
allowed a better interpretation of the active site contents. In consequence, the vanadate-
enzyme interaction network can be described in more detail, helping to understand the 
inhibition of phosphatases by vanadate and also elucidating the molecular details of 
phosphoryl group binding and transfer through a reaction intermediate mimic.  
The currently accepted catalytic mechanism for histidine phosphatases involves primarily 
the phosphorylation of a histidine residue simultaneously to proton transfer from a 
glutamate residue to the substrate, followed by histidine dephosphorylation concomitantly 
to the nucleophilic attack of the phosphoryl group by a water molecule previously 
activated by the negatively charged glutamate (see chapter 1 section 1.3.1). In the 
MtuGpgP-vanadate complex, Glu84 is located at a hydrogen-bond distance to the 
negatively charged O4 of VO4, which suggests that it is likely to be protonated and 
hydrogen bound to VO4. During the phosphorylation of His11, Glu84 is at an adequate 
distance to donate a proton directly to the leaving GG. Moreover, the presence of 
trivanadate glycerol molecules covalently bound to Glu84 suggests that this amino acid 
residue may have performed a nucleophilic attack directly to the trivanadate glycerol. The 
presence of orthovanadate and trivanadate glycerol molecules in the active site of 
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MtuGpgP may highlight the ability of Glu84 to shift between protonated and ionized forms, 
suggesting that Glu84 may have a fundamental role in the dephosphorylation reaction. 
 
2.3.5. MtuGpgP in complex with vanadate and GG 
MtuGpgP was also crystallized in the presence of orthovanadate and of the reaction 
product, GG. The main goal was to obtain a ternary complex mimicking the enzyme-
substrate complex. This approach was inspired on a previous work (Davies, Staker et al. 
2011) in which the spontaneous generation of vanadate-3-phosphoglycerate from 
vanadate and 3-phosphoglycerate was observed. Vanadate-3-phosphoglycerate is an 
analogue of 2,3-bisphosphoglycerate, the intermediate of the reaction catalysed by the 
2,3-bisphosphoglycerate-depent PGM from Burkholderia pseudomallei. The vanadate-3-
phosphoglycerate was found covalently bound to the catalytic residue via vanadium atom, 
mimicking the 2,3-bisphosphoglycerate-enzyme intermediate. This transition-state mimic 
allowed the identification of key amino acid residues involves in substrate binding and 
catalysis. 
Although a similar result was expected for MtuGpgP, the substrate analogue glucosyl-3-
vanadate-glycerate was not found in the active site of MtuGpgP. Indeed, the active site of 
MtuGpgP co-crystallized with sodium orthovanadate and GG is occupied by VO4 
alternating with TVG molecules as observed for the MtuGpgP-vanadate complex. 
However, an additional electron density blob compatible with GG at an arginine and 
histidine rich region is present in each active site cleft (Figure 2.7A and B).  
The large electron density blob present at the entrance of the active site of molecule A 
(Figure 2.7A) is difficult to interpret, and is likely to result from different poses of GG. In 
molecule B the electron density blob is smaller and somewhat discontinuous suggesting 
that GG may have lower occupancy in this active site (Figure 2.7B). The different 
occupancy displayed by GG in the active site of molecule A and B is probably due to 
crystal packing constrains. Since the active site of molecule B is in a superopen state, the 
bonding network is probably weaker and thus GG is less frequently observed in this active 
site. In both cases, the electron density present in each cleft is within hydrogen bond 
distance of residues from molecules A and B, which highlights the interdependence of the 
two monomers of MtuGpgP for substrate binding. 
A GG molecule was modelled in the active site of molecule B (Figure 2.7B), establishing 
polar contacts with Arg106 and Arg110 of molecule B, and with Met1, Arg5 and Arg208 of 
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molecule A. Water mediated contacts are also present, involving the residues His95 of 
molecule B, and His195 and Asp210 of molecule A (Figure 2.7C). 
The electron density of GG and surrounding residues suggests a transient interaction, 
compatible with the inward movement of the substrate and the outward shuttling of the 
product from the catalytic pore. Since the glucose moiety seems to be poorly stabilised, 
the negatively charged phosphoryl group of the substrate likely plays an essential role in 
substrate binding and correct orientation. The phosphoryl group-containing substrate is 
likely to be first electrostatically attracted to the positively charged active site cleft. Then, 
transient polar contacts with the glucose moiety of the substrate may be established, 
holding the substrate and allowing its movement to the active site. In the active site, a 
complex network of hydrogen bonds with the phosphoryl group may be finally established, 
ensuring the correct orientation and stabilisation of the substrate necessary for the 
reaction. 
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Figure 2.7 – Structure of MtuGpgP in complex with GG. A and B – Active site clefts of the 
MtuGpgP dimer, highlighting the position of GG (orange) in the active site of molecule B. Molecule 
A (molA) and molecule B (molB) are coloured pale green and teal, respectively. The electron 
density 2Fo-Fc map (blue) was contoured at 1 σ. C – Polar contacts established between GG and 
MtuGpgP residues, revealing the contribution of both monomers for substrate binding. Polar 
contacts are represented as dashed lines. Water molecules (w) are labelled. Molecules A (molA) 
and B (molB) are coloured as in A and B. 
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2.4. Supplemental information 
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Supplemental figure S2.1 – X-ray diffraction patterns from MtuGpgP crystals. The data from the 
iodide-containing crystal (A) and from the higher-resolution diffracting crystal (B) were collected at 
a synchrotron radiation source using 1.55 or 0.98 Å wavelength X-rays, respectively. The 
diffraction patterns in A and B are the result of merging 20 and 5 consecutive 0.1º rotation images, 
respectively. The red circles correspond to the resolution limits indicated. 
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Supplemental figure S2.2 – Unit cell arrangement of MtuGpgP crystals. A – Unit cell content of 
MtuGpgP crystals belonging to space group P21 in two different orientations. The molecules of the 
two asymmetric units are coloured in different shades of blue. The origin of the Cartesian 
coordinate system is indicated as 0. The unit cell a, b and c-axes are indicated and are 97, 46, 
and 103 Å in length, respectively. The angle β (104º) is indicated. B – Unit cell content of 
MtuGpgP belonging to space group C2 in two different orientations. Molecules in the four 
asymmetric units are coloured blue, pale cyan, pale green and wheat. The origin of the Cartesian 
coordinate system is indicated as in A. The unit cell a, b and c-axes are indicated and are 99, 49, 
and 93 Å in length, respectively. The angle β (104º) is indicated. 
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Supplemental figure S2.3 – Theoretical scattering coefficients of iodide and vanadium as a 
function of X-ray energy. The theoretical values of fʺ (thick line) and fʹ (thin line) for iodide (red) and 
vanadium (blue) were traced over a range of energies from 5,004 eV (2.47 Å) to 16,000 eV (0.77 
Å). The plot was generated using the online tool X-ray Anomalous Scattering 
(http://skuld.bmsc.washington.edu/scatter/AS_index.html). The X-ray wavelengths used for data 
collection from the iodide-containing crystal (dashed line) and from all other MtuGpgP crystals 
(solid line) are indicated. The theoretical L-I absorption edge of iodide (5,188 eV, 2.39 Å) and K 
absorption edge of vanadium (5,465 eV, 2.27Å) are labelled. 
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Supplemental figure S2.4 – MtuGpgP three-dimensional structure coloured according to the 
atomic B-factor value. The segment Trp196-Ile205 of molecule A (molA) and molecule B (molB) 
displays different values of B-factor due to crystal packing constrains. In molecule A, the segment 
Trp196-Ile205 is stabilised by the neighbour molecule (symmetry operator -x, y, -z) displaying 
lower B-factor values, whereas in molecule B higher B-values are observed due to high mobility. 
Atoms were coloured from minimum to maximum B-factor values with a spectrum of colours from 
dark blue to red, respectively. 
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3.1. Introduction 
In a changing environment the basic requirements for bacterial growth are not always 
available. When exposed to growth-limiting stress, such as desiccation, temperature and 
pH variations, oxidative stress, antibiotics, and nutrient limitations, bacterial populations 
balance between cell death and decreased growth rates (Finkel 2006, Lipworth, 
Hammond et al. 2016). Some of the surviving cells can slow down or suspend their growth 
to a viable non-replicating state that can persist for months or years (Corper and Cohn 
1933). This process, known as dormancy, allows the viable population size to be 
maintained during the period of stress (Jones and Lennon 2010). Despite genetically 
identical to replicating bacteria, dormant cells are more tolerant to external stress, 
including heat and antibiotics (Dhar and McKinney 2007, Eldar and Elowitz 2010, Balazsi, 
van Oudenaarden et al. 2011). 
The dormancy state requires several structural modifications to maintain cell viability, 
including the accumulation of carbon stores (Hosaka and Yamashita 1984, Sillje, Paalman 
et al. 1999, Bourassa and Camilli 2009). Although the type of carbon source varies, the 
main goal seems to be common: to guarantee a rapidly mobilisable energy source to 
promote fast cell proliferation when the environmental conditions improve (Shi, Sutter et 
al. 2010), which is an advantage at the moment of outcompeting neighbouring organisms. 
In mycobacteria, the dormancy state seems to be associated to the accumulation of 
triacylglycerol (Daniel, Deb et al. 2004) and wax esters (Sirakova, Deb et al. 2012). 
However, it was demonstrated that mycobacteria accumulate GG under nitrogen-limiting 
conditions (Behrends, Williams et al. 2012, Alarico, Costa et al. 2014), which are able to 
induce dormancy in M. smegmatis (Shleeva, Mukamolova et al. 2004, Anuchin, Mulyukin 
et al. 2009). In vitro, GG prevented the loss of activity for a number of enzymes 
(Sawangwan, Goedl et al. 2010), suggesting that GG is also likely to contribute for protein 
stability in vivo during a slow-growing or non-replicating phase. In M. smegmatis and M. 
hassiacum, intracellular GG accumulated during nitrogen starvation is quickly depleted 
when nitrogen availability is restored, a reduction associated to the up-regulation of a 
gene coding for a glucosylglycerate hydrolase (GgH) (Alarico, Costa et al. 2014). Although 
no data are available on the role of GgH in bacterial survival, dormancy and infection, the 
high degree of conservation of GgH among rapid-growing mycobacteria and other 
unrelated phyla strongly suggests that the ability to produce this hydrolase is an evolutive 
advantage. Moreover, since it is up-regulated upon relief of the growing-limiting stress, 
GgH is likely to participate in the resuscitation phase of mycobacteria by hydrolysing GG 
into glucose and glycerate (Alarico, Costa et al. 2014) that can be quickly used for energy 
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production and for the synthesis of structural molecules necessary for fast bacterial 
proliferation. 
The antibiotics currently in use for fighting mycobacterial infections mainly counter DNA 
replication or RNA, proteins or cell wall synthesis, indispensable functions for cell growth 
(Kohanski, Dwyer et al. 2010). Since these processes are almost suppressed in dormant 
cells, these are more likely to survive treatment with antibiotics. Indeed, dormant cells 
have been associated to post-treatment relapse and development of genetic resistance 
(Gomez and McKinney 2004, Levin and Rozen 2006). Targeting essential molecules for 
bacterial dormancy and resuscitation, such as potentially GgH, may be a viable path for 
an effective treatment (Lewis 2007, Rittershaus, Baek et al. 2013). 
M. hassiacum GgH (MhaGgH) belongs to the CAZy GH63 family of glycoside hydrolases 
(CAZy database, http://www.cazy.org) (Lombard, Golaconda Ramulu et al. 2014), for 
which only four of more than 1900 assigned members have been structurally 
characterized (Kurakata, Uechi et al. 2008, Barker and Rose 2013, Miyazaki, Ichikawa et 
al. 2015). Although MhaGgH displays only 36% sequence identity to the recently 
characterized MgH from Thermus thermophilus (Tt8MGH) (Miyazaki, Ichikawa et al. 
2015), it catalyses a similar reaction (Alarico, Empadinhas et al. 2013). 
In order to unveil its molecular mechanism of action, a thorough structural and functional 
characterization of MhaGgH was performed, elucidating the quaternary architecture of the 
enzyme and providing an atomic detail view of the determinants of substrate specificity. 
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3.2. Materials and methods 
3.2.1. Cloning and site-directed mutagenesis of the gaMhaGgH 
variants 
The gene encoding MhaGgH was amplified by PCR from a pET-30a-based construct 
(Alarico, Costa et al. 2014) with primers 5’-
TATACGTCTCACATGCCGCACGACCCGAGTTTCAC-3’ and 5’-
CGAATTCTTAGCCCAGCCAGTCGAGCACC-3’ containing recognition sequences for 
BsmBI and EcoRI enzymes (underlined), respectively, and cloned into the NcoI/EcoRI 
restriction sites of pETM11, originating the pETM11-MhaGgH expression vector (see 
Table 3.1 for details). 
The point mutants of MhaGgH were obtained by site-directed mutagenesis using 
pETM11-MhaGgH as template and primers 5’-
CACATGTGGAGTTGGGCCGCCGCGTTC-3’ and 5´-
GAACGCGGCGGCCCAACTCCACATGTG-3’ (originating pETM11-D43A), 5’-
GAGTCCGGGATGGCCAACTCG-3’ and 5’-CGAGTTGGCCATCCCGGACTC-3’ 
(originating pETM11-D182A), 5’-TCGTTCGCCGCGTACTACGAA-3’ and 5’-
TTCGTAGTACGCGGCGAACGA-3’ (originating pETM11-E419A), and 5’-
CGTTGGGCAGCATGCAGTTCTCCTGGACC-3’ and 5’-
GGTCCAGGAGAACTGCATGCTGCCCAACG-3’  (originating pETM11-Q434F). 
 
3.2.2. Expression and purification of MhaGgH-His6 and gaMhaGgH 
variants 
E. coli BL21 (DE3) cells transformed with pET30a-MhaGgH (Alarico, Costa et al. 2014), 
pETM11-MhaGgH, pETM11-D43A, pETM11-D182A, pETM11-E419A or pETM11-Q434F 
plasmids were grown in LB medium supplemented with 50 g mL-1 kanamycin at 28°C to 
an OD600 of 0.7-1.0. At this point, the temperature was decreased to 25°C and the 
expression induced with 0.5 mM IPTG. After overnight growth, the cells were harvested, 
resuspended in lysis buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 5 mM MgCl2, 1  μg 
mL-1 DNAse, 0.3 mg mL-1 lysozyme, 1 mM PMSF), and stirred gently on ice for 1 h. The 
protein extracts were clarified by centrifugation, supplemented with 20 mM imidazole, and 
loaded onto immobilized metal affinity columns (Agarose Bead Technologies) loaded with 
nickel and pre-equilibrated in buffer B (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 20 mM 
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imidazole). Bound MhaGgH variants were eluted with 100 mM imidazole in buffer B. For 
histidine tagless MhaGgH variants (named gaMhaGgH due to the presence of a Gly-Ala 
dipeptide at the N-terminus of the proteins at the end of the purification procedure), 
MhaGgH-containing fractions were pooled and the hexahistidine tag removed by digestion 
with tobacco etch virus (TEV) protease (1:5 molar ratio) at 4°C concomitantly to an 
overnight dialysis against dialysis buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 0.5 mM 
EDTA, 1 mM DTT). Untagged gaMhaGgH was separated from the hexahistidine tag, 
tagged MhaGgH and TEV protease by a second immobilized-metal affinity 
chromatography step (see above for experimental conditions). The flowthrough containing 
gaMhaGgH was concentrated on 10 kDa cut-off ultrafiltration devices (Millipore) and 
loaded onto a HiPrep 26/60 Sephacryl-200 HR (GE Healthcare) size exclusion column 
using 20 mM Tris-HCl pH 8.0, 400 mM NaCl (storage buffer) as mobile phase. Fractions 
containing gaMhaGgH were pooled and concentrated on a 10 kDa cut-off ultrafiltration 
device (Millipore). For the hexahistidine-tagged MhaGgH variant (MhaGgH-His6), 
MhaGgH-containing fractions from the immobilized-metal affinity chromatography were 
pooled, concentrated and loaded onto the HiPrep 26/60 Sephacryl-200 HR column using 
the same procedure as for gaMhaGgH variants. The size-exclusion chromatography 
fractions containing MhaGgH-His6 were pooled and concentrated as described for 
gaMhaGgH variants. The concentration of the purified proteins was estimated by 
measuring their absorbance at 280 nm. The protein solutions were flash-frozen in liquid 
nitrogen and kept at -80°C until needed. 
 
3.2.3. Expression and purification of selenomethionine-containing 
gaMhaGgH 
E. coli B834 (DE3) cells transformed with pETM11-MhaGgH were grown in 25 mL LB 
medium overnight at 37°C. Cells were collected and washed thrice with sterile deionized 
water and used to inoculate 1 L SelenoMethionine Medium (Molecular Dimensions). The 
culture was grown at 30°C until an OD600 of 0.7-0.8 before inducing expression with 0.5 
mM IPTG. After overnight growth, the cells were harvested, resuspended in lysis buffer, 
and incubated on ice with gentle agitation for 1 h. The protein extract was clarified by 
centrifugation, supplemented with 20 mM imidazole and 5 mM β-ME, and loaded onto an 
immobilized metal affinity column (Agarose Beads Technologies) loaded with nickel and 
pre-equilibrated with buffer B supplemented with 5 mM β-ME. Bound protein was eluted 
with 100 mM imidazole and 5 mM β-ME in buffer B. Fractions containing 
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selenomethionine-labelled gaMhaGgH (SeMet-gaMhaGgH) were pooled and dialysed in 
the presence of TEV protease (1:5 molar ratio) against 50 volumes of dialysis buffer for 2 
h at room temperature followed by an overnight incubation at 4°C. Untagged SeMet-
gaMhaGgH was separated from non-cleaved material and TEV protease by a second 
immobilized-metal affinity step under the same experimental conditions. The flowthrough 
containing the untagged protein was concentrated to 2.3 mg mL-1 in a 30 kDa cutoff 
ultrafiltration device (Millipore) with concomitant buffer exchange to storage buffer 
supplemented with 0.5 mM EDTA and 1 mM DTT. 
 
3.2.4. Analytical size-exclusion chromatography 
Analytical size-exclusion chromatography was performed on a Superdex 200 increase 
5/150 GL column (GE Healthcare) pre-equilibrated with storage buffer. The column was 
calibrated with blue dextran (2,000 kDa), ferritin (440 kDa), aldolase (158 kDa), 
conalbumin (75 kDa), ovalbumin (43 kDa) and ribonuclease A (13.7 kDa) standards. The 
Kav vs log MW was calculated with the equation 𝐾𝑎𝑣 =
𝑉𝑒− 𝑉0
𝑉𝑡−𝑉0
, where Ve is the elution 
volume of the protein, V0 is the void volume of the column and Vt is the column bed 
volume. 
 
3.2.5. Dynamic light scattering analysis 
Dynamic light scattering (DLS) analysis was performed on a Zetasizer Nano ZS DLS 
system (Malvern Instruments). Protein samples were centrifuged at 13,000xg and 4°C for 
20 min, loaded on a ZEN2112 cuvette, and three independent measurements recorded at 
20°C. All data were analysed using Zetasizer software 7.11 (Malvern Instruments). 
 
3.2.6. Differential scanning fluorimetry 
The melting temperature of all MhaGgH variants was determined by a thermal shift 
(Thermofluor) assay. Each protein sample (0.5 mg mL-1 final concentration) was 
centrifuged at 13,000xg and 4°C for 15 min, mixed with 5x SYPRO Orange (Life 
Technologies) in storage buffer, and loaded in white 96-well PCR plates (Bio-Rad), sealed 
with Optical-Quality Sealing Tape (Bio-Rad). The plate was heated from 25 to 95°C in 
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0.5°C steps with 30 s hold time per step on an iCycler iQ5 Multicolor Real-Time PCR 
Detection System (Bio-Rad) and the fluorescence was followed using a Cy3 dye filter (545 
nm excitation / 585 nm emission). The experiment was performed in triplicate. The melting 
curves were analysed using the CFX Manager software (Bio-Rad), and the melting 
temperature determined as the inflexion point of the melting curve. 
 
3.2.7. Chemical synthesis of GG, MG and GGlycolate 
The chemical synthesis of glucosylglycerate [GG, 2-O-(α-D-glucopyranosyl)-D-glycerate], 
mannosylglycerate [MG, 2 -O-(α-D-mannopyranosyl)-D-glycerate] and glucosylglycolate 
[GGlycolate, 2-O-(α-D-glucopyranosyl)-D-glycolate) were performed by Eva Lourenço and 
Rita Ventura (Bioorganic Chemistry Group, ITQB, Universidade Nova de Lisboa, Portugal) 
as previously described (Lourenço et al. 2009; Lourenço and Ventura, 2011). 
 
3.2.8. Substrate specificity of gaMhaGgH 
The activity of gaMhaGgH was evaluated in a 50 µL reaction mixture containing 2.75 µM 
enzyme, 20 mM GG, 25 mM sodium phosphate pH 6.0, 5 mM MgCl2, 100 mM KCl 
(standard reaction). The hydrolysis of GG was detected by thin layer chromatography 
(TLC) (Silica Gel 60, Merck) using a solvent system composed of 
chloroform/methanol/acetic acid/water (30:50:8:4, v/v/v/v) and the products stained as 
previously described (Alarico, Costa et al. 2014). Enzyme specificity was probed with 5 
mM and 20 mM MG, GGlycolate or glucosylglycerol [GGlycerol, 2-O-(α-D-glucopyranosyl-
D-glycerol; Bitop, Germany] as substrates (experimental conditions described above). All 
reactions were performed at 42°C and 50°C for 1h, 3h and overnight. Control reactions 
without enzyme were also performed. The reaction products were analysed by TLC as 
described above, except for the reactions containing GGlycerol in which the solvent 
system used was a chloroform/methanol/ammonia 25% (30:50:25, v/v/v) mixture. These 
experiments were performed by Susana Alarico (Molecular Mycobacteriology Group, CNC 
– Center for Neuroscience and Cell Biology, University of Coimbra, Portugal). 
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3.2.9. Catalytic activity analysis of gaMhaGgH mutants 
The activity of gaMhaGgH point mutants (D43A, D182A, E419A, Q434F) was evaluated 
with GG and MG in 50 µL reactions containing 2.75 µM enzyme and 10 or 20 mM GG or 
MG in 25 mM buffer (sodium phosphate pH 6.0, or sodium acetate pH 4.5 or pH 5.0, or 
Bis-Tris Propane (BTP) pH 7.0, or Tris-HCl pH 8.0), 5 or 10 mM MgCl2, in presence or 
absence of 100 mM KCl. Reactions were performed at 37°C, 42°C and 50°C for 1 h and 
overnight. Reaction mixtures with and without wild-type gaMhaGgH were used as controls. 
Substrate hydrolysis was evaluated by TLC, as described above. The experiments for the 
evaluation of Q434F mutant activity were performed by Susana Alarico (Molecular 
Mycobacteriology Group, CNC, University of Coimbra, Portugal). 
 
3.2.10. Biochemical and kinetic parameters of gaMhaGgH 
The effect of temperature, pH, metallic cations and salt concentration on gaMhaGgH 
activity and its half-life were evaluated by quantifying the glucose released upon GG 
hydrolysis by gaMhaGgH using the Glucose Oxidase Assay Kit (Sigma-Aldrich), as 
previously described (Alarico, Costa et al. 2014). The temperature profile of gaMhaGgH 
and MhaGgH-His6 variants was traced from 20 to 60°C using 20 mM GG, in 20 mM 
sodium phosphate pH 6.0, 100 mM KCl, 5 mM MgCl2 reaction buffer. The effect of pH on 
the activity of gaMhaGgH and MhaGgH-His6 was determined at 55 and 42°C, respectively, 
using 20 mM sodium acetate (pH 4.0-5.5) or 20 mM sodium phosphate (pH 5.8-7.0). For 
gaMhaGgH, the effect of pH was also analysed at 37°C using 20 mM sodium acetate (pH 
5.0-5.5), sodium phosphate (pH 6.0-8.0), Tris-HCl (7.0-9.0) or CAPSO (9.0-9.5) buffers. 
The pH values were adjusted using the conversion factor (pKa/T [°C]) of 0.002 for 
sodium acetate, -0.0028 for sodium phosphate and -0.031 for Tris-HCl (Good, Winget et 
al. 1966). The effect of metallic cations on gaMhaGgH activity was examined by adding 5 
mM chloride salts of Mg2+, Mn2+, Co2+, Ca2+, Fe2+, Zn2+ or Cu2+ to the standard reaction. 
Reactions without metallic cations or with 5 mM EDTA were performed as controls. The 
effect of KCl concentration on gaMhaGgH activity was tested from 40 to 250 mM KCl. The 
half-life of the enzymes was evaluated by incubating MhaGgH aliquots (25 µL of a 2.8 μg 
μL-1 protein solution in storage buffer) at 42°C (MhaGgH-His6) or 55°C (gaMhaGgH). 
Reaction aliquots were collected at different time points (up to 24h), cooled on ice, and the 
residual activity was quantified under the optimized reaction conditions. 
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Kinetic parameters of gaMhaGgH activity against GG and MG were determined by 
quantifying the release of glucose (as described above) or mannose using the K-MANGL 
01/05 assay kit (Megazyme), respectively. A constant concentration of the enzyme (2.75 
μM) was incubated with increasing concentrations of GG or MG in 20 mM sodium 
phosphate pH 6.0, 100 mM KCl, 5 mM MgCl2 at 50°C. Maximum velocity (Vmax) and half 
constant (K0.5) were calculated with Prism (GraphPad Software), using the allosteric 
sigmoidal equation. All experiments were performed in triplicate by Susana Alarico, 
(Molecular Mycobacteriology Group, CNC, University of Coimbra, Portugal). 
 
3.2.11. Crystallization of gaMhaGgH variants 
Initial crystallization conditions were screened at 20°C with commercial sparse-matrix 
crystallization screens. Sitting-drop vapour-diffusion experiments were set up in 96-well 
CrystalQuick plates (Greiner Bio-One) using a Cartesian PixSys 4200 crystallization robot 
(Genomic Solutions) at the High Throughput Crystallization Laboratory (HTX Lab) of the 
EMBL Grenoble Outstation (Grenoble, France). The drops consisted of equal volumes 
(100 nL) of gaMhaGgH (at 9.5 mg mL-1 in storage buffer) and crystallization solution and 
were equilibrated against an 88 µL reservoir. Three-dimensional wild-type gaMhaGgH 
crystals appeared in condition 95 of the Morpheus sparse-matrix screen (Molecular 
Dimensions) after one day. The crystals were optimized in-house using 24-well Cryschem 
M plates (Hampton Research) from drops composed of equal volumes (1 µL) of protein 
and precipitant solutions equilibrated against 300 µL of 0.1 M Tris-Bicine pH 8.5, 0.1 M 
amino acids (glutamate, alanine, glycine, lysine and serine at equal molar concentration) 
and 24-34% GOL_P4K (2:1 of (v/v) glycerol to (w/v) PEG 4,000) as precipitant. Crystals 
were obtained after 1 to 2 d, and those growing from less than 30% GOL_P4K were first 
transferred to a solution containing at least 30% GOL_P4K before flash-cooling in liquid 
nitrogen. Both SeMet-gaMhaGgH and the gaMhaGgH point mutants were crystallized in 
the same conditions, although wild-type gaMhaGgH macro-seeds were employed to 
promote crystal growth of the point mutants. The complexes of D182A with GG, MG and 
GGlycolate were obtained by soaking the crystals in mother liquor supplemented with 100 
mM of ligand for 2 h (GG or MG) or 25 min (GGlycolate) before flash-cooling in liquid 
nitrogen. The complexes of E419A with GG, MG, GGlycolate and GGlycerol were 
obtained by soaking the crystals in mother liquor supplemented with 100 mM of ligand for 
5 (GG), 50 (MG), 40 (GGlycolate) or 10 min (GGlycerol). Crystals of wild-type gaMhaGgH 
were also obtained in the absence of serine, by omitting this compound from the amino 
acid mixture of the crystallization buffer. An additional crystallization condition was 
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identified in-house, in 24-well plates at 20°C, yielding crystals within a day from drops 
containing equal volumes (1 µL) of protein (at 9.5 mg mL-1 in storage buffer) and 
precipitant solution, equilibrated against 300 µL of solution 22 (0.1 M ADA pH 6.5, 1.0 M 
ammonium sulfate) of the MembFac sparse-matrix screen (Hampton Research). Crystals 
of Q434F mutant were also obtained in this last crystallization condition, containing 0.4-
1.0 M ammonium sulfate. The gaMhaGgH and Q434F crystals were cryo-protected with 
Perfluoropolyether PFO-X175/08 (Hampton Research) or the crystallization condition 
supplemented with 30% (w/v) glucose, respectively, before being flash-cooled in liquid 
nitrogen.  
 
3.2.12. Data collection and processing 
Diffraction data were collected from cryo-cooled (100 K) single crystals at beamlines ID23-
2 (Flot, Mairs et al. 2010), ID29 (de Sanctis, Beteva et al. 2012), ID30A-1 (Bowler, Nurizzo 
et al. 2015, Svensson, Malbet-Monaco et al. 2015), ID30A-3 (Theveneau, Baker et al. 
2013) and ID30B (Mueller-Dieckmann, Bowler et al. 2015) of the European Synchrotron 
Radiation Facility (ESRF, Grenoble, France) and PROXIMA-2A (Duran, Le Couster et al. 
2013) of the French National Synchrotron Source (SOLEIL, Gif-sur-Yvette, France) (see 
Table 3.2 for details). All data sets were automatically processed by the Grenoble 
Automatic Data ProcEssing pipeline (Monaco, Gordon et al. 2013), except those collected 
at ID30B-3 and PROXIMA-2A beamlines, which were processed with XDS (Kabsch 2010) 
and reduced with utilities from the CCP4 program suite (Winn, Ballard et al. 2011). The 
data sets from the selenomethionine-substituted crystals were scaled with XSCALE 
(Kabsch 2010). X-ray diffraction data collection and processing statistics are summarized 
in Table 3.2. 
 
3.2.13. Structure determination, model building and refinement 
The structure of gaMhaGgH was solved by two-wavelength anomalous diffraction using 
the anomalous signal of a selenium-substituted gaMhaGgH crystal with the 
SHELXC/SHELXD/SHELXE pipeline (Sheldrick 2010) and the HKL2MAP GUI (Pape and 
Schneider 2004). Automated model building was subsequently performed with 
ARP/wARP (Langer, Cohen et al. 2008). The refined coordinates were used as search 
model to solve the structure of all other gaMhaGgH variants and complexes by molecular 
replacement using PHASER (McCoy, Grosse-Kunstleve et al. 2007). Alternating cycles of 
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model building with Coot (Emsley, Lohkamp et al. 2010) and refinement with PHENIX 
(Adams, Afonine et al. 2010) were performed until model completion. Refined coordinates 
and structure factors were deposited at the Protein Data Bank (Berman, Westbrook et al. 
2000) under the PDB accession codes indicated in Table 3.3. Refinement statistics are 
summarized in Table 3.3. 
 
3.2.14. Analysis of crystallographic structures 
The crystallographic models were superposed with Coot (Emsley, Lohkamp et al. 2010) 
and the secondary structure elements were identified with DSSP (Kabsch and Sander 
1983, Touw, Baakman et al. 2015). The interface area between the monomers was 
determined using PISA (Krissinel and Henrick 2007). The molecular surface electrostatic 
potential was calculated with APBS (Baker, Sept et al. 2001) using the AMBER force field 
(Cornell, Cieplak et al. 1995). Figures depicting molecular models were created using 
PyMOL (Schrödinger). 
 
3.2.15. SAXS measurement and analysis 
SAXS measurements were performed at beamline BM29 (Pernot, Round et al. 2013) of 
the ESRF (Grenoble, France) with radiation of 0.9919 Å wavelength on a Pilatus 1M 
detector (Dectris). Protein was loaded onto a Superdex 200 3.2/300 GL (GE Healthcare) 
column and eluted with storage buffer. Measurements (1 Hz data collection rate) were 
performed on the column eluate at 4°C over a scattering vector (s = 4πsinΘ/λ) range of 
0.033-4.933 nm-1. Data were processed and analyzed with the ATSAS package 
(Petoukhov, Franke et al. 2012). A Guinier plot was calculated using PRIMUS QT 
(Konarev, Volkov et al. 2003). The theoretical scattering curve from the crystallographic 
model was fitted to the experimental scattering curve with CRYSOL (Svergun, Barberato 
et al. 1995). 
 
3.2.16. MST analysis 
Interactions between catalytically inactive D182A or E419A gaMhaGgH mutants and GG 
or MG were assessed by microscale thermophoresis (MST) on a Monolith NT.115 
instrument (NanoTemper Technologies). Purified proteins were labelled using the 
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Monolith NT™ Protein Labelling Kit RED-NHS (NanoTemper Technologies) according to 
the manufacturer’s instructions after buffer exchange to 50 mM HEPES pH 7.8, 300 mM 
NaCl, 0.05% Tween

-20 (labelling buffer). Labelled proteins were separated from the 
free dye on a gravity flow column using 50 mM Tris-HCl pH 7.8, 150 mM NaCl, 10 mM 
MgCl2, 0.05% Tween

-20 (MST buffer) as mobile phase. Protein concentration was 
estimated by measuring the absorbance at 280 nm. A constant concentration of labelled 
protein [160 nM, diluted 1:25 in 100 mM Tris-HCl pH 8.0, 400 mM NaCl (MST assay 
buffer)] was incubated with increasing concentrations of substrate (6.10 μM - 200 mM) in 
MST assay buffer in a 10 μL reaction volume. Measurements were performed at room 
temperature on Monolith™ NT.115 MST Premium Coated Capillaries (NanoTemper 
Technologies) with 50% LED power and 40% MST power. Three and two independent 
experiments were performed for D182A and E419A, respectively. Data were analysed 
and images were prepared using PALMIST (Scheuermann, Padrick et al. 2016).  
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3.3. Results and discussion 
3.3.1. MhaGgH production and crystallization 
MhaGgH variants were expressed in E. coli and purified to homogeneity by a combination 
of immobilized metal-affinity and size exclusion chromatography. Initially, the 
crystallization experiments were performed using the MhaGgH-His6 construct, containing 
a C-terminal hexahistidine tag linked to the native MhaGgH sequence (Table 3.1), and for 
which biochemical characterization was previously performed (Alarico, Costa et al. 2014). 
The initial crystallization trials were performed at EMBL Grenoble Outstation HTX Lab 
(France). Spherulites were obtained in drops composed of 2.5 to 10% PEG (3,350, 5,000, 
6,000, 8,000 or MME 5,000) and buffered from pH 8.0 to 9.5 with 100 mM Tris-HCl, bicine 
or CHES.  The quality of the crystals was subsequently improved to thin individual crystal 
plates by adjusting the crystallization solution composition (precipitant type and 
concentration, buffer type and pH and additives) and vapour-diffusion rate (oil barrier, 
protein-to-precipitant drop ratio and drop-to-reservoir ratio) and by micro [cat whisker, 
Seed BeadTM Kit (Hampton research)] and macroseeding. Similar results were also 
obtained by microseed matrix screening (Ireton and Stoddard 2004) (Figure 3.1A), 
however none of the crystals tested diffracted X-rays to high resolution. 
Since the C-terminal tag could be interfering with crystallization, a new construct was 
produced. The new construct contained a N-terminal hexahistidine tag separated from the 
native MhaGgH sequence by a TEV recognition site that allowed proteolytic tag removal 
(Table 3.1). The TEV protease cleavage resulted in an additional Gly-Ala dipeptide N-
terminal to the native MhaGgH amino acid sequence and therefore this construct was 
named gaMhaGgH. Initial crystallization conditions were identified using extensive 
sampling of commercial sparse-matrix crystallization screens at HTX Lab (France). Three-
dimensional crystals were obtained in condition 95 of the Morpheus sparse-matrix screen 
(Molecular Dimensions) within 1 day. These crystals were reproduced in-house (Figure 
3.1B).  
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Table 3.1 – Macromolecule production information. 
 MhaGgH-His6 gaMhaGgH 
Source organism M. hassiacum DSM 44199  
Expression vector pET30a pETM11 
Complete amino-acid 
sequence of the 
construct produced
a
 
MPHDPSFTPTQLAARAAYLLRGNDL
GTMTTAAPLLYPHMWSWDAAFVAIG
LAPLSVERAVVELDTLLSAQWRNGM
IPHIVFANGVDGYFPGPARWATATL
ADNAPRNRLTSGITQPPVHAIAVQR
ILEHARTRGRSTRAVAEAFLDRRWG
DLMRWHRWLAECRDRNERGRITLYH
GWESGMDNSPRWDSAYANVVPGKLP
EYQRADNVIITDPSQRPSDGEYDRY
LWLLEEMKAVRYDDERLPSVMSFQV
EDVFFSAIFSVACQVLAEIGEDYKR
PHADVKDLYLWAERFRAGVVETTDQ
RTGAARDFDVLAEKWLVTETAAQFA
PLLCGGLPHDRERALLKLLEGPRFC
GHPDLKYGLIPSTSPVSRDFRPREY
WRGPVWPVLTWLFSWCFARRGWAER
ARLLRQEGLRQASDGSFAEYYEPFT
GEPLGSMQQSWTAAAVLDWLGKLAA
ALEHHHHHH 
MKHHHHHHPMSDYDIPTTENLYFQG
AMPHDPSFTPTQLAARAAYLLRGND
LGTMTTAAPLLYPHMWSWDAAFVAI
GLAPLSVERAVVELDTLLSAQWRNG
MIPHIVFANGVDGYFPGPARWATAT
LADNAPRNRLTSGITQPPVHAIAVQ
RILEHARTRGRSTRAVAEAFLDRRW
GDLMRWHRWLAECRDRNERGRITLY
HGWESGMDNSPRWDSAYANVVPGKL
PEYQRADNVIITDPSQRPSDGEYDR
YLWLLEEMKAVRYDDERLPSVMSFQ
VEDVFFSAIFSVACQVLAEIGEDYK
RPHADVKDLYLWAERFRAGVVETTD
QRTGAARDFDVLAEKWLVTETAAQF
APLLCGGLPHDRERALLKLLEGPRF
CGHPDLKYGLIPSTSPVSRDFRPRE
YWRGPVWPVLTWLFSWCFARRGWAE
RARLLRQEGLRQASDGSFAEYYEPF
TGEPLGSMQQSWTAAAVLDWLG 
No of amino acids 459 472 (tagged), 448 (untagged) 
Theoretical molecular 
weigth (Da) 
52,288 53,895 (tagged), 50,897 
(untagged) 
Mutants produced None D43A, D182A, E419A, Q434F 
a
 The residues removed by TEV protease cleavage are italicized. The sequence of native MhaGgH 
is underlined. 
 
In order to solve the phase problem selenomethionine-containing gaMhaGgH was also 
produced. This variant was considerable less soluble than the unlabelled protein under 
the same experimental conditions. Therefore, SeMet-gaMhaGgH could only be 
concentrated to a fourfold lower concentration than the unlabelled material. Under 
crystallization conditions similar to the wild-type enzyme, two SeMet-gaMhaGgH crystals 
were obtained after four months (Figure 3.1C). The slower crystallogenesis of selenium-
labelled gaMhaGgH is most likely due to the lower sample concentration. 
Point mutants of active site residues potentially involved in catalysis and/or substrate 
binding were also produced (Table 3.1). These mutants (D43A, D182A, E419A, Q434F) 
were produced and crystallized in condition identical to the wild-type gaMhaGgH, albeit 
with the addition of wild-type seeds to promote crystal growth (Figure 3.1E to G). The 
crystals of mutant Q434F grew at a significantly slower rate and reached a considerable 
smaller size than the other mutants. 
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Three-dimensional crystals of gaMhaGgH were also obtained in-house within 1 day in 
another crystallization condition containing 0.1 M ADA pH 6.5, 1.0 M ammonium sulfate 
(Figure 3.1D). Due to the difficulty in crystallizing the Q434F mutant, the ability of this 
condition to promote Q434F crystal growth was also tested. Crystals of Q434F were easily 
obtained without requiring the addition of wild-type crystal seeds to promote crystal growth 
(Figure 3.1H).  
 
Figure 3.1 – Crystals from MhaGgH variants. A – Crystals of MhaGgH-His6 obtained by microseed 
matrix screening. B – gaMhaGgH crystal grown from a mixture of Tris-Bicine, amino acids and 
GOL_P4K. C – SeMet-gaMhaGgH crystal obtained in the same crystallization condition as in B. D 
– gaMhaGgH crystal obtained from the ammonium sulfate containing crystallization solution. E to G 
– Crystals of the gaMhaGgH point mutants D43A (E), D182A (F) and E419A (G) obtained by 
macroseeding from the same crystallization condition as in B. H – Crystals from mutant Q434F 
obtained in the same crystallization condition as in D. The scale bars represent a length of 0.2 mm.  
 
3.3.2. Overall structure of gaMhaGgH 
The X-ray diffraction from cryo-protected crystals was measured at synchrotron radiation 
sources (Table 3.2; Supplemental figure S3.1). Two diffraction data sets were recorded 
from a single SeMet-gaMhaGgH crystal at wavelengths corresponding to the peak and the 
inflexion point of the K absorption edge of selenium (Supplemental figure S3.2). The 
crystal belonged to the monoclinic space group P21 and diffracted X-rays to 2.0 Å 
(Supplemental figure S3.3A). The collected data sets were used to solved the phase 
Chapter 3 
113 
 
problem by two-wavelength anomalous diffraction phasing with the 
SHELXC/SHELXD/SHELXE pipeline (Sheldrick 2010) and the HKL2MAP GUI (Pape and 
Schneider 2004). SHELXD identified 27 of the 36 (nine per molecule) selenium atoms 
present in the asymmetric unit (CCall = 23.6%; CCweak = 17.8%), corresponding to SeMet 
residues 153, 232, 246 and 432 of all molecules, as well as SeMet residue 28 of 
molecules B and C, SeMet residue 39 of molecules A, B and C, and SeMet residues 75 
and 181 of molecules A, B and D. Experimental phasing with density modification using 
SHELXE resulted in excellent electron-density maps, with a final FOM of 0.652 and a 
pseudo-free CC of 71.3%. The autotracing function of SHELXE produced a 1,411-residue 
poly-Ala model (CC for partial structure against native data = 36.1%). Subsequent 
automated model building with ARP/wARP (Langer, Cohen et al. 2008) using the 
SHELXE-derived phases resulted in an initial model with 1,677 (out of 1,792) residues 
built and sequenced. The crystallographic model of gaMhaGgH was further improved 
through alternating cycles of manual building with Coot (Emsley, Lohkamp et al. 2010) 
and refinement with PHENIX (Adams, Afonine et al. 2010). The asymmetric unit contains 
four gaMhaGgH monomers, corresponding to a Matthews coefficient of 3.07 Å3 Da-1 and a 
solvent content of 59.9%.  
Refined coordinates of the SeMet-gaMhaGgH model were used to solve the phase 
problem of a higher-resolution data set (1.68 Å) collected from a native gaMhaGgH 
crystal. Although crystallizing in identical conditions, the unlabelled gaMhaGgH crystals 
belong to space group P21212 (Supplemental figure S3.3B). The crystal contains two 
molecules in the asymmetric unit, corresponding to a Matthews coefficient of 2.95 Å3 Da-1 
and a solvent content of 58.3%. The crystallographic structure was improved by 
alternating cycles of manual model building with Coot (Emsley, Lohkamp et al. 2010) and 
refinement with PHENIX (Adams, Afonine et al. 2010). The structure solution and 
refinement statistics are summarized in table 3.3. 
 
 
Chapter 3 
114 
 
Table 3.2 – Data collection and processing statistics
a
 (continued on next page). 
Crystal 
SeMet gaMhaGgH gaMhaGgH 
SER-GOL 
gaMhaGgH 
w/o Serine 
gaMhaGgH 
Apo 
D43A 
SER-GOL 
D182A 
SER-GOL 
E419A 
SER-GOL Peak Inflexion point 
Synchrotron 
radiation facility 
ESRF ESRF ESRF ESRF ESRF ESRF ESRF 
Beamline ID29 ID30B ID30A-3 ID29 ID30A-1 ID30A-3 ID30A-1 
Detector Dectris PILATUS3 6M 
Dectris 
PILATUS 6M 
Dectris 
EIGER X 4M 
Dectris 
PILATUS3 6M 
Dectris 
PILATUS3 2M 
Dectris 
EIGER X 4M 
Dectris 
PILATUS3 2M 
Wavelength (Å) 0.97909 0.97924 0.97265 0.96770 0.96863 0.96598 0.96770 0.96600 
Frames 1,500 1,500 2,400 1,200 1,300 2,180 2,500 640 
Rotation (°) 0.1 0.1 0.05 0.1 0.05 0.05 0.05 0.2 
Space group P21 P21212 P21212 P6222 P21212 P21212 P21212 
Unit cell 
parameters 
a=90.8 Å; b=86.1 
Å; c=159.7 Å; 
=93.0° 
a=90.9 Å; b=86.3 
Å; c=159.7 Å; 
=93.0° 
a=86.0 Å; b=158.8 
Å; c=87.8 Å 
a=85.9 Å; b=159.3 
Å; c=91.2 Å 
a=b=167.0 Å; 
c=243.3 Å 
a=85.9 Å; b=159.1 
Å; c=88.2 Å 
a=86.3 Å; b=158.1 
Å; c=87.7 Å 
a=86.2 Å; b=159.4 
Å; c=88.4 Å 
Resolution range 
(Å) 
57.4 – 2.04 
(2.07 – 2.04) 
58.6 – 2.06 
(2.09 – 2.06) 
48.6 – 1.68 
(1.74 – 1.68) 
40.3 – 2.00 
(2.04 – 2.00) 
49.9 – 2.54 
(2.63 – 2.54) 
48.7 – 1.78 
(1.85 – 1.78) 
42.2 – 1.75 
(1.78 – 1.75) 
48.8 – 2.07 
(2.14 – 2.07) 
Reflections 
(measured/unique) 
428,683/151,619 419,987/148,763 595,791/135,623 390,265/84,736 474,316/66,272 460,425/114,314 581,967/119,738 338,529/73,877 
Completeness (%) 96.5 (82.1) 97.4 (87.6) 99.0 (98.4) 99.6 (99.8) 99.8 (99.7) 98.9 (93.5) 98.8 (99.3) 98.9 (92.6) 
Multiplicity 2.8 (2.8) 2.8 (2.7) 4.4 (4.5) 4.6 (4.8) 7.2 (7.3) 4.0 (4.0) 4.9 (5.0) 4.6 (4.0) 
Anomalous 
completeness 
68.3 (53.3) 85.0 (71.9)       
Anomalous 
multiplicity 
1.2 (1.7) 1.3 (1.5)       
Rmerge
b 
0.105 (0.637) 0.105 (0.561) 0.047 (0.860) 0.084 (1.276) 0.109 (1.165) 0.057 (0.824) 0.070 (0.987) 0.094 (1.032) 
Rmeas
c 
0.128 (0.776) 0.129 (0.690) 0.053 (0.972) 0.094 (1.426) 0.117 (1.254) 0.066 (0.954) 0.079 (1.102) 0.106 (1.176) 
Rp.i.m.
d 
0.072 (0.438) 0.074 (0.397) 0.025 (0.444) 0.042 (0.622) 0.043 (0.459) 0.032 (0.472) 0.035 (0.480) 0.048 (0.551) 
Half-set correlation 
CC1/2 
0.990 (0.659) 0.990 (0.657) 0.999 (0.637) 0.998 (0.559) 0.998 (0.673) 0.999 (0.529) 0.998 (0.579) 0.997 (0.625) 
Half-set 
anomalous 
correlation CCAnom 
0.355 (-0.028) 0.166 (0.018)       
Mean (I)/ (I) 7.6 (1.6) 7.1 (1.8) 16.4 (1.7) 12.1 (1.2) 11.9 (1.8) 13.0 (1.7) 11.6 (1.6) 10.0 (1.3) 
Protomers per 
asymmetric unit 
4 4 2 2 2 2 2 2 
Matthews 
coefficient (Å
3
Da
-1
) 
3.07 3.08 2.95 3.07 4.82 2.97 2.94 2.99 
Solvent content 
(%) 
59.9 60.1 58.3 59.9 74.5 58.6 58.2 58.9 
Average mosaicity 0.17 0.20 0.04 0.17 0.08 0.10 0.06 0.23 
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Table 3.2 – Data collection and processing statistics
a
 (continued from previous page). 
a 
Values in parenthesis correspond to the outermost resolution shell. 
b 𝑅𝑚𝑒𝑟𝑔𝑒 =  ∑  ∑  |𝐼𝑖(ℎ𝑘𝑙) −  〈𝐼ℎ𝑘𝑙〉|𝑖 ℎ𝑘𝑙   ∑ ∑ 𝐼𝑖(ℎ𝑘𝑙)𝑖 ℎ𝑘𝑙 ⁄ , where 𝐼𝑖(ℎ𝑘𝑙) is the observed intensity and 〈𝐼ℎ𝑘𝑙〉 is the average intensity of multiple observations of symmetry-related reflections. 
c
 𝑅𝑚𝑒𝑎𝑠 = ∑ √
𝑛
𝑛−1ℎ𝑘𝑙
∑ |𝐼𝑖(ℎ𝑘𝑙) − 〈𝐼ℎ𝑘𝑙〉|
𝑛
𝑖=1 ∑ ∑ 𝐼𝑖(ℎ𝑘𝑙)𝑖ℎ𝑘𝑙⁄ , where 𝐼𝑖(ℎ𝑘𝑙)  is the observed intensity and 〈𝐼ℎ𝑘𝑙〉 is the average intensity of multiple observations of symmetry-related reflections. 
d
 𝑅𝑝.𝑖.𝑚. = ∑ √
1
𝑛−1
 ∑  |𝐼𝑖(ℎ𝑘𝑙) − 〈𝐼ℎ𝑘𝑙〉| 
𝑛
𝑖=1ℎ𝑘𝑙  ∑  ∑ 𝐼𝑖(ℎ𝑘𝑙)𝑖 ℎ𝑘𝑙⁄ , where 𝐼𝑖(ℎ𝑘𝑙) is the observed intensity and 〈𝐼ℎ𝑘𝑙〉  is the average intensity of multiple observations of symmetry-related reflections. 
Crystal 
D182A 
GG 
D182A 
MG 
D182A 
GGlycolate 
E419A 
GG 
E419A 
MG 
E419A 
GGlycolate 
E419A 
GGycerol 
Q434F 
SER-GOL 
Q434F 
Apo 
Synchrotron 
radiation facility 
ESRF ESRF ESRF ESRF ESRF SOLEIL ESRF ESRF ESRF 
Beamline ID30A-1 ID30A-1 ID23-2 ID30A-1 ID30B PROXIMA 2 ID30A-3 ID30A-3 ID30A-3 
Detector 
Dectris 
PILATUS3 2M 
Dectris 
PILATUS3 2M 
Dectris 
PILATUS3 2M 
Dectris 
PILATUS3 2M 
Dectris 
PILATUS 6M 
Dectris 
EIGER X 9M 
Dectris 
EIGER X 4M 
Dectris 
EIGER X 4M 
Dectris 
EIGER X 4M 
Wavelength (Å) 0.96600 0.96600 0.87290 0.96599 0.97625 0.98011 0.96770 0.96770 0.96770 
Frames 3,200 900 3,200 2,500 3,600 1,800 2,200 3,600 3,600 
Rotation (°) 0.05 0.2 0.05 0.05 0.05 0.1 0.05 0.1 0.05 
Space group P21212 P21212 P21212 P21212 P21212 P21212 P21212 P21212 P6222 
Unit cell parameters 
a=85.3 Å; 
b=159.6 Å; 
c=91.0 Å 
a=85.3 Å; 
b=159.6 Å; 
c=91.2 Å 
a=86.2 Å; 
b=158.9 Å; 
c=88.0 Å 
a=86.1 Å; 
b=159.1 Å; 
c=88.4 Å 
a=87.8 Å; 
b=158.2 Å; 
c=87.6 Å 
a=86.9 Å; 
b=157.7 Å; 
c=87.6 Å 
a=86.9 Å; 
b=158.8 Å; 
c=87.7 Å 
a=85.6 Å; 
b=158.8 Å; 
c=88.3 Å 
a=b=169.2 Å; 
c=241.8 Å 
Resolution range 
(Å) 
49.1 – 1.71 
(1.77 – 1.71) 
49.1 – 1.79 
(1.85 – 1.79) 
48.7 – 1.93 
(2.00 – 1.93) 
48.7 – 2.17 
(2.25 – 2.17) 
48.8 – 2.06 
(2.13 – 2.06) 
45.1 – 2.06 
(2.10 – 2.06) 
45.3 – 2.05 
(2.09 – 2.05) 
48.6 – 2.32 
(2.40 – 2.32) 
47.9 – 2.60 
(2.67 – 2.60) 
Reflections 
(measured/unique) 
801,298/133,666 780,685/117,039 547,439/91,224 301,215/64,817 475,955/74,395 500,266/75,133 322,372/76,309 712,653/52,533 1,280,221/62,925 
Completeness (%) 99.5 (99.0) 99.4 (95.9) 99.8 (98.7) 99.8 (99.5) 98.0 (89.3) 100.0 (100.0) 99.4 (100.0) 99.3 (93.5) 99.5 (100.0) 
Multiplicity 6.0 (6.1) 6.7 (6.5) 6.0 (6.2) 4.6 (4.5) 6.4 (6.0) 6.7 (6.9) 4.2 (4.4) 13.6/10.4 20.3 (21.0) 
Anomalous 
completeness 
         
Anomalous 
multiplicity 
         
Rmerge
b 
0.070 (1.081) 0.074 (1.052) 0.126 (1.227) 0.091 (0.790) 0.086 (0.979) 0.124 (1.410) 0.091 (0.901) 0.115 (1.492) 0.123 (1.923) 
Rmeas
c 
0.077 (1.183) 0.080 (1.141) 0.139 (1.340) 0.102 (0.897) 0.094 (1.069) 0.135 (1.526) 0.104 (1.027) 0.119 (1.568) 0.126 (1.969) 
Rp.i.m.
d 
0.031 (0.474) 0.031 (0.436) 0.056 (0.533) 0.047 (0.417) 0.037 (0.423) 0.052 (0.579) 0.049 (0.488) 0.032 (0.471) 0.028 (0.425) 
Half-set correlation 
CC1/2 
0.999 (0.659) 0.999 (0.660) 0.994 (0.560) 0.998 (0.642) 0.998 (0.715) 0.997 (0.575) 0.997 (0.552) 0.999 (0.536) 0.999 (0.805) 
Half-set anomalous 
correlation CCAnom 
         
Mean (I)/ (I) 13.8 (1.8) 16.5 (1.7) 8.8 (1.5) 11.3 (1.8) 12.1 (1.5) 8.2 (1.3) 9.4 (1.6) 15.4 (1.6) 18.5 (2.0) 
Protomers per 
asymmetric unit 
2 2 2 2 2 2 2 2 2 
Matthews 
coefficient (Å
3
Da
-1
) 
3.05 3.06 2.97 2.98 3.00 2.96 2.98 2.95 4.91 
Solvent content (%) 59.7 59.8 58.6 58.8 59.0 58.4 58.8 58.3 75.0 
Average mosaicity 0.07 0.13 0.05 0.10 0.09 0.14 0.09 0.15 0.08 
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Table 3.3 – Structure solution and refinement statistics (continued on next page). 
Crystal SeMet gaMhaGgH 
gaMhaGgH 
SER-GOL 
gaMhaGgH 
w/o Serine 
gaMhaGgH 
Apo 
D43A 
SER-GOL 
D182A 
SER-GOL 
E419A 
SER-GOL 
PDB code 5OHZ 5OI0 5OHC  5OIV 5OI1 5OIE 
Resolution range (Å) 57.4 – 2.04 48.6 – 1.68 40.3 – 2.00 49.9 – 2.54 45.4 – 1.78  40.0 – 1.75 48.8 – 2.07 
Rfactor
a
/Free Rfactor
b
 
(%) 
19.9/24.5 14.6/17.2 16.7/21.0 16.8/20.8 14.9/17.9 14.6/17.2 16.7/20.8 
Unique reflections 
(working/test set) 
255,146/12,657 135,565/6,808 84,685/4,330 66,186/3,360 114,235/5,735 119,673/5,953 73,714/3,718 
Completeness 
(working/test) (%) 
82.5/4.96 98.8/5.02 99.4/5.11 99.6/5.08 98.8/5.02 98.7/4.97 98.6/5.04 
Wilson B-factor (Å
2
) 28.4 25.1 33.4 53.0 29.3 26.0 39.9 
Total number of 
atoms 
15,955 8,595 8,115 7,607 8,365 8,421 7,767 
B-factor (Å
2
)        
Overall 36.1 33.4 39.1 60.0 38.1 34.2 49.4 
Protein 35.5 31.7 38.2 60.0 36.7 32.7 48.9 
Ligands 46.2 48.4 54.6  56.5 48.5 71.8 
Waters 41.3 47.3 47.2 60.8 50.4 47.8 54.3 
RMSD        
Bond lengths (Å) 0.010 0.010 0.010 0.010 0.010 0.010 0.010 
Bonds angles () 1.099 1.031 0.993 1.101 1.009 1.019 1.004 
DPI (Å) 0.164 0.073 0.130 0.180 0.086 0.080 0.140 
Polypeptide length 
A: 443 
(Asp4 – Gly446) 
B/D: 442 
(Pro5 – Gly446) 
C: 444 
(His3 – Gly446) 
445 
(Pro2 – Gly446) 
445 
(Pro2 – Gly446) 
A: 443 
(Asp4 – Gly446) 
B: 448  
(Gly-1 – Gly446) 
445 
(Pro2 – Gly446) 
445 
(Pro2 – Gly446) 
445 
(Pro2 – Gly446) 
Polypeptide gaps 0 0 0 0 0 0 0 
Water molecules 1,289 838 705 365 761 776 420 
Ligands SER, GOL SER, GOL GOL  SER, GOL SER, GOL SER, GOL 
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Table 3.3 – Structure solution and refinement statistics (continued from previous page). 
Crystal 
D182A 
GG 
D182A 
MG 
D182A 
GGlycolate 
E419A 
GG 
E419A 
MG 
E419A 
GGlycolate 
E419A 
GGlycerol 
Q434F 
SER-GOL 
Q434F 
Apo 
PDB code 5OIW 5OJ4 5ONZ 5OJU 5OJV 5OO2 5ONT   
Resolution range 
(Å) 
45.9 – 1.71 49.1 – 1.79 48.7 – 1.93 45.5 – 2.17 48.8 – 2.06 41.9 – 2.06 45.3 – 2.05 41.3 – 2.32 46.6 – 2.60 
Rfactor
c
/Free Rfactor
d
 
(%) 
14.6/16.8 14.4/17.3 14.9/18.5 15.6/19.8 15.5/19.4 16.2/20.2 15.4/19.5 15.3/20.3 18.2/22.1 
Unique reflections 
(working/test set) 
133,615/6,717 116,974/5,861 91,157/4,566 64,760/3,281 74,327/3,733 75,046/3,625 76,246/3,909 52,473/2,595 62,782/3,089 
Completeness 
(working/test) (%) 
99.3/5.03 99.4/5.01 99.7/5.01 99.7/5.07 97.8/5.02 99.9/4.83 99.2/5.13 99.3/4.95 99.4/4.92 
Wilson B-factor 
(Å
2
) 
24.9 25.6 28.3 35.7 39.5 39.7 33.7 50.8 60.4 
Total number of 
atoms 
8,376 8,421 8,283 7,817 7,840 7,868 7,944 7,503 7,473 
B-factor (Å
2
)          
Overall 33.8 33.5 36.3 44.0 44.3 52.7 44.0 60.0 65.4 
Protein 32.1 31.8 34.9 43.6 43.6 52.3 43.3 59.8 65.3 
Ligands 49.2 48.5 49.1 56.2 55.8 64.3 53.7 81.1  
Waters 45.9 46.5 48.6 47.8 53.0 57.0 51.3 62.2 68.5 
RMSD          
Bond lengths 
(Å) 
0.010 0.010 0.010 0.009 0.009 0.010 0.010 0.009 0.010 
Bonds angles () 1.025 0.986 0.984 1.005 0.985 1.030 1.011 0.974 1.139 
DPI (Å) 0.072 0.083 0.108 0.150 0.130 0.135 0.129 0.1787 0.1987 
Polypeptide length 
445 
(Pro2 – Gly446) 
445 
(Pro2 – Gly446) 
445  
(Pro2 – Gly446) 
445  
(Pro2 – Gly446) 
445  
(Pro2 – Gly446) 
445  
(Pro2 – Gly446) 
A: 440  
(Pro2 – Gly446) 
B: 437  
(Pro2 – Gly446) 
445 
(Pro2 – Gly446) 
A: 440 
(Asp4 – Gly446) 
B: 438 
(Pro5 – Gly446 
Polypeptide gaps 0 0 0 0 0 0 
2 
(A: Asp206 – 
Ile210; 
B: Gln203 – 
Ile210) 
0 
2 
(A: Tyr202 – 
Asp206;  
B: Arg204 – 
Asn207) 
Water molecules 847 846 677 419 463 426 566 255 280 
Ligands 9WN 2M8 GOL, SER, 9YW 9WN GOL, SER, 2M8 GOL, SER, 9YW A0K GOL, SER  
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The two macromolecules present in the asymmetric unit (hereby termed molecule A and 
molecule B) were modelled from residue Pro2 to Gly446. The overall globular MhaGgH 
monomer (Figure 3.2) is composed of two domains: an (α/α)6-barrel domain that in MhaGgH 
encompasses helices α2, α4, α6, α8, α10 and α12 in the inner layer and α1, α3, α5, α7, α9 
and α11 in the outer layer, and a more flexible cap domain that constrains access to the 
active site of the enzyme and can in turn be divided into two subdomains, termed A’-region 
(residues 163 to 252) and B’-region (residues 68 to 118). Five mobile loops are also 
noteworthy: loop-A (between α1 and β1, residues 23-38), loop-B (between B’β1 and B’α1a, 
residues 81-91), loop-C (between A’ α2b and A’α3, residues 193-205), loop-D (between α9 
and α10, residues 346-381) and loop-E (between β6 and α12, residues 430-434).  
MhaGgH displays 68% secondary structure identity with the single structurally characterized 
mannosylglycerate hydrolase (Thermus thermophilus HB8 MgH, Tt8MGH; PDB accession 
codes 4WVA, 4WVB and 4WVC) (Miyazaki, Ichikawa et al. 2015), despite the much lower 
36% sequence identity (calculated with PDBeFold (http://www.ebi.ac.uk/msd-srv/ssm) 
(Krissinel and Henrick 2004)). So far, only other three MgH enzymes have been 
biochemically characterized: the orthologues from Selaginella moellendorffii (Nobre, 
Empadinhas et al. 2013), from T. thermophilus HB27 (99% amino acid sequence identity to 
Tt8MgH), and from Rubrobacter radiotolerans (Alarico, Empadinhas et al. 2013). Despite 
relatively low overall amino acid sequence conservation, substrate interacting residues are 
highly conserved among all characterized MgH enzymes (Supplemental figure S3.4). 
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Figure 3.2 – Three-dimensional structure of MhaGgH. A – Topology diagram of gaMhaGgH with 
helices (α1 to α12, A’α1 to A’α6, and B’α1), strands (β1 to β5, A’β1 to A’β2, and B’β2) and mobile 
loops (Loop-A to Loop-E) represented as salmon cylinders, blue arrows and yellow ovals, respectively. 
Catalytic residues are labelled in red. The A’ and B’ regions are highlighted in pink and blue, 
respectively. B – Overall structure of the gaMhaGgH monomer (carton representation). Rotation of the 
top view 90° around x-axis originates the bottom view. The (α/α)6 domain is coloured mauve, and A’ 
and B’-regions are coloured salmon and blue, respectively. The N and C-termini are indicated in 
yellow. 
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3.3.3. Quaternary structure of gaMhaGgH 
The molecular size of gaMhaGgH in solution was evaluated by size exclusion 
chromatography and DLS (Figure 3.3A and B). Despite its theoretical molecular weight of 
50.9 kDa, the gaMhaGgH variant displayed an apparent molecular weight of 178.65 kDa, 
corresponding to approximately 3.5 times the expected mass of the monomer and 
compatible with a trimeric or a tetrameric organization. On the other hand, the MhaGgH-His6 
variant displayed an apparent molecular weight of 92.64 kDa, only 1.8-fold higher than the 
molecular weight of the monomer and compatible with a dimer (Figure 3.3A). The DLS 
analysis of the MhaGgH-His6 and gaMhaGgH variants reveals an increase in the hydration 
radius from 5.75 to 7.34 nm, also supporting a difference in the oligomeric organization of the 
two variants (Figure 3.3B). Moreover, DLS analysis also revealed a lower polydispersity 
index for the gaMhaGgH solution, indicating higher homogeneity. 
The thermal stability of MhaGgH-His6 and gaMhaGgH was evaluated by differential scanning 
fluorimetry. Both variants produced a typical denaturation curve with a clear and sharp 
temperature transition, allowing the straightforward estimation of the Tm from the inflexion 
point of the melting curve. The gaMhaGgH variant displayed significantly higher thermal 
stability (Tm = 62ºC) than MhaGgH-His6 (Tm = 56ºC) in the experimental conditions used 
(Figure 3.3D).  
Altogether, these results suggest that the hexahistidine tag present at the C-terminus of the 
MhaGgH-His6 variant affects protein stability probably by interfering with protein 
oligomerization.  
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Figure 3.3 – Biophysical characterization of MhaGgH variants. A – Analytical size-exclusion 
chromatography of MhaGgH-His6 (dotted line) and gaMhaGgH (solid line) variants. The standards 
used for column calibration (see Material and Methods) are indicated as downward black triangles. B – 
Analysis of MhaGgH-His6 (dotted line) and gaMhaGgH (solid line) by DLS. The gaMhaGgH sample 
displayed a larger hydrodynamic radius (RH = 7.34 nm) and lower polydispersity index (PdI = 0.092) 
than the MhaGgH-His6 variant (RH = 5.75 nm; PdI = 0.201). C – Superposition of the experimental 
small X-ray scattering (SAXS) data and the theoretical SAXS curve calculated from the tetrameric 
crystallographic model of MhaGgH. D – Melting temperature of MhaGgH variants determined by 
differential scanning fluorimetry, highlighting the lower stability of the MhaGgH-His6 variant. 
 
In the crystals, gaMhaGgH is arranged as a dimer of dimers with approximate dimensions 85 
x 80 x 65 Å3 (Figure 3.4). The total surface area of each monomer is 17,298 Å2. All 
monomers of the tetramer share an interface with each other. The largest interface area 
(900 Å2) occurs between molecules A and C (interface A:C), and molecules B and D, and is 
maintained by 14 (A:C) and 12 (B:D) hydrogen bonds. The interface area between the A:B 
and C:D dimers is 478 Å2, and includes 10 salt bridges. The interface between molecules A 
and D and molecules B and C is the smallest one with an area of 261 Å2, involving a single 
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hydrogen bond. The total interface area per monomer is approximately 1,636 Å2 (9.5% of the 
total surface area). No covalent bonds are found at the intermonomer interfaces 
(Supplemental table S3.1) (PISA analysis) (Krissinel and Henrick 2007).  
 
 
 
 
Figure 3.4 – Quaternary structure of gaMhaGgH. The monomers (cartoon representation) are 
coloured in green (molecule A), wheat (molecule B), cyan (molecule C) and blue (molecule D). The 
interfaces A:B or A:C are indicated. The active site is highlighlited in salmon. The α-helices are 
numbered. The approximate dimensions of the homotetramer are indicated. 
 
The evaluation of gaMhaGgH dimensions in solution was also performed by SAXS. A Guinier 
analysis of the SAXS data was performed with PRIMUS QT (Konarev, Volkov et al. 2003), 
allowing the direct estimation of a radius of gyration of 41.9 Å, which is similar to the 
approximate dimensions of the crystallographic model (Figure 3.4). Also, a theoretical SAXS 
curve was generated from the atomic structure data and fitted to the experimental scattering 
curves with CRYSOL (Svergun, Barberato et al. 1995), revealing a good agreement between  
the SAXS data and the crystallographic model (Figure 3.3C).  
The structural analysis of the gaMhaGgH tetramer revealed that the C-termini of molecules A 
and C, and of molecules B and D (Figure 3.5) are hydrogen bound. The C-terminus of each 
molecule adopts two different conformations (Figure 3.5B and C), the most frequent of which 
(52% occupancy in the highest resolution structure) (Figure 3.5B) is the only conformation 
observed in lower resolution models. In this conformation, the carboxyl group of Gly446 is 
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stabilised by two hydrogen bonds with the side chains of Thr8 and Thr10, located at helix α1 
of the neighbour molecule. Interestingly, these two threonine residues are separated by a 
proline (Pro9), which confers rigidity to this segment. Water-mediated contacts are also 
present, involving His129, Leu442, Asp443, and Gln11. The other conformation of the C-
terminus is illustrated in figure 3.5C, with Gly446 establishing polar contacts with the side 
chain of Gln11 and the main chain of Leu442. Additionally, the carbonyl group of Leu445 is 
hydrogen bonded to the side chain of Thr10. A glycerol molecule is likely to contribute to the 
stabilisation of this alternative conformation by interacting with Gly446 (Figure 3.5C). 
However, in glycerol-free crystals (Figure 3.1D) the C-terminus of GgH seems to adopt a 
single conformation similar to the conformation less frequently found in glycerol-containing 
crystals (Figure 3.5C and D). While the latter is stabilised by polar contacts with the glycerol 
molecule, in glycerol-free crystals the C-terminus is stabilised by a hydrogen bond with 
His129. 
The biophysical analysis of the MhaGgH-His6 variant pointed towards the formation of a 
dimer in solution, suggesting that the hexahistidine C-terminal tag interferes with tetramer 
formation by avoiding the interaction between dimers. Indeed, the space available at the 
centre of the tetramer is too small to accommodate four tags of 13 amino acids each (Table 
3.1). Thus, the hexahistidine tags are likely to physically impair the contact between dimers. 
Also, the C-terminal tag may affect the hydrogen bond network between the C-terminus and 
helix α1 occurring between molecules A and C, and molecules B and D (Figure 3.5). 
However, the largest intermonomer contact area in the gaMhaGgH tetramer is found 
between these molecules, doubling the contact area observed between A-B or C-D dimers, 
and in which other interactions are also present (Supplemental table S3.1). Therefore, it is 
more likely that the MhaGgH-His6 variant oligomerizes forming dimers equivalent to those 
corresponding to molecules A and C (or B and D) in the gaMhaGgH structure.  
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Figure 3.5 – Contribution of the C-terminus for oligomerization. A – Interface between monomers B 
(wheat) and D (blue), highlighting the polar contacts between the C-terminus of one monomer and 
helix α1 of the neighbouring monomer. The two alternative conformations of the C-terminus of 
molecules B and D are coloured in different shades of yellow and blue, respectively (inset). Hydrogen 
bonds are represented by dashed lines. B – Network of polar contacts at the C-terminus, with Gly446 
stabilised by polar contacts with Thr8 and Thr10 of the neighbour monomer. Hydrogen bonds are 
represented by dashed lines. C – Alternative conformation of the C-terminus, stabilised by an 
intramolecular hydrogen bond between Leu442 and Gly446, and by intermolecular contacts between 
Leu445 and Thr10, and Gly446 and Glu11. A glycerol (GOL) molecule (salmon) is at hydrogen 
bonding distance of Gly446 and may contribute for the alternative conformation of the C-terminus. 
Hydrogen bonds are represented as in B. D – C-terminus of GgH in glycerol-free crystals, stabilised by 
intramolecular hydrogen bonds with His129, Leu442 and Asp443 and by intermolecular contacts 
between Leu445 and Thr8 and Thr10. Hydrogen bonds are represented as in B. 
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3.3.4. Biochemical characterization of MhaGgH variants  
The biochemical characterization of the MhaGgH-His6 variant was performed previously 
(Alarico, Costa et al. 2014). Unlike its bacterial homologues from T. thermophilus HB27 and 
R. radiotolerans, which display identical activity against GG and MG (Alarico, Empadinhas et 
al. 2013), MhaGgH-His6 seems to be more efficient for GG than MG. Since the quaternary 
structure was affected by the presence of the hexahistidine tag, a new biochemical 
characterization was performed for the untagged variant. 
The activity of gaMhaGgH against GG and MG was first evaluated by TLC (Figure 3.6), 
confirming the ability of this enzyme to hydrolyse both substrates. Despite lower efficiency for 
MG, the gaMhaGgH variant was able to produce more mannose compared to the MhaGgH-
His6 variant for a given reaction time. The increased production of mannose is probably 
associated to the higher stability of gaMhaGgH.  
 
 
 
 
 
 
 
Figure 3.6 - Hydrolysis of GG and MG by MhaGgH variants. The different MhaGgH variants were 
incubated with GG (A) or MG (B) and their ability to hydrolyse the substrate was evaluated by TLC. 
Both MhaGgH-His6 and gaMhaGgH variants were able to hydrolyse GG and MG, however a lower 
residual substrate amount was detected for the gaMhaGgH variant. None of the point mutants 
(D182A, E419A and D43A) produced a detectable amount of glucose or mannose. 
 
Under the conditions tested, gaMhaGgH displays maximum activity at 55°C (Figure 3.7A), 
which is 13°C higher than the previously reported value for MhaGgH-His6 variant (42°C) 
(Alarico, Costa et al. 2014), in agreement with the optimal temperature of growth of M. 
hassiacum (50°C) (Tiago, Maranha et al. 2012). The higher optimal temperature of activity of 
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gaMhaGgH variant reflects its higher thermal stability (Figure 3.3D), which in turns explains 
its longer half-life (Figure 3.7B).  
 
Figure 3.7 – Effect of temperature on the activity of gaMhaGgH and MhaGgH-His6. A – The 
temperature profile was determined between 20 and 60°C. The optimal temperature of activity for 
gaMhaGgH (55°C) is significantly higher than that of MhaGgH-His6 (42°C) (Alarico, Costa et al. 2014). 
B – Time-dependent activity profile of gaMhaGgH (55°C) and MhaGgH-His6 (42°C), highlighting the 
higher resistance of the gaMhaGgH variant to thermal inactivation. (Experiments performed by 
Susana Alarico, Molecular Mycobacteriology Group, CNC, University of Coimbra, Portugal). 
 
At the optimal temperature of activity, the gaMhaGgH variant displayed maximum activity at 
pH 6.0, which is very similar to the value reported for the MhaGgH-His6 variant (pH 5.8) 
(Alarico, Costa et al. 2014). As also observed for the MhaGgH-His6 variant, the activity of 
gaMhaGgH seems to be slightly increased by the presence of divalent cations, especially by 
Mg2+ (25% increase). The activity of gaMhaGgH was maximal in the presence of 100 mM 
KCl, which allowed optimizing the buffer composition for the downstream biochemical 
analysis of gaMhaGgH activity.  
The kinetics parameters for gaMhaGgH were determined at 50°C (Supplemental figure 
S3.5A and C). A more adequate fitting of the experimental data into an allosteric sigmoidal 
curve was observed for both MhaGgH-His6 and gaMhaGgH variants, with a Hill coefficient 
higher than 1, which supports the hypothesis of positive cooperativity (Table 3.4). Moreover, 
the calculated Hill coefficient was higher for the gaMhaGgH variant than for MhaGgH-His6, 
suggesting a higher cooperative effect in the tetramer compared to the dimer.  
The kinetic values found for the hydrolysis of GG and MG by gaMhaGgH reflect an 
approximately 10-fold higher hydrolysis efficiency for GG. However, the kinetic curve 
obtained for MG is incomplete, resulting in a large standard-deviation for the value of Khalf, 
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and a larger range of MG concentrations would have to be tested. Nevertheless, the different 
efficiency for both substrates is clear. Additionally, an activity curve was also measured at 
37°C and pH 8.0, where the reaction is slower (Supplemental figure S3.6B). The sigmoidal 
character of this curve is more evident, supporting the fitting of the data to an allosteric 
kinetic model.   
 
Table 3.4 – Kinetic parameters of GG and MG hydrolysis at 50°C. Experimental data were analyzed 
using the allosteric kinetic model. The higher h value for the gaMhaGgH variant suggested an 
increased cooperative effect. A lower affinity for MG is expected due to the higher estimated Khalf 
value. 
Kinetic parameters 
GG MG 
MhaGgH-His6 gaMhaGgH gaMhaGgH 
Vmax (μmol/min mg protein) 9.34 ± 0.58 3.60 ± 0.18 3.09 ± 0.66 
Khalf (mM) 6.53 ± 0.76 9.36 ± 0.69 84.18 ± 30.27 
h 1.44 ± 0.15 1.77 ± 0.20 1.29 ± 0.23 
R2 0.993 0.974 0.990 
 
 
3.3.5. Open and closed: mobility as an essential feature for substrate 
binding and hydrolysis 
In the orthorhombic crystals, the gaMhaGgH molecules adopt a closed conformation, 
concomitant to the presence of two ligands – a molecule of glycerol and a molecule of L-
serine, components of the crystallization buffer – at the active site (gaMhaGgH-SER-GOL). 
The glycerol molecule occupies subsite -1 and serine subsite +1 of the active site, inducing 
the closed state of gaMhaGgH and rendering them inaccessible to the solvent. Interestingly, 
the enzyme crystallized in the absence of serine also adopts a similar conformation, with 
subsite +1 occupied by water molecules (Supplemental figure S3.6). 
In an alternative crystallization condition, gaMhaGgH crystallized in space group P6222, with 
two protomers in the asymmetric unit (Supplemental figure S3.7). These two molecules 
correspond to dimer A-C and were modelled from Asp4 (molecule A) or Gly-1 (molecule C) 
to Gly446. The active site of gaMhaGgH contains only solvent (hence the name gaMhaGgH-
Apo) and adopts an open conformation. 
In the open conformation, the active site is accessible to the exterior through a negatively 
charged tunnel (Figure 3.8A). The tunnel is lined by the side chains of Gln115, Asp212, 
Gln215, Asp43, Ser214, Gln434, Tyr88 and the carbonyl groups of Trp177 and Gly180. 
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Interestingly, the putative catalytic residues, Asp182 and Glu419, are pointing away from the 
active site cavity. Asp182 is stabilised by polar contacts with the side chains of Tyr191 and 
Tyr225 and with the carbonyl group of Arg216 through a water molecule (Supplemental 
figure S3.8). The side chain of Glu419 is hydrogen bonded to the side chain of Ser435 and 
the amide nitrogens of Met432 and Thr437 (Supplemental figure S3.8). 
When serine and glycerol molecules occupy the active site, the cavity completely closes to 
the solvent (Figure 3.8B). The ligands are stabilised and oriented mainly by hydrogen bonds 
with the binding site residues, and the putative catalytic residues are facing the lumen of the 
active site cavity. 
The two structures of gaMhaGgH, corresponding to open and closed conformations, reveal 
the structural modifications occurring upon substrate binding (Figure 3.9). The active site is 
surrounded by mobile loops that allow active site exposure and guarantee a polar surface for 
substrate binding and accommodation. Indeed, several residues involved in substrate 
binding are present in these loops, including Tyr36 (loop A), His78, Tyr88 (loop B), Tyr375, 
Trp376 (loop D) and Gln434 (loop E). The access to the active site is also restricted by a 
flexible cap that also contains important residues for substrate binding (Gly180, Arg216 and 
Tyr222) as well as the putative catalytic residue Asp182. Substrate binding contributes for 
the formation of an additional helix in this cap (residues 206-209) that is absent in the open 
conformation.  
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Figure 3.8 – Open and closed conformations of MhaGgH. A and B – Surface electrostatic potential 
(contoured from -8kT/e (red) to 8kT/e (blue)) of the MhaGgH monomer in open (A) and closed (B) 
conformations. In the open conformation, an opening leading to an acidic cavity is observed on the 
surface of the molecule (dashed ellipse), which is absent in the closed conformation state. C and D – 
Cross section of MhaGgH monomer in open (C) and closed (D) conformation.  In the open state, a 
negatively charged tunnel (arrow) connects the active site cavity to the exterior of the molecule. In the 
closed state, the active site cavity (marked with an asterisk) becomes inaccessible to solvent. 
Substrate-binding residues are highlighted in yellow. The molecular surface was coloured by 
electrostatic potential as in A and B. 
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Figure 3.9 – Conformational changes in gaMhaGgH induced by substrate binding. Open (lighter hues) 
and closed (darker hues) states of monomeric gaMhaGgH are shown. The A’-region (flexible 
segment), and loops A, B, D and E are coloured salmon, blue, yellow, green and brown, respectively. 
Some of the substrate-interacting residues present in the highlighted regions [Tyr36 (loop A), Tyr88 
(loop B), Arg216, Tyr222 (A’-region), Tyr375, Trp376 (loop D) and Gln434 (loop E)] are represented as 
sticks. 
 
A particularly significant modification is observed in the segment Arg21-Ala31 (loop A) 
(Figure 3.9). In the open conformation, this loop displays higher mobility and covers the 
segment Ser431-Ser435 that contains the substrate-interacting residue Gln434. In the closed 
conformation, Gln434 faces the active site and binds to the substrate, while Gln433 moves 
outward (6Å), forcing the segment Arg21-Ala31 to move away from its initial position. 
Moreover, upon substrate binding this segment is stabilised by polar contacts with the 
substrate via Tyr36 and with helices α3 and α12.  
In the open conformation structure, the segment Arg21-Ala31 is localized close to a 
symmetry axis relating molecules A and C. The electron density map in this region suggests 
the presence of alternative conformations. Therefore, it is possible that this segment interacts 
with the equivalent region of the neighbour molecule, and thus impacts enzyme activity. 
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3.3.6. Molecular details of substrate and substrate-analogue binding 
3.3.6.1. Inactive point mutants of gaMhaGgH 
In order to understand the molecular determinants underlying substrate binding and 
specificity, crystals of wild-type gaMhaGgH were also obtained in the presence of its 
substrates (GG and MG), substrate analogues (GGlycerol and GGlycerate) and products of 
reaction (glucose, mannose and glycerate) or soaked into the crystallization condition 
containing these compounds. However, none of these ligands could be found in the active 
site of wild-type gaMhaGgH crystals. To avoid substrate hydrolysis during crystallization or 
soaking, three catalytically inactive point mutants were produced. The mutations were 
performed based on sequence alignment with other characterized MgHs and on the 
gaMhaGgH-SER-GOL ternary complex structure. Two putative catalytic residues (Asp182 
and Glu419) and one substrate holder residue (Asp43) were identified (Suplemental figure 
S3.4) and replaced by alanine to produce three point mutants (D43A, D182A and E419A).  
The gaMhaGgH point mutants were produced using the protocol developed for wild-type 
gaMhaGgH. The solubility of the mutants was very similar to that of the wild-type enzyme, 
except for the D182A mutant which was considerably less soluble. The thermal stability of 
these mutants was evaluated by differential scanning fluorimetry (Figure 3.3D) and no 
significant difference was observed, except for mutant D43A that displayed a 3°C lower Tm 
than wild-type gaMhaGgH. 
The ability of the mutants to hydrolyse GG and MG was analysed by TLC (Figure 3.6). In the 
conditions tested, none of the mutants produced detectable amounts of glucose or mannose 
and thus were considered inactive.  
 
3.3.6.2. Inactive point mutants in complex with substrates 
The inactive point mutants produced were crystallized in the same condition as wild-type 
gaMhaGgH. Since the mutants were less crystallogenic, macroseeds of wild-type 
gaMhaGgH were used to accelerate crystallization. Crystals of the mutants were soaked into 
crystallization buffer containing GG or MG to yield binary complexes.  
The crystals obtained belong to space group P21212, diffract to 1.75-2.1 Å and contain 2 
molecules per asymmetric unit, corresponding to dimer A-B of the tetramer (Table 3.2). 
Analysis of the active site of mutants D182A and E419A revealed the presence of residual 
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electron density, compatible with the substrates (Figure 3.10). However, for mutant D43A 
none of the substrates was found in the active site, independently on the soaking time, 
reflecting the important contribution of Asp43 for substrate binding. This residue is a 
substrate holder and establishes two hydrogen bonds with the glucose or mannose moiety of 
the substrate (Figure 3.11). 
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Figure 3.10 – Substrates and substrate analogues of MhaGgH. The substrate GG (A) and MG (B), 
and the substrate analogues GGlycerol (C) and GGlycolate (D) were soaked into the crystals of 
mutants D182A (middle) and E419A (right) to yield binary complexes. Chemical representation of the 
ligands is on the left. The oxygen atom numbering is indicated. The D182A-GGlycerol complex could 
not be obtained. The 2Fo-Fc electron density maps (blue) are contoured at 1 σ. 
 
The gaMhaGgH D182A and E419A mutants in complex with each substrate were modelled 
from Pro2 to Gly446. No significant differences were observed in the active site of the 
D182A-GG and E419A-GG complexes (RMSD=0.177 Å, for 14 aligned atoms). In both 
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cases, the glucose and the glycerate moieties of GG occupy subsites -1 and +1 of the active 
site, respectively. The glucose moiety is stabilised mainly by hydrogen bonds with the side 
chains of residues Trp42, Asp43, Gln115, Asp182, Tyr375, Trp376 and Gln434 and with the 
carbonyl group of Gly180 (Figure 3.11A). The glucose moiety is also oriented by hydrophobic 
contacts with Tyr36, Trp40, Trp376, Trp436 and Trp381, and also interacts with Glu419 
through a water-mediated contact. The glycerate moiety of the substrate is stabilised by 
hydrogen bonds with Trp40, Tyr88, Asp 182, Arg216 and Tyr375. In the E419A mutant, the 
Tyr36-to-glycerate distance is decreased (from 3.75 to 3.00 Å), suggesting that in this mutant 
Tyr36 may also establish a polar contact with the glycerate moiety. Water-mediated contacts 
with the side chains of Tyr222 and Trp177 also contribute for substrate binding, as do 
hydrophobic contacts with Trp177. In the case of mutant D182A, a water molecule is 
occupying the space of Asp182 side chain (w4 in Figure 3.11A), whereas in E419A the 
contacts established by Glu419 are mimicked by two water molecules. The substrate-
interacting residues in the GG-mutants complexes are organized in a very similar way to that 
observed for the gaMhaGgH-SER-GOL (RMSD=0.191 Å, for 14 aligned atoms). The serine 
and glycerol molecules present in the active site of the gaMhaGgH-SER-GOL structure 
partially mimic a substrate, with serine superposing nicely to the glycerate moiety and the 
glycerol establishing the two hydrogen bonds with the substrate holder residue (Asp43) 
(Figure 3.11B). In the high resolution structure of wild-type gaMhaGgH, it is clear that bound 
serine can adopt more than one conformation. The conformation more frequently found (57% 
occupancy) is the one that better superposes to the glycerate moiety in the other complexes. 
Altogether, these results suggest that the GG-mutants and gaMhaGgH-SER-GOL complexes 
are likely to represent the substrate-binding mode of GG for active gaMhaGgH.  
The active site of both mutants is also very similar when MG is present (RMSD=0.106 Å, for 
10 aligned atoms) (Figure 3.11C). However, a better superposition is observed for the active 
sites containing GG, independently on the catalytic residue mutated. On the other hand, the 
worse superposition of the active sites containing MG, suggests that each active site 
undergoes a distinct rearrangement to accommodate this substrate. Due to the lower 
plasticity of the active site of wild-type gaMhaGgH, the binding of MG may be energetically 
more demanding than GG. Nevertheless, a similar hydrogen bonding network seems to be 
established for both substrates (Figure 3.11A and C), with the most significant difference 
observed for atom O15 of the substrate. In the MG-E419A mutant, O15 loses the hydrogen 
bond with Asp182 and Tyr375, and becomes at hydrogen bonding distance of the putative 
nucleophilic water (Figure 3.11C). 
In the active site, the glycosidic oxygen of both substrates is within hydrogen bonding 
distance of the catalytic residue Asp182, and Glu419 establishes a water-mediated contact 
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with substrates. The distances between the catalytic residues and substrates, and the 
presence of a single water mediating the Glu419-substrate contact suggest that MhaGgH is 
likely to hydrolyse GG and MG using an inverting mechanism that requires Asp182, Glu419 
and a water molecule, as acid, base and nucleophile, respectively (Figure 3.11D). During 
hydrolysis, the negatively charged Glu419 is likely to activate the water molecule that 
performs a nucleophilic attack on the anomeric carbon, while Asp182 donates a proton to the 
leaving glycerate. Inversion of the anomeric configuration of the glucose is expected. In a 
previous work, hydrolysis of MG by an inverting mechanism was confirmed for the 
homologous MgHs enzymes from T. thermophilus HB27 and R. radiotolerans (Alarico, 
Empadinhas et al. 2013). The ratio between α and β configurations of the mannose produced 
during MG hydrolysis was determined by NMR and found to be higher than the standard α:β-
equilibrium ratio of the mannose anomers in solution. Since the α:β-equilibrium ratio of 
glucose (ΔGºα→β = -0.35 kcal/mol) is reached faster than for mannose (ΔGºα→β = 0.45 
kcal/mol), the possible shift occurring upon hydrolysis may be difficult  to detect (Miljković 
2010). 
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Figure 3.11 – The active site of gaMhaGgH variants in complex with substrates. A – Superposition of 
the active site region of gaMhaGgH mutants D182A and E419A in complex with GG. The position of 
GG (dark or light orange for D182A or E419A, respectively) in the active site of D182A (light blue) and 
E419A (wheat) is stabilised mainly by direct hydrogen bonds or by water-mediated contacts (dashed 
lines) with the side chains of the labelled residues. The polar contacts between GG and mutant D182A 
residues are represented by black dashed lines, while the alternative contacts observed in mutant 
E419A are coloured grey. Water molecules (labelled w1 to w4) of mutants D182A or E419A are 
represented by red or salmon spheres, respectively.  Catalytic residues (D182 and E419) are 
highlighted in red. B – Superposition of the active site region of the gaMhaGgH D182A-GG complex 
(light blue with ligand in orange) to that of the gaMhaGgH-SER-GOL ternary complex (wheat). The 
ligands serine (cyan) and glycerol (yellow) mimic the substrate, allowing closure and stabilisation of 
the active site as observed for substrate-mutant complexes. The serine molecule may adopt two 
positions (coloured in different shades of cyan), with the darker shade of cyan indicating the more 
frequent position. Hydrogen bonds between glycerol or serine (dark cyan) and the residues of the 
active site are represented by dashed lines. C – Superposition of the active site region of gaMhaGgH 
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mutants D182A and E419A in complex with MG. The hydrogen bonding network involved in stabilising 
MG in the active site of the gaMhaGgH variants is similar to that observed for GG (interacting residues 
are shown as in A). The newly established contacts are represented by dashed lines. Water molecules 
are coloured as in A, highlighting the absence of w2 and nucleophilic water (wn) in the E419A-MG 
complex. D – Active site region of gaMhaGgH in complex with GG. The position of GG (orange) 
relative to the catalytic residues and the nucleophilic water are shown. The proposed mechanism of 
hydrolysis is illustrated by the arrows. 
 
 
3.3.6.2.1. Binding affinity of the substrates GG and MG 
The difference in hydrolysis efficiency of MhaGgH for GG and MG may be a consequence of 
different binding affinities. Thus, the binding affinities of the substrates were also analysed. 
Given the limited availability of the synthetic substrates, the binding affinities of the 
substrates were evaluated by MST at the Structural Biology & Genomics platform of the 
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) (Strasbourg, France), 
to which access was provided by Instruct (www.structuralbiology.eu).  
Determining the binding affinity of a substrate to its processing enzyme by MST may be 
complicated by the formation of the reaction products. Measurements performed on an 
ongoing enzymatic reaction can yield hard to interpret results, arising from all possible 
complexation states: from free enzyme to enzyme-substrate and enzyme-product 
complexes. In order to circumvent this problem, the two mutants for the catalytic residues 
were used. As demonstrated by TLC, D182A and E419A are catalytically inactive against GG 
and MG, but still able to bind to the substrates, as indicated by the three-dimensional 
structures of mutant-substrate complexes. Also, the analysis of both mutants can allow the 
identification of the individual contribution of the residues for substrate binding.  
The determination of binding affinities in a Monolith NT.115 equipment requires proteins to 
be labelled. The MhaGgH mutants were labelled with N-hydroxysuccinimide-ester dye that 
reacts efficiently with primary amines, forming highly stable dye-protein conjugates. Primary 
amines are found in lysines, which are usually solvent accessible and therefore suitable for 
labelling reactions, and at the protein N-terminus. Recombinant gaMhaGgH contains seven 
lysine residues per monomer and all are at the molecule surface and accessible to the 
solvent. Moreover, the N-terminus is disordered in the three-dimensional structures, 
suggesting that it is also prone to be labelled. Altogether, thirty two amines per gaMhaGgH 
molecule are likely to be labelled.  
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The binding affinity of the mutants for the substrates was evaluated based on changes in the 
thermophoresis (particle movement in a temperature gradient) of fluorescently labelled-
proteins in presence of different substrate concentrations. Because low affinity was 
expected, the substrate concentration was increased to the highest achievable value with the 
existing stock solution.  
Three independent measurements were performed for mutant D182A, whereas for E419A 
only two measurements were possible in the allocated time slot for the equipment. The 
D182A mutant displayed higher affinity for both substrates than variant E419A (Figure 3.12). 
This difference is likely related to mutated residue position and the corresponding 
interactions. Asp182 is localized deeply in the active site, establishing contacts almost 
exclusively with the substrate. Mutation of this residue does not affect the position of the 
other substrate-interacting residues. On the other hand, Glu419 is localized in a mobile 
segment and stabilised by polar contacts with the backbone amine of Ser431, the side chain 
of Tyr36 and through a solvent molecule with Arg216 and Tyr420. These interactions are 
important for active site closure and substrate-enzyme complex stabilisation. The substitution 
of Glu419 for an alanine is accompanied by the loss of this network of polar contacts and 
thus substrate binding is severely affected. 
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Figure 3.12 – Effect of GG and MG in the thermophoretic movement of catalytically inactive 
gaMhaGgH mutants. The binding affinities of D182A (A and B) and E419A (C and D) for GG (A and C) 
or MG (B and D) were analysed by microscale thermophoresis. The thermophoresis of the fluorescent 
protein in presence of different substrate concentrations (increasing concentrations are coloured blue 
to red) through a temperature gradient was detected and quantified (upper graphic). The microscopic 
temperature gradient is induced by turning on (dashed line) and off (dotted line) an infrared laser. The 
fluorescence average before (light blue area) and after heating (light pink area) was calculated and 
plotted against substrate to yield the dose-response curve (lower graphic). Sigmoid curves were 
obtained for the titration of D182A with GG (A) or MG (B), which allows the determination of the 
binding affinity of the interaction. The binding curve obtained for E419A with GG (C) or MG (D) lacks 
the plateau of the high ligand dose and the binding affinity cannot be determined. 
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Table 3.5 – Dissociation constant for GG and MG. 
 KD GG (mM) KD MG (mM) 
D182A 15.33  1.53 0.35  0.13 
E419A  80  300 
 
The gaMhaGgH D182A mutant displayed an approximately 100-fold lower KD for MG (0.35 
mM) than for GG (15 mM) (Table 3.5). Structurally, the active site of mutant D182A 
containing MG or GG is similar (RMSD=0.065 Å, for 12 aligned atoms). The hydrogen bonds 
observed between MG and residues Tyr36, Trp40, Trp42, Asp43, Tyr88, Gln115, Arg216, 
Tyr222 and Gln434 are also present in the GG-mutant complex with identical distances 
(Figure 3.13A). The major differences in the active site of the complexes are induced by the 
position of the substrate O15 atom. Atom O15 of GG establishes a larger number of contacts 
compared to the same atom in MG. In GG, O15 is hydrogen bonded to Tyr375, Trp376 and 
water molecule w4, while in MG O15 loses all but the interaction with Trp376 and establishes 
a new polar contact with the nucleophilic water. Although conserved, the distance between 
O15 and Trp376 is 0.2 Å longer in the MG-mutant complex (DPIGG-D182A complex=0.072 Å; 
DPIMG-D182A complex=0.083 Å). In consequence, other structural modifications in the active site 
are also observed. In the MG-D182A complex, Tyr375 is bonded to water w4, inducing a 
1.1 Å shift in Tyr375 position compared to the GG-D182A complex. Also, a 0.3 Å inward 
movement of the segment Arg371-Arg377 is noticed. The loss of the hydrogen bonding with 
water w4 in the MG complex is also accompanied by a 0.9 Å backward movement of the 
Ala182 α-carbon. While in GG-D182A complex the carbonyl group of Ala182 is bonded to 
Tyr191 by a water mediated contact, in the MG-D182A complex the backward movement of 
the Ala182 allows formation of a direct hydrogen bond with Tyr191.  
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Figure 3.13 – Active site of gaMhaGgH D182A and E419A mutants in complex with GG or MG. A – 
Superposition of the active site of mutant D182A in complex with GG (orange with residues in wheat) 
or MG (blue with residues in light blue). The hydrogen bonds between the active site residues and GG 
or MG are represented as black or grey dashed lines, respectively. B – Superposition of the active site 
of mutant E419A in complex with GG (orange with residues in wheat) or MG (blue with residues in 
light blue). The hydrogen bonds are represented as in A. 
 
The gaMhaGgH E419A mutant displayed a considerable lower affinity for both substrates 
compared to the D182A mutant. Despite using the same substrate concentration range as for 
D182A, the plateau corresponding to the substrate-mutant complex was not reached and 
higher substrate concentrations would be necessary. Since a typical sigmoidal binding curve 
was not obtained, the KD values of GG or MG binding to E419A could not be determined. 
Nevertheless, the shape of the binding curve suggests higher affinity for GG than for MG 
(Figure 3.12C and D). The data obtained suggest that E419A-GG and E419A-MG 
interactions are likely to have KD values higher than 80 and 300 mM, respectively (Table 3.5). 
This difference in affinity is also reflected in the lower occupancy of MG in the active site of 
the E419A mutant. Despite MG being present in both molecules of the asymmetric unit, in 
one of them its occupancy refined to a value of 42%, co-existing with glycerol and serine in 
the remaining molecules.  
Structurally, the active site of E419A in complex with GG or MG is identical (RMSD=0.08 Å, 
for 12 aligned atoms), with the active site residues occupying similar positions (Figure 
3.13B). However, the superposition of GG and MG is clearly worse than for mutant D182A-
substrate complexes. The hydrogen bonds with Tyr36, Asp43, Trp40, Trp42, Tyr88, Arg216, 
Tyr222 and Gln115 are present for both substrates. The most significant changes are 
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induced by atom O15 of the substrate. In the case of the E419A-GG complex, O15 is able to 
establish polar contacts with Asp182, Tyr375 and Trp376, whereas in the E419A-MG 
complex the hydrogen bond to Trp376 is the only one preserved, with an increase of 0.3 Å 
in length. In contrast to the E419A-GG complex, the nucleophilic water is absent when MG is 
in the active site of the E419A mutant. Thus, residues Asp182, Tyr375 and Trp376 are 
involved in the specific recognition of glucose moiety of GG. Since all these residues are 
preserved in the E419A mutant, it is more likely to reflect the different binding affinity of wild-
type gaMhaGgH for GG and MG.  
In mutant D182A, the substrates are identically oriented because Ala182 can shift 0.9 Å 
allowing the movement of Tyr375. In mutant E418A, the position of Tyr375 is not allowed to 
change due to the presence of the side chain of Asp182. This residue is stabilised by water-
mediated contacts with Gln115 and Trp177 in the E419A-GG complex, while in the E419A-
MG complex the water mediating the contact to Trp177 is absent, and Asp182 is directly 
bound to the glycosidic oxygen of MG. In the E419A-MG complex, MG O18 is shifted 0.4 Å, 
impairing hydrogen bonding to Gln434 and the nucleophilic water. Indeed, the nucleophilic 
water is absent in the MG-E419A complex and Gln434 adopts two conformations (50% 
occupancy each). Since Glu419 contributes for Gln434 orientation through hydrophobic 
contacts, its absence allows Gln434 to establish new water-mediated contacts with the 
amide of Ser431.  
A Cremer-Pople analysis (Cremer-Pople parameter calculator, http://enzyme13.bt.a.u-
tokyo.ac.jp/CP/) was also performed for the cyclic moiety of GG and MG present in the active 
site of the mutants. Independently of the substrate or mutant, the moieties of glucose or 
mannose adopt a 4C1 chair conformation with an α-anomeric configuration. 
 
3.3.6.3. Inactive mutants in complex with substrate analogues 
The activity of gaMhaGgH was also tested against the substrate analogues GGlycerol and 
GGlycolate. These compounds are composed of glucose and glycerol or glycolate moieties. 
Despite their similarity to GG, gaMhaGgH was unable to hydrolyse these compounds 
(Supplemental figure S3.9). In order to clarify the molecular determinants impairing the 
hydrolysis of these compounds, GGlycerol and GGlycolate were soaked into crystals of wild-
type gaMhaGgH, and of mutants D182A and E419A.  
Only the structure of the E419A mutant in complex with both substrate analogues and that of 
D182A in complex with GGlycolate could be obtained (Figure 3.10). Similar to the substrate-
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mutant complexes, these structures were obtained from crystals belonging to space group 
P21212 that diffract to between 1.9 and 2.1 Å and contain 2 molecules in the asymmetric unit 
Table 3.3). The structures of E419A-GGlycolate, E419A-GGlycerol and D182A-GGlycolate 
complexes were modelled from Pro2 to Gly446. 
Comparing the active site of E419A in complex with GGlycolate or GG (RMSD=0.357 Å, for 
13 aligned atoms), no significant differences are observed in the residues interacting with the 
glucose moiety (Figure 3.14A). In the E419A-GGlycolate complex, the polar contacts with 
Tyr36, Arg216, Tyr222 and Tyr375 are absent. Therefore, the Glu201-Ser218 segment has 
higher mobility, resulting in a poorly defined electron density map in this region. In molecule 
B, the segment Gln203-Ile210 was modelled from residual electron density and the 
occupancy of the side chains of these residues was set to zero. In the E419A-GGlycolate 
complex, the glycolate moiety is stabilised by hydrogen bonds to Trp40 and Tyr88, and by a 
water-mediated contact with Gln115 and Trp177. Interestingly, the catalytic water is absent in 
the E419A-GGlycolate complex. Although GGlycolate is present in the active site of both 
molecules of the asymmetric unit, in molecule A it displays an occupancy of 36%, 
alternating with serine and glycerol. As described before, the presence of these compounds 
in the active site contributes for active site closure by mimicking the substrate. In this 
molecule, the residues known to interact with the substrate can be nicely superposed to the 
E419A-GG complex. Due to the high occupancy of the serine and glycerol over the 
GGlycolate, the active site arrangement may not represent a realistic model of GGlycolate 
binding. Indeed, important contacts for the stabilisation of the closed state, such as substrate 
binding to Arg216 and Tyr375, are absent when GGlycolate is present. 
In the case of mutant D182A, GGlycolate is present in the active sites of both molecules in 
the asymmetric unit, although with partial occupancy. In molecule A, GGlycolate seems to 
adopt two different positions (33 and 23% occupancy), whereas in molecule B a single 
conformation is present (44% occupancy) (Figure 3.14B), in both cases alternating with 
serine and glycerol molecules. In mutant D182A, GGlycolate can adopt an identical position 
to that in mutant E419A, with the glycolate moiety establishing contacts with Trp40, Tyr88, 
Gln115 and Trp177. Nevertheless, in this mutant GGlycolate seems to preferentially adopt a 
different position, stabilised by hydrogen bonds to Tyr88, Arg216, Tyr222 and Tyr375. Also, 
the glycosidic oxygen is likely to establish a polar contact with water molecule w4, 
contributing for GGlycolate stabilisation. The presence of Glu419 contributes for orienting 
GGlycolate into the most frequent position through hydrogen bonding with Tyr36 and Arg216. 
The correct positioning of Arg216 also orients Tyr375 to face the active site. In mutant 
D182A, the most frequent conformation of GGlycolate is a close mimic of the gaMhaGgH 
substrate.  
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Figure 3.14 – Alternative gaMhaGgH ligands: GGlycolate and GGlycerol. A – Superposition of the 
active site region of gaMhaGgH mutant E419A in complex with GGlycolate (ligand and interacting 
residues are in green and wheat, respectively) and with GG (ligand and interacting residues are in 
orange and light blue, respectively). The grey dashed lines represent the contacts between mutant 
E419A residues and GG that are absent in the E419A-GGlycerol complex. Black dashed lines 
represent newly established contacts. B – Superposition of the active site region of gaMhaGgH mutant 
D182A in complex with GGlycolate (ligand and interacting residues are in green and wheat, 
respectively) and with GG (interacting residues are in light blue; GG is not shown). The bound 
GGlycolate molecule adopts two conformations (dark and light green) with the most frequent one 
coloured dark green. Polar contacts are represented as grey or black dashed lines depending on 
GGlycolate conformation. C – Superposition of the active site region of mutant E419A in complex with 
GGlycerol (ligand and interacting residues are in dark red and wheat, respectively) and with GG 
(ligand and interacting residues are in orange and light blue, respectively). The hydrogen bonds 
between mutant E419A and GG absent in the E419A-GGlycerol complex are represented by grey 
dashed lines. The new contacts are represented by black dashed lines. 
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In the structure of the E419-GGlycerol complex, segments Asp206-Ile210 of molecule A and 
Gln203-Ile210 of molecule B were not modelled, due to the absence of interpretable electron 
density in these regions. GGlycerol was found in both molecules of the asymmetric unit, 
seemingly with full occupancy. The residues of subsite -1 are in a similar position to that 
found in the E419A-GG complex, establishing identical contacts with the glucose moiety 
(Figure 3.14C). A single exception is observed for the position of Gln434 that can adopt two 
different conformations in the E419A-GGlycerol complex. The most significant differences 
are in subsite +1. The absence of one oxygen atom in the glycerol moiety compared to 
glycerate affects hydrogen bonding to Tyr36, Arg216, and Tyr375. Since Arg216 is not 
stabilised by contacts with the substrate, the hydrogen bond between Arg216 and Asp206 is 
also lost, resulting in higher mobility of the segment Glu201-Ser218. The glycerol moiety of 
GGlycerol is poorly stabilised by polar contacts with Tyr88, and with Asp182 and Tyr222 by 
water-mediated contacts. Nevertheless, the hydrogen bonds with Trp40, and Gln115 through 
a water molecule are still conserved in the reducing end of GGlycerol. 
Several contacts are absent in the E419A-GGlycerol complex, especially those implicated in 
active site closure. The replacement of Asp182 by an alanine in the D182A mutant 
represents an additional lost bond that is likely to contribute for the reduction of GGlycerol 
binding. Moreover, the loss of a hydrogen bond with Tyr375 may destabilise several 
interactions necessary to properly orient the substrate and the catalytic residue Glu419 in the 
D182A mutant. Indeed, serine and glycerol were always found in the active site of the D182A 
mutant, regardless of the GGlycerol concentration used (up to 100mM) or the time of 
soaking. The ternary complex of D182A, serine and glycerol is likely more stable than the 
D182A-GGlycerol complex. 
Despite all attempts to obtain the structure of the wild-type gaMhaGgH in complex with these 
substrate analogues, the active site of gaMhaGgH was always occupied by serine and 
glycerol. In the mutants, replacement of the catalytic residues by a small alanine allowed the 
rearrangement of the active site to accommodate the substrates, GG and MG, and likely the 
substrate analogues, GGlycerol and GGlycolate. Since a lower plasticity of the active site of 
wild-type gaMhaGgH is expected, the ligands that can be accepted are more limited. 
Substrate binding in MhaGgH is a well-coordinated event that involves flexible loops and 
highly conserved residues. This enzyme evolved to harbour specific substrates, especially 
GG. The presence of glycerol and serine in the active site of wild-type gaMhaGgH indicates 
a higher affinity for these molecules than for the substrate analogues. 
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3.3.7. Modulation of MhaGgH substrate specificity: an attempt 
The structure of a MhaGgH homologue from T. thermophilus HB8 (Tt8MGH) was published 
recently (Miyazaki, Ichikawa et al. 2015). Although no biochemical study was performed for 
Tt8MGH, an enzyme with 99% amino acid sequence identity (Tt27MGH) was previously 
characterized (Alarico, Empadinhas et al. 2013). Tt27MGH is able to hydrolyse GG and MG 
with comparable efficiency. The high degree of amino acid sequence conservation between 
Tt8MGH and Tt27MGH suggests that the enzymatic activity is also conserved. Thus, the 
differences in MhaGgH and Tt27MGH active sites are likely to be responsible for the 
discrepancy in substrate preference. 
A single substitution in the substrate-interacting residues is present in Tt8MGH and 
MhaGgH. While in MhaGgH position 434 (MhaGgH numbering) is occupied by a glutamine, 
in Tt8MGH this residue is a phenylalanine (Supplemental figure S3.4). As described above, 
residue Gln434 is localized in subsite -1 of the MhaGgH active site that hosts the glucose or 
mannose moiety of GG or MG, respectively. Therefore, it is likely that this substitution might 
contribute for substrate preference.  
In order to evaluate the impact of the substitution of Gln434 for a phenylalanine in substrate 
hydrolysis by gaMhaGgH, a Q434F mutant was produced. The thermal stability of the Q434F 
mutant was evaluated and no significant differences were observed compared to the wild-
type variant, suggesting that the mutation is unlikely to affect the protein folding and stability 
(Figure 3.3D). 
The impact of the glutamine-to-phenylalanine substitution in gaMhaGgH activity was also 
analysed. Under the conditions tested, the mutant displayed considerable lower activity than 
wild-type gaMhaGgH (Supplemental figure S3.10). Also, no alteration in substrate preference 
was noticed, and apparently mutant Q434F is still more efficient hydrolysing GG than MG. 
The Q434F mutant was crystallized in the same experimental conditions as gaMhaGgH and 
both open and closed conformations were obtained. While the crystals containing the 
enzyme in open conformation were easily obtained, the crystals of the closed conformation 
were only obtained by cross-seeding with wild-type crystal seeds. Moreover, the crystals of 
closed Q434F displayed a slower and poorer growth compared to the other mutants. X-ray 
diffraction data were collected from both types of crystals and the structures were solved by 
molecular replacement using the SeMet-gaMhaGgH coordinates as search model. 
The active site residues of the gaMhaGgH Q434F mutant display an arrangement similar to 
that of wild-type gaMhaGgH or mutant D182A in complex with GG (Figure 3.15A). However, 
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a severe alteration is observed in the position of Trp436 (Figure 3.15B). This residue, 
together with Trp42, Trp381 and Trp376, contributes for substrate orientation through 
hydrophobic contacts. The movement of Trp436 alters the hydrophobic surface that 
accommodates the glucose ring, affecting substrate binding. Moreover, since the crystals 
corresponding to the closed conformation of the enzyme were difficult to grow, it is likely that 
replacement of Gln434 by a phenylalanine affects active site closure. 
The position of the active site residues of Tt8MGH in complex with glucose (PDB accession 
code: 4WVB) is also comparable to that of gaMhaGgH Q434F (Figure 3.15C). However, 
when analysing the neighbourhood of Trp436 in wild-type gaMhaGgH, it becomes clear why 
there is not a phenylalanine in position 434 of gaMhaGgH (Figure 3.15D). In Tt8MGH, 
Glu393, Ile356 and Ser411 residues are all connected by a water-mediated hydrogen 
bonding network. Also, Trp410 is in an adequate position to establish an additional hydrogen 
bond with the same water molecule (labelled w in Figure 3.15D). In gaMhaGgH, a similar 
interaction is observed, with the catalytic Glu419 hydrogen bound via a water molecule to 
Thr437 and Val383. However, the substitution of isoleucine for a less flexible proline in 
gaMhaGgH forces the following residue (Val383) to interact with the water molecule. In 
consequence, Trp436 is repelled by the approximation of Val383 and moves towards 
Gln434. This movement is allowed due to the presence of glutamine, less bulky than 
phenylalanine. When residue 434 is replaced by a phenylalanine in gaMhaGgH, Trp436 is 
pushed away from both Phe434 and Val383. This movement also impacts the neighbouring 
residues, such as Phe46, slightly affecting their position. 
In MhaGgH, the substitution of a glutamine for a phenylalanine represents a dramatic 
change. Besides their chemical differences, the residue size has also an impact in the 
restricted space of the closed active site of MhaGgH. When Gln434 is replaced by a 
phenylalanine, it interferes with the active site arrangement and/or substrate binding and 
orientation, and ultimately enzyme function. During evolution several amino acid substitutions 
are likely to occur. While some modifications are structural and biochemically well tolerated, 
others require additional substitutions to minimize their impact. In MhaGgH, Gln434 is well 
tolerated due to the presence of proline and valine at positions 382 and 383, respectively. 
These three residues, located on both sides of Trp436, contribute to positioning its side chain 
appropriately for substrate binding. Concomitant replacement of the residues at positions 382 
and 383 by isoleucine and asparagine, respectively, would result in a triple mutant more 
likely to succeed as a mimic of the active site of the Tt8MGH enzyme. 
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Figure 3.15 – Active site of gaMhaGgH Q434F mutant. A – Superposition of the active site region of 
wild-type gaMhaGgH and mutants Q434F and D182A. The active site of Q343F (salmon) and 
gaMhaGgH (wheat) is occupied by serine (cyan) and glycerol (yellow), while that of D182A (light blue) 
has GG (orange). B – Superposition of the active site region of the Q434F (salmon) and D182A (light 
blue) mutants in complex with GG (orange), highlighting the hydrophobic surface where the glucose 
ring of the substrate is accommodated. Some of the hydrogen bonds between GG and the D182A 
mutant are represented as black dashed lines, whereas the hydrogen bond that is absent upon 
replacement of Glu434 for phenylalanine is coloured grey. The position of Trp436 is severely affected 
by the amino acid substitution, as indicated by the arrow. Proteins are coloured as in A. C – 
Superposition of the active site region of gaMhaGgH Q434F and Tt8MGH in complex with glucose 
(dark green) (PDB accession code: 4WVB). The active site content of mutant Q434F is coloured as in 
A. The residues of gaMhaGgH Q434F and Tt8MGH are represented by wheat and pale green sticks, 
respectively. D – Superposition of the Trp436 neighbourhood in Tt8MGH (pale green), gaMhaGgH 
(pale cyan) and Q434F (wheat). The hydrogen bonds in Tt8MGH, gaMhaGgH and Q434F are 
coloured green, teal and wheat, respectively. 
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3.4. Supplemental information 
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Supplemental figure S3.1 – Diffraction patterns from gaMhaGgH crystals. A and B – Diffraction 
patterns from SeMet-gaMhaGgH (A) and gaMhaGgH (B) crystals belonging to space groups P21 and 
P21212, respectively. C – Diffraction pattern from a gaMhaGgH crystal belonging to the hexagonal 
space group P6222. Each diffraction pattern was obtained by merging five consecutive 0.1° rotation 
images. The resolution limits corresponding to the circumscribed red circles are indicated. 
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Supplemental figure S3.2 – Theoretical scattering factors of selenium. The theoretical values of f′′ 
(thick line) and f′ (thin line) for selenium were plotted over a range of energies, from 5,004 eV (2.47 Å) 
to 20,000 eV (0.62 Å). The plot was generated using the online tool X-ray Anomalous Scattering 
(http://skuld.bmsc.washington.edu/scatter/AS_index.html). The theoretical K absorption edge of 
selenium (12,658 eV, 0.97Å) is labelled. 
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Supplemental figure S3.3 – Unit cell arrangement of monoclinic and orthorhombic gaMhaGgH 
crystals. The unit cells of gaMhaGgH crystals belonging to space group P21 (A) or P21212 (B) are 
represented in two different orientations. The origin of the Cartesian coordinate system is indicated as 
0. The unit cell a, b and c-axes are indicated and are 90 Å (A) or 86 Å (B), 86 Å (A) or 159 Å (B), 
and 159 Å (A) or 88 Å (B) in length, respectively. The angle β (93º) of the monoclinic crystal unit 
cell is indicated. The molecules of the asymmetric unit are shown in blue, while the symmetry 
equivalent molecules are cyan, wheat or green. 
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Supplemental figure S3.4 – Amino acid sequence alignment of characterized 
mannosylglycerate/glucosylglycerate hydrolases. Amino acid sequences of Mycobacterium hassiacum 
GgH (GenBank: EKF25940.1) and of MgH enzymes from Rubrobacter radiotolerans (GenBank: 
AFC76324.1), Selaginella moellendorffii (GenBank: XP_002961898.1), Thermus thermophilus HB27 
(GenBank: WP_011173059.1) and T. thermophilus HB8 (GenBank: WP_011228344.1) were aligned 
with Clustal Omega (Sievers, Wilm et al. 2011). Secondary structure elements of M. hassiacum GgH 
and T. thermophilus HB8 MgH were identified with DSSP (Kabsch and Sander 1983) and are 
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indicated above and below the alignment, respectively. Residues are coloured from white to red 
according to increasing conservation. Catalytic residues are indicated by black triangles and other 
substrate-interacting residues by black circles. Figure prepared with ALINE (Bond and Schuttelkopf 
2009). 
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Supplemental table S3.1 – Analysis of the quaternary structure of gaMhaGgH. The total surface and 
total interface areas of each monomer (upper table) and the inter-monomer area and interactions 
(lower table) were determined using PISA (Krissinel and Henrick 2007). 
 
 
Monomer 
Total 
surface 
area (Å
2
) 
Total 
interface 
area 
(Å
2
) 
A 17,378 1,637 
B 17,218 1,633 
C 17,381 1,639 
D 17,216 1,633 
Average 17,298 1,636 
 
Interface 
Interface 
area (Å
2
) 
Interface interaction 
Hydrogen 
bonds 
Salt 
bridges 
A:B 477 0 10 
C:D 478 0 10 
A:C 900 14 0 
B:D 895 12 0 
A:D 260 1 0 
B:C 261 1 0 
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Supplemental figure S3.5 – Kinetic curves of GG and MG hydrolysis by gaMhaGgH. The sigmoidal 
shape of the experimental curve suggests that a cooperative effect between the tetramer subunits 
may exist. A – Kinetic curve obtained at 50°C and pH 6.0 using GG as substrate. B – Kinetic curve 
obtained at 37°C and pH 8.0 using GG as substrate. C – Kinetic curve of MG hydrolysis obtained at 
50°C and pH 6.0. (Experiments performed by Susana Alarico, Molecular Mycobacteriology Group, 
CNC, University of Coimbra, Portugal) 
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Supplemental figure S3.6 – Active site of gaMhaGgH. A – Active site of gaMhaGgH crystallized in a 
condition containing serine and glycerol. Subsites -1 and +1 are occupied by glycerol (yellow) and L-
serine (cyan) molecules (gaMhaGgH-SER-GOL complex), respectively. L-serine adopts two different 
conformations (different shades of cyan) in the active site. Serine and glycerol are stabilised by direct 
and water-mediated polar contacts (dashed lines) with the active site residues. The catalytic residues 
are highlighted in red. The nucleophilic water (nw) is indicated. The 2Fo-Fc electron density map is 
contoured at 1 σ.  B – Active site of gaMhaGgH crystallized in the absence of serine in the 
crystallization condition. Three water molecules (coloured crimson) replace the serine molecule 
present in A. The position of the substrate-binding residues is similar to that in the gaMhaGgH-SER-
GOL complex. The catalytic residues and the nucleophilic water are indicated as in A. The 2Fo-Fc 
electron density map is contoured as in A. 
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Supplemental figure S3.7 – Unit cell arrangement of hexagonal gaMhaGgH crystals. The unit cell of 
the gaMhaGgH crystals belonging to space group P6222 is represented in two different orientations. 
The origin of the Cartesian coordinate system is indicated as 0. The unit cell a, b and c-axes are 
indicated and are 167, 167 and 243 Å in length, respectively. The molecules of the asymmetric 
unit are shown in blue, while the symmetry equivalent molecules are cyan, wheat, green or salmon. 
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Supplemental figure S3.8 – Active site of gaMhaGgH in open state. The catalytic residues (yellow 
sticks) are facing away from the active site cavity (salmon spheres), stabilised by direct hydrogen 
bonds and by water (w)-mediated contacts with the neighbour residues (dashed lines). Upon substrate 
binding, the catalytic residues (teal sticks) turn towards the active site cavity, establishing new polar 
contacts (not represented). 
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Supplemental figure S3.9 – Analysis of GGlycolate and GGlycerol hydrolysis by gaMhaGgH. The 
ability of gaMhaGgH to hydrolyse GGlycolate (A) and GGlycerol (B) was evaluated by TLC. A – 
Different concentrations of GGlycolate were incubated with gaMhaGgH at 50°C for 2 h. Glucose 
production was not detected for any of the concentrations tested. B – The gaMhaGgH was 
incubated with GGlycerol for 10 min, 1h and 3h at 50°C. The production of glucose from GGlycerol 
was not observed. (Experiments performed by Susana Alarico, Molecular Mycobacteriology Group, 
CNC, University of Coimbra, Portugal) 
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Supplemental figure S3.10 – Analysis of GG and MG hydrolysis by gaMhaGgH mutant Q434F. 
The ability of the Q434F mutant to hydrolyse GG and MG was evaluated by TLC. Wild-type 
gaMhaGgH and Q434F mutant (2.7 μM) were incubated with 20 mM GG or MG at different 
temperatures for 1 h. A considerable lower production of glucose or mannose was observed for 
mutant Q434F (marked with asterisk) compared to the wild-type enzyme (marked with a double 
asterisk). (Experiments performed by Susana Alarico, Molecular Mycobacteriology Group, CNC, 
University of Coimbra, Portugal) 
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Mycobacteria constitute a large and diverse group of organisms. Although most of them 
are environmental, many of these ubiquitous bacteria are opportunistic pathogens 
capable of causing infections in humans, especially in immunocompromised or 
immunosuppressed individuals. Moreover, mycobacteria also comprehend highly 
aggressive species, including the causative agents of tuberculosis. Currently, tuberculosis 
is one of the top 10 causes of death worldwide and the leading cause of death by a single 
infectious agent. Mycobacteria in general display high resilience against stress conditions, 
including antibiotics and disinfectant action. Thus, the treatment of mycobacterial 
infections is usually challenging and demands long duration multidrug therapy. Worse, the 
emergence of multidrug and extensively drug-resistant strains limits the ability to control 
mycobacterial infections. Altogether, the increasing drug resistance of mycobacteria and 
the long duration required for the treatment urges for the development of new, shorter and 
more efficient anti-mycobacterial therapies. 
Polymethylated polysaccharides are unique carbohydrates found exclusively in 
mycobacteria and related genera, including Nocardia and Streptomyces. Although these 
molecules were discovered more than 50 years ago, their physiological role and 
biosynthesis are still not fully understood. PMPSs are subdivided into 3-O-methylmannose 
polysaccharides and 6-O-methylglucose lipopolysaccharides. MGLPs are the only type of 
PMPSs common to all mycobacteria examined thus far and to a few other members of the 
Actinobacteria phylum. The genes proposed to participate in MGLPs biosynthesis are 
highly conserved among mycobacteria, and several of them were considered essential for 
mycobacterial in vitro growth, highlighting their contribution for survival and their potential 
as drug targets. 
In this thesis, two mycobacterial enzymes are structurally characterized: glucosyl-3-
phosphoglycerate phosphatase and glucosylglycerate hydrolase. GpgP and GgH are 
involved in the metabolism of glucosylglycerate, one of the earlier intermediates of 
MGLPs. While GpgP catalyses the dephosphorylation of glucosyl-3-phosphoglycerate 
producing GG (Chapter 2), GgH converts the later to glucose and glycerate (Chapter 3). 
Although the structure of a recombinant M. tuberculosis GpgP was recently reported 
(Zheng, Jiang et al. 2014), the structure described in this thesis was determined at a 
considerable higher resolution (1.5 Å), allowing a better interpretation of the active site 
content.   
The mycobacterial GpgP was first annotated as a phosphoglycerate mutase due to its 
sequence similarities to other enzymes of this type. However, biochemical analysis of a 
recombinant M. tuberculosis GpgP revealed that it displays a phosphatase activity – 
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preferentially on GPG – and only residual phosphoglycerate mutase activity, leading to its 
reclassification as glucosyl-3-phosphoglycerate phosphatase (Mendes, Maranha et al. 
2011). 
MtuGpgP is a homodimeric protein, composed of central β-strands flanked on both sides 
by α-helices. The electrostatic surface of MtuGpgP reveals two positively charged clefts, 
clearly shaped by both monomers, where the active sites are located. The contribution of 
both monomers for the active site clefts suggests that the dimer is likely the minimal 
functional unit, which was underscored by the inability of individual monomers to 
dephosphorylate a synthetic substrate (Zheng, Jiang et al. 2014).  
The substrate binding mode of MtuGpgP was elucidated by the structure of its complex 
with vanadate (Figure 2.5). The large electron density blob found in the active site of 
MtuGpgP co-crystallized with vanadate can be explained by the presence of three 
chemical species: a vanadate ion and two trivanadate glycerol esters. Vanadate was 
found covalently linked to the catalytic histidine and stabilised through a network of polar 
contacts with neighbour residues, including three highly conserved amino acids: two 
arginines (Arg10 and Arg60) and one histidine (His159). The vanadate-histidine complex 
is a mimic of the phosphohistidine transiently formed during the course of the reaction, 
which allowed the identification of the residues implicated in substrate binding and 
catalysis. 
The trivanadate glycerol esters described here are novel. These molecules highlighted the 
presence of a hydrophobic surface, lined by residues Met22, Leu87, and Trp109, that is 
likely to contribute for accommodating the glucose ring of the substrate. This surface is 
surrounded by polar residues (His95, Arg110 and Arg123) that may participate in glucose 
stabilisation through polar contacts.  
In the vanadate-MtuGpgP structure, the proton donor Glu84 is located within hydrogen 
bonding distance of the oxygen that is protonated during the phosphorylation of the 
catalytic histidine, suggesting that it is likely to donate a proton directly to the leaving 
group. In the trivanadate-glycerol-MtuGpgP complex, the distance between the vanadium 
atom V3 of trivanadate and Glu84 is compatible with a covalent bond, which suggests that 
Glu84 may have performed a nucleophilic attack directly to the vanadate. The structures 
of MtuGpgP in complex with vanadate and trivanadate glycerol suggest that Glu84 is able 
to shift between protonated and ionized forms as expected. 
The structure of MtuGpgP in complex with vanadate and GG was also obtained (Figure 
2.7). The ternary complex suggests that GG may establish transient interactions with the 
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residues lining the active site cleft, which are likely to facilitate the inward and outward 
movement of substrate and of product, respectively. The substrate binding mode of 
MtuGpgP could be better clarified by the structure of wild-type and/or catalytic inactive 
MtuGpgP in complex with the substrate GPG. Catalytic inactive MtuGpgP could likely be 
obtained by replacing Glu84 and/or His11 by alanine. Indeed, a catalytically inactive 
mutant of MtuGpgP was successfully generated by replacing His11 by an alanine (data 
not shown). Crystals of wild-type and catalytically inactive MtuGpgP were soaked into the 
crystallization condition containing substrate GPG or synthetic substrate PNPP. However, 
none of the ligands were found in the active site of the macromolecules. Different times of 
soaking and higher concentrations of ligands should be used in the future. 
MtuGpgP contains a C-terminal hexahistidine tag linked to the native M. tuberculosis 
GpgP sequence by a seven amino acid residue linker. In the higher-resolution structure, 
the linker and the hexahistidine tag are organized into an α-helix. Although the molecules 
in the asymmetric unit have different crystallographic contacts, the C-terminal helices are 
in equivalent positions. In the iodide-containing crystal, the different crystal packing results 
in an increased space between macromolecules at this region, allowing the engineered C-
terminal tail to have higher mobility, as suggested by the absence of electron density map 
that limits the C-terminal modelling from the end of native GpgP sequence. 
Although scarce, there are reports pointing to contribution of the C-terminus for the 
mutase activity. Removal of the C-terminal region led to a markedly decreased mutase 
activity for the Saccharomyces cerevisiae phosphoglycerate mutase (S. cerevisiae 
PGAM) (Walter, Nairn et al. 1999). Also, the C-terminal tail of S. cerevisiae PGAM 
showed higher resistance to proteolysis in presence of the cofactor 2,3-
bisphosphoglycerate, suggesting the participation of the C-terminal in substrate binding. 
The crystallographic study of the cofactor-dependent phosphoglycerate mutase from 
Escherichia coli showed that the C-terminal region displayed higher mobility in the apo 
form of the enzyme, while in phosphohistidine-activated and vanadate-inactivated forms 
the C-terminal was found to interact with the residues implicated in substrate binding 
(Bond, White et al. 2001, Bond, White et al. 2002). A similar observation was made for the 
cofactor-dependent phosphoglycerate mutase from Bacillus stearothermophilus (PhoE): 
its C-terminus could only be modelled for the phosphate and vanadate complexes 
(Rigden, Littlejohn et al. 2003). The interaction of the C-terminal with the substrate-binding 
residues is thus likely to offer additional stabilisation of the active conformation of the 
catalytic core. 
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Since the C-terminal tail of mutases can have variable length and no evident sequence 
pattern, it is not possible to predict protein function based on the C-terminal sequence 
alone. The overall structure of B. stearothermophilus PhoE, E.coli PGM and MtuGpgP is 
similar, with the C-terminal tails displaying different length but occupying similar positions. 
The amino acid segment of MtuGpgP preceding the engineered tag seems to be 
unstructured and mobile, as supported by the iodide-containing structure, and thus 
suitable to interact with the active site residues. Therefore, it would be interesting to 
evaluate the impact of the engineered C-terminal tag in mycobacterial GpgP activity. 
Although more challenging to purify, it would be more reliable to evaluate the activity of a 
tag-free GpgP protein. On the other hand, the production of a recombinant GpgP 
containing an additional Gly-Ala dipeptide at the N-terminus using a similar strategy as for 
GgH, would facilitate the purification step. Also, due to the localization of the N-terminus in 
dimeric GpgP, the engineered N-terminal dipeptide would be unlikely to affect enzyme 
activity. 
The biochemical and structural characterization of a recombinant GgH from M. hassiacum 
was reported in Chapter 3. GgH seems to be restricted to rapid-growing mycobacteria. 
The subdivision of mycobacteria into slow and rapid-growing mycobacteria is based on 
their growth rate, which reflects their phylogenetic divergency (Tortoli, Fedrizzi et al. 
2017). Interestingly, when comparing the growth rate with pathogenicity, the highly 
pathogenic bacteria (such as M. tuberculosis and M. leprae) are in the slow-growing 
group, while non-pathogenic species (such as M. phei and M. thermoresistible) are among 
the rapid-growing mycobacteria. However, the link between virulence and growth rate is 
narrow and a number of RGM have also been associated to human infections, especially 
in immunosusceptible individuals,  with M. abscessus, M. chelonae and M. fortuitum 
(formerly known as M. ranae) as the most common infectious agents (Brown-Elliott and 
Philley 2017). Alarmingly, RGM are not susceptible to the first-line anti-TB drugs and drug 
therapeutic regimens are selected based on their unique in vitro susceptibility patterns 
(Nunes-Costa, Alarico et al. 2016, Akram and Bhimji 2017, Brown-Elliott and Philley 
2017). The treatment of rapid-growing mycobacterial infections is becoming a 
considerable clinical challenge for which the therapeutic solutions are scarce 
(Kasperbauer and De Groote 2015). 
GgH from M. hassiacum was proposed to be involved in the decrease of intracellular GG, 
accumulated during mycobacterial growth under nitrogen-limiting conditions, by catalysing 
its hydrolysis to glucose and glycerate (Alarico, Costa et al. 2014). Although considered a 
compatible solute accumulated in diverse organisms to avoid the loss of water in high 
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salinity environments,  the  accumulation of GG in mycobacteria was shown to be 
independent of osmotic stress (Behrends, Williams et al. 2012). The accumulation of GG 
was exclusively linked to nitrogen starvation and, so far, no data is available regarding GG 
accumulation in other growth-limiting conditions.  
Under stress, bacteria prepare themselves to enter a hibernation-like state known as 
dormancy that allows cells to keep viable until improvement of the environmental 
conditions (Rittershaus, Baek et al. 2013). In growth-limiting conditions, cells accumulate 
carbon stores to use as a rapidly mobilisable source of energy to promote cell growth and 
division and outcompete the neighbouring microorganisms. In agreement, the growth 
curve of M. hassiacum (Alarico, Costa et al. 2014) shows a small jump of growth after the 
addition of nitrogen to the medium, concomitant with the decrease of intracellular GG 
content. In M. tuberculosis, the dormancy state seems to the accompanied by the 
accumulation of triacylglycerol (Daniel, Deb et al. 2004) and wax esters (Sirakova, Deb et 
al. 2012). Since slow-growing mycobacteria, such as M. tuberculosis, seem to lack a GgH 
ortholog-encoding gene, it is likely that SGM and RGM have developed different 
strategies to survive to growth-limiting conditions. In order to clarify if RGM accumulate 
GG as a general response to stress, it would be fundamental to evaluate the accumulation 
of GG by other RGM and in different growth-limiting conditions, including in the absence 
of other nutrients, at lower oxygen levels, and at lower or higher pH and temperature. 
The dormancy state is associated to a high relapse rate of a number of infections, 
including tuberculosis (Lewis 2007, Lipworth, Hammond et al. 2016). The drugs currently 
in use are mostly directed to cell growth and division. Since these functions are almost 
supressed in dormant cells, they are more likely to survive the treatment. Thus, targeting 
functions linked to dormancy and resuscitation would likely result in a more efficient 
treatment (Cano-Muniz, Anthony et al. 2018). GgH is likely involved in cell resuscitation of 
RGM by promoting the rapid mobilisation of energy upon relief of growing-limiting stress 
and thus a promising target for the development of new anti-RGM drugs. However, 
physiological evidence on GgH role in rapid-growing mycobacterial survival, dormancy 
and pathogenesis is still needed. 
GgH from M. hassiacum was produced recombinantly with a C-terminal hexahistidine tag 
(Alarico, Costa et al. 2014). Although active, this recombinant protein did not crystallize 
into three-dimensional crystals. Under the hypothesis that the C-terminal tag could be 
affecting crystallization, a new construct was produced containing a N-terminal 
hexahistidine tag separated from the native M. hassiacum GgH sequence by a TEV 
cleavage peptide sequence. Removal of the N-terminal tag by proteolytic cleavage 
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resulted in a protein with a Gly-Ala dipeptide N-terminal to the native GgH sequence at the 
end of the purification procedure. Size-exclusion chromatography and dynamic light 
scattering analysis of both constructs suggested a change in the oligomeric state from the 
C-terminal tagged GgH (MhaGgH-His6) to the untagged protein (gaMhaGgH), 
accompanied by the increase in both protein solution homogeneity and melting 
temperature. Unlike MhaGgH-His6, the gaMhaGgH variant yielded crystals able to diffract 
X-rays to high resolution that allowed its structure to be determined. 
M. hassiacum GgH is a homotetrametic protein, composed of a dimer of dimers (Figure 
3.4). Each monomer contains the (α/α)6-barrel domain typical of the family 63 of glycoside 
hydrolases (GH63), to which GgH belongs. The (α/α)6-barrel domain is covered by a cap 
domain that can be subdivided into A’ and B’-regions. The active site is localized between 
the (α/α)6 and cap domains and opens to the solvent through a negatively charged tunnel. 
The active site of  GgH displays a typical topology of monosaccharidases (Davies and 
Henrissat 1995). Upon substrate binding, the active site becomes inaccessible to the 
solvent, in a closed like state. The open and closed state of GgH is determined by the 
well-coordinated movement of several mobile loops that contain some of the substrate-
interacting residues. 
The biochemical data showed that GgH was able to hydrolyse in vitro GG and MG, with 
higher efficiency for the former. The difference in hydrolysis efficiency of GgH for GG and 
MG may result from distinct binding affinities. Since active GgH would lead to the release 
of reaction products and difficult result interpretation, catalytic inactive point mutants, 
gaMhaGgH D182A and E419A, were used to evaluate the binding affinity of GgH for the 
substrates. The gaMhaGgH E419A mutant loses Glu419-mediated polar contacts 
necessary to stabilise the closed state of the enzyme. Although displaying lower affinity for 
both substrates, this mutant is likely the most adequate to evaluate the molecular 
determinants of GG and MG binding specificities. The α-D-glucose and α-D-mannose 
differ in the stereochemistry at the C2 position; while the C2 hydroxyl group in α-D-glucose 
is equatorial, in α-D-mannose it is axial. The glucose and mannose moieties of the 
substrates are recognized by subsite -1. The C2 hydroxyl group of the glucose moiety of 
GG establishes polar contacts with Asp182, Tyr375 and Trp376, while that of the 
mannose moiety of MG is only hydrogen bonded to Trp376. Thus, these residues are 
involved in specific recognition of the non-reducing end of GG and likely in the higher 
efficiency of GgH to hydrolyse this substrate.  
The contribution of subsite +1 to substrate recognition was also evaluated by using the 
substrate analogues glucosylglycerol and glucosylglycolate that differ from the substrate 
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GG in the reducing end moiety. In vitro, GgH seems to be unable to hydrolyse any of 
these compounds, and the structure of active GgH in complex with GGlycerol or 
GGlycolate could not be obtained in the experimental conditions used. However, the 
structures of the catalytically inactive mutants in complex with these substrate analogues 
were determined, revealing the important contribution of the reducing end of the substrate 
for active site closure. Also, since these compounds were found in the active site of 
catalytically inactive mutants concomitantly with glycerol and serine from the 
crystallization solution, the affinity of gaMhaGgH D182A and E419A for GGlycerol and 
GGlycolate is likely lower than for those molecules. 
In M. hassiacum GgH, substrate binding is a well-coordinated event, involving highly 
conserved residues and a complex hydrogen bond network. During evolution, the active 
site of GgH was optimized to harbour specific substrates, such as GG. The presence of 
MG in M. hassiacum cells was not reported so far. Assuming that M. hassiacum is unable 
to produce MG, the ability of GgH to hydrolase this compound can be just a vestigial 
function from an ancestor enzyme. On the other hand, since cells are able to interchange 
molecules with the exterior using different strategies – from passive diffusion to active 
transport of specific molecules – it is also possible that M. hassiacum possesses 
adequate machinery for capturing MG from the exterior as a possible source of carbon 
and energy, and uses GgH for its hydrolysis. 
Although the MGLP biosynthetic pathway is becoming clearer, there are still steps in 
MGLP maturation that need to be explored. Several genes were proposed to participate in 
MGLP biosynthesis based on their genomic neighbourhood and encoded protein 
sequence similarity to other characterized enzymes. However, not only physiological 
evidence on their contribution for MGLP production is still missing, as their specific 
function needs to be confirmed. Nevertheless, the results presented in this thesis 
contribute for a better comprehension of the biochemistry of the mycobacterial enzymes, 
GpgP and GgH, involved in the metabolism of GG, one of the earlier intermediates in 
MGLP biosynthesis and an important carbon store of rapid-growing mycobacteria. 
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